

BARKING, HAVERING & REDBRIDGE UNIVERSITY NHS TRUST

FORMULARY MAY 2022

CONTENTS

Please use Ctrl + F or the binoculars to search an item

	INTRODUCTION	1
1	GASTRO-INTESTINAL SYSTEM	4
2	CARDIOVASCULAR SYSTEM	8
3	RESPIRATORY SYSTEM	19
4	CENTRAL NERVOUS SYSTEM	23
5	INFECTIONS	32
6	ENDOCRINE SYSTEM	38
7	OBSTETRICS, GYNAECOLOGY & URINARY-TRACT DISORDERS	45
8	MALIGNANT DISEASE & IMMUNOSUPPRESSION	49
9	NUTRITION & BLOOD	54
10	MUSCULOSKELETAL & JOINT DISEASE	61
11	EYE	65
12	EAR, NOSE & OROPHARYNX	68
13	SKIN	70
14	IMMUNOLOGICAL PRODUCTS & VACCINES	76
15	ANAESTHESIA	78
	POLICY AND GUIDELINES FOR PRESCRIBING FOR SELF, FAMILY, COLLEAGUES AND FRIENDS	81
16	Unlicensed & Specialists Use Drugs Approved by MOG	83

INTRODUCTION

AIM

The aim of the formulary is to:

- promote safe, effective and economic use of drugs
- rationalise prescribing within the hospitals
- rationalise the number of preparations stocked by pharmacies, thus reducing stock holding and drug wastage

GUIDELINES FOR USING THIS BOOKLET

The text is laid out in the same order as the British National Formulary (BNF). It should be used in conjunction with the current BNF. The Drug Formulary is not intended to be a replacement for it. Drugs can be located using the BNF section number or by the alphabetical list in the index at the back. If the BNF section has not been included, all preparations in that section are non-formulary.

Strengths, formulations available, prescribing restrictions and notes for local guidance are included in the main text.

The new British Approved Name (BAN) has been used, with the former name in brackets after. In some instances the trade name, indicated by ®, is included where it is necessary or with some compound preparations. Where there are modified release preparations, this is indicated by m/r and enteric coated preparations by e/c.

Some sizes or strengths of preparations are currently available only on particular sites. Please refer to the pharmacy for further information.

Various guidelines and protocols are referred to in the text. Details are available from pharmacy on request. In general the drugs listed are those stocked in Pharmacy. For requests for non-formulary drugs please refer below.

REQUESTING A DRUG FOR INCLUSION INTO THE FORMULARY

The Drug and Therapeutics Committee meets every two months to consider requests from Consultants. A 'new drug request form' is available from the Trust Intranet. The Consultant should complete this fully, providing information about the intended indication, estimate patient numbers and supply supporting evidence for the inclusion of the drug. The form should be completed and signed by the Consultant, his/her Clinical Director, General Manager and clinical lead pharmacist. Funding will then need to be found. The pharmacy department will then produce an evidence-based evaluation for the Drug and Therapeutics Committee. Managing the entry of new drugs is a Trust requirement as part of its Medicines Management initiative.

INITIATION OF A NON-FORMULARY PREPARATION OR DRUG

All preparations initiated within BHR for in- and out-patient prescribing should be from this formulary. According to Trust directives, prescriptions for non-formulary drugs will be queried by pharmacy staff, who will suggest alternatives from the formulary, where appropriate.

REQUESTING URGENT, NON-FORMULARY DRUGS

In exceptional circumstances non-formulary drugs may be requested for use by a prescriber. A Principal/ Senior Principal Pharmacist will discuss the circumstances with the relevant Consultant. The pharmacist may authorise use or refer the matter to the Chairman of the Drug and Therapeutics Committee for a decision. If there are significant clinical risks or financial implications, then the matter will be discussed with the relevant Clinical Director.

CONTINUATION OF THERAPY

Supplies of medication are usually obtained for patients already established on non-formulary preparations. Patients on non-formulary products such as laxatives, indigestion remedies, calcium supplements, OTC analgesia etc., should be switched to an equivalent formulary preparation.

SPECIAL CONSIDERATIONS

- **RESTRICTED DRUGS**
Where specified, initiation may be by the request of a Specialist. For example, many antibiotics are restricted to Microbiologists only. This is to help prevent resistance emerging and contain costs.
- **MODIFIED RELEASE PREPARATIONS AND PHARMACEUTICAL FORMS**
In some cases a drug may be approved, but not in all the pharmaceutical forms available: e.g. the oral preparation may be formulary but the injection or the

cream, non-formulary. Some modified release preparations are disproportionately costly for the benefit they offer and are therefore not included.

- **SPECIFIC CLINICAL NEEDS**

Non-formulary drugs for individual patients may be approved via Trust procedure. There will be occasions where a patient's clinical needs cannot be met by any of the preparations listed. Special requirements must be discussed in the first instance with the Ward/ Liaison pharmacist. This may then be referred to a Senior Principal Pharmacist, who may authorise the approval for purchase.

PAYMENT BY RESULTS (PbR) EXCLUSIONS

Throughout the formulary some drugs have been labelled with **nPbR. Non PbR** drugs are those expensive drugs that have been agreed nationally should be reported to the CCGs on a monthly basis and invoiced accordingly. It has been agreed on a London-wide basis that the prescribing of these drugs should be only for NICE indications or for approved licensed indications where NICE has not yet reviewed (see details on the intranet). Before these drugs can be dispensed we must be provided with full patient details, including the clinical indication for the drug.

The drugs that are included in this group are:

Anti TNFs e.g. Etanercept, Infliximab

Antifibrinolytic drugs and haemostatics e.g. Drotrecogin alfa

Torsion dystonia and other involuntary movements e.g. Riluzole and Botulinum Motor Neurone Disease

Antifungals e.g. liposomal amphotericin

Hepatitis B & C Peginterferon alfa, ribavirin

Growth Hormone (Somatropin)

Drugs affecting bone metabolism e.g. Teriparatide

Immunomodulating drugs e.g. Alpha and Beta Interferon

Somastatin analogues e.g. Octreotide

Natalizumab

Glatiramer

Treatment of Macular Degeneration (Age –related) e.g. Lucentis and Avastin

Drugs used in neutropenia e.g. Filgastrim

Drugs used in metabolic disorders e.g. Laronidase

Hyperuricaemia associated with cytotoxic drugs e.g. Rasburicase

Immunoglobulins

Tisseel

The minimum data set required by CCGs before they will pay for a patient's treatment is:

Patient name

NHS Number

Hospital number

Diagnosis

Cost of drug

Strength and form of drug

Date dispensed

Consultant code/ cost centre

CCGs

Unless previously agreed with the CCGs on a named-patient basis, we will only be funded for treatment that has been undertaken in line with NICE guidance and the CCGs will require assurance that prescribing has been in accordance with NICE.

Prescribing of these drugs should only be in accordance with NICE guidance **OR** for licensed indications that have been approved by the Drugs and Therapeutics Committee.

If a Consultant has a patient whom you believe requires one of these drugs but does not come under NICE or a licensed indication the Chief Pharmacist should be contacted before a request to a CCG or GP is made. Such requests will then be 'fast-tracked' to the Drugs and Therapeutics Committee for a decision.

MEDICINES INFORMATION SERVICE

The Medicines Information service is based at Queen's Hospital (QH) and may be contacted on extension 3354. It provides a source of up to date medicines information and advice on drug therapy and related areas to all healthcare professionals. The Trust Intranet also provides drug-related information under the section "Medicines Information for Doctors" and carries the Electronic Medicines Compendium

OUT OF HOURS SERVICE

The on-call Pharmacist for Queen's Hospital (QH) and King George Hospital (KGH) can be contacted via Queen's Hospital (QH) switchboard and/or King George Hospital switchboard outside opening hours.

BHRUT Medicines Optimisation Group

Chair: Dr. John McAuley, Consultant Neurologist

EDITORS:

Oluwakemi Aregbesola, Pharmacist (Formulary and Medicines Information)

REVISED: Updated to reflect MOG decisions up to May 2022

1 GASTRO-INTESTINAL SYSTEM

1.1 DYSPEPSIA & GASTRO-OESOPHAGEAL REFLUX DISEASE

1.1.1 ANTACIDS & DIMETICONE

Magnesium trisilicate mixture

Asilone® suspension
(Aluminium hydroxide, light magnesium oxide & dimeticone)

1.1.2 COMPOUND ALGINATE & PROPRIETARY INDIGESTION PREPARATIONS

Gaviscon® Advance suspension

Infant Gaviscon® oral powder

Notes: Magnesium trisilicate should be prescribed when a simple antacid is needed.

Gaviscon is an antacid-alginate preparation, indicated for treatment of reflux & hiatus hernia.

Caution: Some antacids can contain high levels of sodium, e.g magnesium trisilicate mixture. Gaviscon liquid contains about 6 mmol sodium/ 10 ml

1.2 ANTISPASMODICS & OTHER DRUGS ALTERING GUT MOTILITY

Atropine sulphate

600 mcg tablet,
500 mcg/ 5 ml syrup (*unlicensed*)
(*Paediatrics & ENT only*)

Dicycloverine (Dicyclomine)

10 mg tablet, 10 mg/ 5 ml syrup

Hyoscine butylbromide (Buscopan®)

10 mg tablet, 20 mg/ ml injection

Mebeverine

135 mg tablet, 50 mg/ 5 ml liquid

Peppermint oil 0.2 ml capsule

Peppermint water

(*Unlicensed preparation*)

MOTILITY STIMULANTS

Metoclopramide

10 mg tablet, 5 mg/ 5 ml syrup,
10 mg/ 2 ml injection

Domperidone

10 mg tablet, 5 mg/ 5 ml suspension,
30 mg suppositories

Notes: Metoclopramide may induce dystonic reactions, especially in young children, young adults & the elderly. Use of metoclopramide in patients under 20 years is not recommended. May cause confusion in the elderly. Avoid in Parkinson's disease

1.3 ULCER HEALING DRUGS

1.3.1 H₂-RECEPTOR ANTAGONISTS

Ranitidine

150 mg tablet, 75 mg/ 5 ml syrup,
50 mg/ 2 ml injection

1.3.3 CHELATES AND COMPLEXES

Sucralfate

1 g tablet, 1 g/ 5 ml suspension

Tripotassium dicitratobismuthate

(De-NolTab®) 120 mg tablet
(*Gastroenterologists only*)

1.3.5. PROTON PUMP INHIBITORS

1st Choice: Omeprazole 10mg & 20mg capsules

2nd Choice: Lansoprazole 15 mg & 30 mg capsules

For adults with swallowing difficulties or on enteral feeding tubes use Lansoprazole 15 & 30mg FasTabs®

Omeprazole MUPS 10mg & 20mg
(*Paediatric use only*)

Esomeprazole 20 mg tablet

(For patients with erosive oesophagitis who have failed to improve with omeprazole)

Omeprazole 40 mg infusion
(In accordance with PPI guidelines)

H. PYLORI ERADICATION THERAPY (ALL FOR SEVEN DAYS)

Lansoprazole 30 mg b.d
Amoxicillin 1g b.d
Clarithromycin 500 mg b.d

or

Lansoprazole 30 mg b.d
Amoxicillin 1g b.d
Metronidazole 400 mg b.d

(Penicillin-allergic patients):

Lansoprazole 30 mg b.d
Clarithromycin 250 mg b.d
Metronidazole 400 mg b.

1.4 ACUTE DIARRHOEA

1.4.2 ANTIMOTILITY DRUGS

Codeine phosphate

15 mg & 30 mg tablets,
25 mg/ 5 ml syrup

Co-phenotrope (equivalent to Lomotil ®)
Tablet

Loperamide

2 mg tablet, 1 mg/ 5 ml syrup

Note: It is important to rule out infective diarrhoea before prescribing anti-diarrhoeals

Eluxadolone (Truberzi®) 75mg and 100mg film-coated tablets

1.5 TREATMENT OF CHRONIC BOWEL DISORDERS

1.5.1 AMINOSALICYLATES

Mesalazine

(Asacol ® MR)

400 mg e/c tablet, 1 g foam enemas,

250 mg & 500 mg suppositories
(Gastroenterologists only)

(Pentasa ®)

500 mg m/r tablet, 1g granules
(Gastroenterologists only)

(Salofalk®) 3g granules and 1g suppositories

Octasa® 400mg & 800mg M/R tablets

Balsalazide 750 mg capsule
(Gastroenterologists only)

Sulfasalazine (Sulphasalazine)

500 mg tablet & e/c tablet,
250 mg/ 5 ml suspension
500 mg suppositories

Notes: The aminosaliculates, mesalazine & sulfasalazine, may cause blood disorders. See B.N.F. Sulfasalazine may colour the urine & stain contact lens

1.5.2 CORTICOSTEROIDS

Beclometasone 5mg m/r tablet
(Clipper®)

Budesonide (Prescribe by brand)

1mg orodispersible tablets (Joverza®)
(Consultant Gastroenterologists only for the treatment of eosinophilic esophagitis)
3 mg CR capsules (Entocort®)

3 mg

(Consultant Gastroenterologists only)

3mg g/r capsule (Budenofalk®)

2mg foam enema (Budenofalk®)

9mg p/r tablet (Cortiment®)

(Consultant Gastroenterologists only)

Hydrocortisone

10% foam application

Prednisolone

25 mg & 5 mg tablet,

2.5 mg & 5 mg e/c tablets,

5 mg soluble tablet, 5 mg suppositories,

20 mg/ 100 ml retention enema,

20 mg foam application

nPbR = Indicates a drug excluded from HRG tariff price

1.5.3 Drugs affecting the immune response

Azathioprine

Mercaptopurine

Methotrexate 2.5mg tablets and various strengths of injections

CYTOKINE INHIBITORS

nPbR **Infliximab** 100 mg IV infusion
(**Remicade®**)

nPbR **Infliximab Biosimilars** 100mg powder for concentrate for solution for infusion

(**Remsima® & Inflectra®**)

(Consultant Gastroenterologists only for Crohn's Disease. All scripts should be referred to a Senior Principal Pharmacist for approval)

nPbR **Adalimumab** (2nd line treatment of crohn's disease if infliximab ineffective or not tolerated)

Biosimilars:

1st line choice Hyrimoz®

2nd line choice Amgevita®

3rd line choice Humira®

4th line choice Idacio®

nPbR **Vedolizumab** 300mg vial

1.6 LAXATIVES

Note: Before prescribing laxatives consider other contributory factors to constipation: inadequate fluid intake, drugs, lack of exercise & dietary fibre

1.6.1 BULK-FORMING LAXATIVES

Ispaghula husk (for Fybogel®)

3.5 g sachets

Notes: **Ispaghula husk** should be stirred into a large glass of water & drunk immediately. This should not be taken at night

1.6.2 STIMULANT LAXATIVES

Bisacodyl

5 mg tablet,

5 mg (paediatric) & 10 mg (adult) suppositories

Dantron (Danthron)

Co-danthramer

25/200 in 5 ml suspension & 75/1000 in 5 ml (strong) suspension
(see guidance note below)

Co-danthrusate

50/ 60 capsule

Notes: Co-danthrusate & co-danthramer should be restricted for terminally ill patients. Both may colour the urine. They should be avoided in incontinent patients, as prolonged contact may irritate the skin

Docusate sodium 100 mg capsule, 12.5 mg/ 5 ml & 50 mg/ 5 ml oral solution

Notes: Docusate is frequently under prescribed. It is a useful laxative, combining both stimulant & lubricant action

Senna

7.5 mg tablet, 7.5 mg/ 5 ml syrup

Glycerin 1 g, 2 g & 4 g suppositories

Sodium picosulphate 5 mg/ 5 ml elixir

Califig® syrup (*NELMHT only*)

1.6.3 FAECAL SOFTENERS

Arachis oil enema

Liquid Paraffin BP oral emulsion

(Consultant Paediatricians only)

1.6.4 OSMOTIC LAXATIVES

Lactulose 3.35 g/ 5 ml solution

nPbR = Indicates a drug excluded from HRG tariff price

Liquid paraffin & magnesium hydroxide (Milpar®) oral emulsion)

Macrogols (Movicol®)
Laxido®

Phosphate Enemas (Fletcher's)

Sodium citrate microenema (Relaxit®)
(Micolette®)

1.6.5 BOWEL CLEANSING SOLUTIONS

Citramag®
Magnesium citrate powder

Fleet Phospho-soda® oral solution

Klean-Prep® oral powder
Where Picolax and Citramag have been ineffective.

Moviprep® oral powder

Picolax® oral powder
Sodium picosulfate & magnesium citrate sachets

AMIDOTRIZOATES

Diatrizoates

Gastrografin® Solution, sodium amidotrizoate 100 mg, meglumine amidotrizoate 660 mg/mL 100ml Bottle

1.6.6 PERIPHERAL OPIOID-RECEPTOR ANTAGONISTS

Naloxegol 12.5 and 25 mg film-coated tablets

Naldemedine 200microgram tablet (For treating opioid-induced constipation as per NICE TA651) Gastroenterologist initiation

1.6.7 5HT4-RECEPTOR AGONISTS

Prucalopride 1mg and 2mg film coated tablets (as per NICE recommendations)

LAXATIVES GUANYLATE CYCLASE-C RECEPTOR AGONISTS

Linacotide 290microgram capsules

1.6 LOCAL PREPARATIONS FOR ANAL & RECTAL DISORDERS

LOCAL PREPARATIONS FOR ANAL AND RECTAL DISORDERS

1.6.1 SOOTHING HAEMORRHOIDAL PREPARATIONS

Anusol®
Cream, ointment & suppositories

1.7.2 PREPARATIONS WITH CORTICOSTEROIDS

Anusol HC® ointment & suppositories

1.7.3 RECTAL SCLEROSANTS

Phenol oily, B.P injection 5 %

1.7.4 Management of anal fissures

1st Choice: Glyceryl Trinitrate Rectal ointment 0.4% (Rectogesic®)

2nd Choice: Diltiazem
2 % cream (*Unlicensed*)

1.8 STOMA CARE

Stomahesive paste

1.9 DRUGS AFFECTING INTESTINAL SECRETION

1.9.1 DRUGS ACTING ON THE GALL BLADDER

Ursodeoxycholic acid
250 mg capsule, 150 mg tablet, 250 mg / 5 ml suspension

nPbR = Indicates a drug excluded from HRG tariff price

1.9.2 BILE ACID SEQUESTRANTS

Colestyramine (Cholestyramine)

4 g sachets

Notes: Other drugs should be taken at least 1 hour before or 4-6 hours after colestyramine to reduce possible interference with absorption

Colesevelam Hydrochloride

625mg tablets

1.9.4 PANCREATIN

Creon ® 10 000 capsule

2 CARDIOVASCULAR SYSTEM

2.1 POSITIVE INOTROPIC DRUGS

2.1.1 CARDIAC GLYCOSIDES

Digoxin

62.5, 125 & 250 micrograms tablets,
50 micrograms/ ml elixir,
500 micrograms/ 2 ml &
100 micrograms/ ml injection

Notes: Hypokalaemia predisposes to digoxin toxicity. Please note difference in bioavailability between the formulations. Use as a guide: **125 mcg tablet = 100 mcg elixir = 75 mcg injection**

DIGOXIN-SPECIFIC ANTIBODY

Digifab ® 40mg/vial digoxin immune Fab injection (RUM drug)

Notes: Please refer to Registrar or Consultant before issuing. BHR Labs measure digoxin levels in nmol/ L. The manufacturers use ng/ ml in the literature, hence conversion may be required. **(new level) ng/ ml= 0.78 X (level) nmol/ L**

2.1.2 PHOSPHODIESTERASE INHIBITORS

Milrinone 10 mg/ 10 ml injection
(RUM drug)
(ITU & Cardiologists only)

nPbR = Indicates a drug excluded from HRG tariff price

2.2 DIURETICS

2.2.1 THIAZIDES & RELATED DIURETICS

Bendroflumethiazide (Bendrofluazide)

2.5 & 5 mg tablets

Notes: Bendroflumethiazide 2.5mg daily is the drug of choice for mild-moderate hypertension. Allow 4 weeks for maximal antihypertensive effect of bendroflumethiazide

Indapamide 2.5mg & 1.5mg m/r tablets

Metolazone 5 mg tablet

Notes: Use metolazone with caution, especially when combined with loop diuretics. Monitor K⁺ and renal function

2.2.2 LOOP DIURETICS

1st choice: Furosemide

20 mg, 40 mg & 500 mg tablets,
20 mg/ 2 ml, 50 mg/ 5 ml &
250 mg/ 25 ml injection,
40 mg / 5 ml oral solution

2nd choice: Bumetanide 1 mg & 5 mg tablets,
1mg/ 5 ml liquid, 2 mg/ 4 ml injection

Note: At low doses 40 mg furosemide is equivalent to 1 mg bumetanide

2.2.3 POTASSIUM-SPARING DIURETICS

Amiloride

5 mg tablet, 5 mg/ 5 ml solution

Notes: Potassium sparing diuretics such as amiloride are usually necessary only if hypokalaemia develops

ALDOSTERONE ANTAGONISTS

1st choice: Spironolactone 25 mg & 100 mg tablets, 25 mg/ 5 ml & 100 mg/ 5 ml suspension, 1 mg/ ml suspension (for paediatrics, unlicensed)

Notes: Spironolactone is licensed only for congestive cardiac failure, nephrotic syndrome, ascites associated with cirrhosis or malignancy & primary aldosteronism

Alternative: Eplerenone 25 & 50mg tablet. For Spironolactone intolerant patients. In view of its high cost it will not replace Spironolactone.

2.2.4 POTASSIUM-SPARING DIURETICS WITH OTHER DIURETICS

Co-amiloride (amiloride/ furosemide) 2.5 mg/ 20 mg & 5 mg/ 40 mg tablet

Co-amilozone (amiloride/ hydrochlorothiazide) 2.5 mg/ 12.5 mg & 5mg/ 25 mg tablets

Co-triamterzide (triamterene/ hydrochlorothiazide) 50 mg/ 25 mg tablet

2.2.5 OSMOTIC DIURETICS

Mannitol 10 % & 20 % infusion

Notes: Crystal formation may occasionally occur in mannitol bags. These disappear on gentle warming before use

2.3 ANTI-ARRHYTHMIC DRUGS

nPbR = Indicates a drug excluded from HRG tariff price

SUPRAVENTRICULAR ARRHYTHMIAS

Adenosine 6 mg/ 2 ml injection

Dronedarone 400mg f/c tablets (as per NICE recommendations)

SUPRAVENTRICULAR & VENTRICULAR ARRHYTHMIAS

Amiodarone 100 mg & 200 mg tablets, 150 mg/ 3 ml injection, 300 mg/ 10 ml minijet (*Resus. only*)

Notes: Liver function & thyroid function tests should be performed at baseline & 6 monthly thereafter. A chest X-Ray should be done before treatment

Flecainide 50 mg & 100 mg tablets, 150 mg/ 15 ml injection

Disopyramide 100 mg capsule, 150 mg & 250 mg SR tablets, 50 mg/ 5 ml injection

Propafenone 150 mg tablet

Notes: Disopyramide, flecainide & propafenone should be used under the guidance of a Consultant Cardiologist only

DRUGS FOR VENTRICULAR ARRHYTHMIAS

Lidocaine (Lignocaine) 1% & 2 % injection, 0.1% & 0.2 %/ glucose 5 % infusion, 100 mg/ 10 ml minijet

Mexiletine 50 mg & 200 mg capsules, 250 mg/ 10 ml injection

Notes: This category of drugs should be used under the guidance of a Consultant Cardiologist only

2.4 BETA-ADRENOCEPTOR BLOCKING DRUGS

Atenolol 25 mg, 50 mg & 100 mg tablets, 25 mg/ 5 ml syrup, 5 mg/ 10ml injection

Metoprolol

50 mg tablet, 5 mg/ 5 ml injection

Propranolol

10 mg, 40 mg & 80 mg tablets,
80 mg & 160 mg SR tablets,
1 mg/ ml injection,
40 mg/ 5 ml oral solution,
10 mg/ 5 ml oral solution,
5 mg/ 5 ml oral solution,

Sotalol 40 mg & 80 mg tablets,
40 mg/ 4 ml injection

Bisoprolol 1.25 mg & 2.5 mg
5 mg & 10 mg tablets

Carvedilol 3.125 mg, 6.25 mg, 12.5 mg
& 25 mg tablets

Esmolol 100 mg/ 10 ml injection
(Theatres only)

Labetalol 50 mg & 100 mg tablets
100 mg/ 20 ml injection

**2.5 DRUGS AFFECTING THE
RENIN-ANGIOTENSIN SYSTEM &
OTHER ANTIHYPERTENSIVES**

**2.5.1 VASODILATOR
ANTIHYPERTENSIVE DRUGS**

Hydralazine

25 mg & 50 mg tablets,
20 mg/ ml injection

Sodium nitroprusside

50 mg/ 5 ml intravenous infusion

**2.5.2 CENTRALLY ACTING
ANTIHYPERTENSIVE DRUGS**

Methyldopa 250 mg/ 5 ml suspension,
125 mg, 250 mg & 500 mg tablet

**2.5.3 ADRENERGIC NEURONE
BLOCKING DRUGS**

Guanethidine 10 mg/ ml injection
(Day Stay (KGH), Dr Ather &
Orthopaedic surgeons (OCH) only)

**2.5.4 ALPHA-ADRENOCEPTOR
BLOCKING DRUGS**

Doxazosin 1 mg, 2 mg & 4 mg tablets

Phentolamine 10 mg/ ml injection

**2.5.5 DRUGS AFFECTING THE
RENIN-ANGIOTENSIN SYSTEM**

**2.5.5.1 ACE (ANGIOTENSIN
CONVERTING ENZYME) INHIBITORS**

1st Choice: Lisinopril

2.5 mg, 5 mg, 10 mg & 20 mg tablets

Alternative: Ramipril (*in accordance with
HOPE guidelines*)

1.25 mg, 2.5 mg & 5 mg & 10 mg tablets

Captopril

12.5 mg, 25 mg & 50 mg tablets

Notes: First dose hypotension can occur in patients who are taking high dose diuretics, volume depleted, on a low-sodium diet or with heart failure. The first dose should always be given at night. Caution with potassium-sparing diuretics. Urea & electrolytes should be checked within 1 week of commencing therapy

**2.5.5.2 ANGIOTENSIN 2 RECEPTOR
ANTAGONISTS**

Angiotensin 2 receptor antagonists (AR2As) should only be used when there is intolerance to ACE inhibitors e.g. cough

TREATMENT OF HYPERTENSION

1st Choice: Candesartan 2 mg, 4 mg & 8mg tablets

Alternative: Losartan 25mg, 50mg and 100mg tablets (*Licensed for Hypertensive patients with left ventricular hypertrophy except black patients*)

**RENAL PROTECTION IN TYPE 2
DIABETIC PATIENTS WITH
NEPHROPATHY**

1st Choice: Losartan (use when intolerant to ACE inhibitors)

TREATMENT OF HEART FAILURE

Sacubitril/Valsartan 24mg/ 26mg,
49mg/51mg & 97mg/103mg film coated
tablets (Entresto®)

nPbR = Indicates a drug excluded from HRG tariff price

(All AR2As are unlicensed for this indication, ACE inhibitors are 1st Choice)

Alternative: Candesartan (use when intolerant to ACE inhibitors)

2.5.5.3 RENIN INHIBITORS

Aliskiren 150mg & 300mg f/c tablets

(Consultant Cardiologists' and Dr. Fahal's use only). To be used as a 4th line agent after all other antihypertensives have been used at their maximum tolerated doses. Rx must include a consultant cardiologists' signature

2.6 NITRATES, CALCIUM-CHANNEL BLOCKERS & POTASSIUM-CHANNEL ACTIVATORS

2.6.1 NITRATES

Glyceryl trinitrate (GTN)

500 micrograms sublingual tablets,
400 micrograms/ dose sublingual spray,
2 mg & 5 mg buccal tablets,
50 mg/ 10 ml injection,
5 mg/ 5 ml injection,
5 mg & 10 mg patch

Isosorbide mononitrate

10 mg & 20 mg tablets & 60mg m/r tablets

Note: All other slow-release nitrates are non- formulary

2.6.2 CALCIUM-CHANNEL BLOCKERS

Notes: Bioavailability *may* vary between different formulations (brands) of diltiazem, verapamil & nifedipine. However, it is Trust policy to use formulations (brands) for diltiazem specified below.

Once daily preparations should be used only when compliance is a problem

Amlodipine 5 mg & 10 mg tablets

Diltiazem

(Twice or Three times daily preparation) 60 mg m/r tablet

(Twice daily preparation: Tildiem Retard)

90 mg, 120 mg & 180 mg m/r tablets

(Once daily formulation: Adizem XL)

120 mg, 180 mg, 200 mg, 240 mg & 300mg m/r capsules

Nifedipine 5 mg & 10 mg capsules,

(Twice daily preparation)

10 mg & 20 mg m/r tablets

(Once daily formulation)

20 mg, 30 mg & 60 mg m/r tablets

Notes: Nifedipine capsules are not recommended by the B.N.F. for angina prophylaxis & hypertension. It should be restricted to treatment of Raynaud's phenomenon only. For brands stocked, please ask pharmacy

Verapamil

40 mg, 80 mg & 120 mg tablets,
120 mg, 180 mg & 240 mg m/r capsules/
tablets,
5 mg/ 2 ml injection

Note: Verapamil frequently causes constipation & should be prescribed with a laxative, such as senna or docusate sodium

Nimodipine 30 mg tablet,

200 micrograms/ ml injection

Note: Nimodipine injection must be administered centrally

2.6.3 OTHER ANTIANGINAL DRUGS

Ivabradine 5mg & 7.5mg tablets

Note: Approved for 3rd line treatment of stable angina pectoris in patients who are intolerant to beta-blockers and diltiazem.

Ivabradine should be initiated in primary care only if there's access to a multidiplinary heart failure team. Dose titration and monitoring should be carried out by a heart failure specialist or in primary care by either a GP with a special interest in heart failure or a heart failure specialist nurse.

nPbR = Indicates a drug excluded from HRG tariff price

(To be restricted to senior members of medical Team)

Nicorandil 10 mg & 20 mg tablets

Ranolazine 375mg, 500mg & 750mg m/r tablets *(as per angina treatment pathway)*

2.6.4 PERIPHERAL & CEREBRAL VASODILATORS

Naftidrofuryl 100 mg capsule

Iloprost infusion

50 microgram/ 0.5 ml injection

(Unlicensed. Refer to the protocol. For severe Raynaud's phenomenon & limb-threatening peripheral arterial occlusive disease only)

Pentoxifylline (Oxpentifylline)

400mg tablet

(Consultant Vascular Surgeons only)

Note: Other peripheral vasodilators are considered less suitable for prescribing by the B.N.F

2.7 SYMPATHOMIMETICS

2.7.1 INOTROPIC

SYMPATHOMIMETICS

Dobutamine 250 mg/ 20 ml injection

Dopamine 200 mg/ 5 ml injection

Dopexamine 10 mg/ ml strong sterile solution *(ITU Consultants only)*

Notes: Dopamine must be administered into a major vein. Peripheral infusions may lead to skin necrosis & thrombophlebitis

See following pages for dobutamine & dopamine infusion tables

DOBUTAMINE INFUSION CHART**Concentration = 250 mg in 100 ml saline or 5 % glucose = 2500 micrograms per ml.****Give through a Baxter Floguard pump**

mcg/ kg/ min	2.5	3.0	4.0	5.0	6.0	7.0	8.0
Patient's Wt. (kg)	infusion rate in ml./hr. (100 ml syringe pump)						
55	3.3	4.0	5.3	6.6	7.9	9.2	10.6
60	3.6	4.3	5.8	7.2	8.6	10.1	11.5
65	3.9	4.7	6.2	7.8	9.4	10.9	12.5
70	4.2	5.0	6.7	8.4	10.1	11.8	13.4
75	4.5	5.4	7.2	9.0	10.8	12.6	14.4
80	4.8	5.8	7.7	9.6	11.5	13.4	15.4
85	5.1	6.1	8.2	10.2	12.2	14.3	16.3
90	5.4	6.5	8.6	10.8	13.0	15.1	17.3
95	5.7	6.8	9.1	11.4	13.7	16.0	18.2
100	6.0	7.2	9.6	12.0	14.4	16.8	19.2

mcg/ kg/ min	9.0	10.0	11.0	12.0	13.0	14.0	15.0
Patient's Wt. (kg)	infusion rate in ml./hr. (100 ml syringe pump)						
55	11.9	13.2	14.5	15.8	17.2	18.5	19.8
60	13.0	14.4	15.8	17.3	18.7	20.2	21.6
65	14.0	15.6	17.2	18.7	20.3	21.8	23.4
70	15.1	16.8	18.5	20.2	21.8	23.5	25.2
75	16.2	18.0	19.8	21.6	23.4	25.2	27.0
80	17.3	19.2	21.1	23.0	25.0	26.9	28.8
85	18.4	20.4	22.4	24.5	26.5	28.6	30.6
90	19.4	21.6	23.8	25.9	28.1	30.2	32.4
95	20.5	22.8	25.1	27.4	29.6	31.9	34.2
100	21.6	24.0	26.4	28.8	31.2	33.6	36.0

nPbR = Indicates a drug excluded from HRG tariff price

When using a 50 ml syringe pump add 250 mg dobutamine to 50 ml normal saline or 5% glucose and halve the above infusion rates.

DOPAMINE INFUSION CHART

Concentration = 200 mg in 100 ml saline or 5 % glucose = 2000 micrograms per ml.
Give through a Baxter Floguard pump

mcg/ kg/ min	2.5	3.0	4.0	5.0	6.0	7.0	8.0
Patient's Wt. (kg)	infusion rate in ml./hr.						
55	4.1	5.0	6.6	8.3	9.9	11.6	13.2
60	4.5	5.4	7.2	9.0	10.8	12.6	14.4
65	4.9	5.9	7.8	9.8	11.7	13.7	15.6
70	5.3	6.3	8.4	10.5	12.6	14.7	16.8
75	5.6	6.8	9.0	11.3	13.5	15.8	18.0
80	6.0	7.2	9.6	12.0	14.4	16.8	19.2
85	6.4	7.7	10.2	12.8	15.3	17.9	20.4
90	6.8	8.1	10.8	13.5	16.2	18.9	21.6
95	7.1	8.6	11.4	14.3	17.1	20.0	22.8
100	7.5	9.0	12.0	15.0	18.0	21.0	24.0

mcg/ kg/ min	9.0	10.0	11.0	12.0	13.0	14.0	15.0
Patient's Wt. (kg)	infusion rate in ml./hr. (100 ml syringe pump)						
55	14.9	16.5	18.2	19.8	21.5	23.1	24.8
60	16.2	18.0	19.8	21.6	23.4	25.2	27.0
65	17.6	19.5	21.5	23.4	25.4	27.3	29.3
70	18.9	21.0	23.1	25.2	27.3	29.4	31.5
75	20.3	22.5	24.8	27.0	29.3	31.5	33.8
80	21.6	24.0	26.4	28.8	31.2	33.6	36.0
85	23.0	25.5	28.1	30.6	33.2	35.7	38.3
90	24.3	27.0	29.7	32.4	35.1	37.8	40.5
95	25.7	28.5	31.4	34.2	37.1	39.9	42.8
100	27.0	30.0	33.0	36.0	39.0	42.0	45.0

When using a 50 ml syringe pump add 200 mg dopamine to 50 ml normal saline or 5% glucose and halve the above infusion rates.

nPbR = Indicates a drug excluded from HRG tariff price

2.7.2 VASOCONSTRICTOR SYMPATHOMIMETICS

Noradrenaline (Norepinephrine)
1 mg/ ml (1/1000) injection

Metaraminol injection 10 mg in 1 ml
(*Unlicensed*)

Phenylephrine 10 mg/ ml (1 %) injection

2.7.3 CARDIOPULMONARY RESUSCITATION

Adrenaline (Epinephrine)
1 mg/ 10 ml minijet

Notes: In accordance with the Trust Resuscitation Policy. See resuscitation drugs list for BHR. Any queries please consult the Resus. Officer.
NELMHT: Please refer to own policy

2.8 ANTICOAGULANTS & PROTAMINE

2.8.1 PARENTERAL ANTICOAGULANTS

Heparin sodium 1000 units/ ml, 5000 units/ ml, 25,000 units/ ml injection, 500 units/ 500 ml sodium chloride 0.9 % infusion

Heparin calcium injection
5000 units/ 0.2 ml prefilled syringe

LOW MOLECULAR WEIGHT HEPARINS

Dalteparin (Fragmin®) injection
2500units/ml 4ml ampoule
(for prophylaxis and treatment of thrombosis in children).
(*Consultant Haematologists and Paediatricians only*)

Enoxaparin (Clexane ®) injection
20 mg in 0.2 ml prefilled syringe
40 mg in 0.4 ml prefilled syringe
60 mg in 0.6 ml prefilled syringe
80 mg in 0.8 ml prefilled syringe

100 mg in 1.0 ml prefilled syringe
120 mg in 0.8 ml prefilled syringe
150 mg in 1.0 ml prefilled syringe

Notes: Monitor renal function and adjust dose if necessary. This should not delay first dosing, but subsequent dosing must be based on the results. Risk of bleeding is increased in severe renal impairment

Argatroban Monohydrate
(Exembol®)100mg/ml

HIRUDINS

Lepirudin
50 mg/ ml injection
(*Haematologists only*)

HEPARIN FLUSHES

Heparinised saline
50 units/ 5 ml injection
(*Paediatric & Hickman lines only*)

EPOPROSTENOL

nPbR Epoprostenol (Flolan®) 500 micrograms injection (*ITU/ HDU patients on haemofiltration with low platelets, SCBU, Vascular Surgeons, KGH only for Peripheral Vascular Disease, unlicensed*)

Fondaparinux sodium 5mg/ml injection
0.5ml pre-filled syringe

2.8.2 ORAL ANTICOAGULANTS

Warfarin 1 mg, 3 mg & 5 mg tablets

Alternative: Acenocoumarol (Nicoumalone)
1 mg tablet

Alternative: Phenindione 10 mg & 25 mg tablets

Rivaroxaban (Xarelto®) 2.5mg, 10mg, 15mg & 20mg film-coated tablet. (*For thromboprophylaxis following knee and hip replacement surgeries, orthopaedics use only*) & Treatment of VTE by Haematologists only. Also approved for prophylaxis of stroke and systemic

nPbR = Indicates a drug excluded from HRG tariff price

embolism in non-valvular atrial fibrillation by Haematologists, Cardiologists and Stroke physicians. Also approved for prophylaxis of atherothrombotic events following ACS as per NICE TA 335)

Apixaban (Eliquis®) 2.5mg & 5mg f/c tablets. *(For prophylaxis of stroke and systemic embolism in non-valvular atrial fibrillation by Haematologists, Cardiologists and Stroke physicians)*

Dabigatran (Pradaxa®) 75mg, 110mg & 150mg capsules. *(For prophylaxis of stroke and systemic embolism in non-valvular atrial fibrillation by Haematologists, Cardiologists and Stroke physicians)*

Edoxaban (Lixiana®) 60mg f/c tablet

(For preventing stroke and systemic embolism in people with non-valvular atrial fibrillation & for treating and preventing deep-vein thrombosis and pulmonary embolism as recommended by NICE TA354 & TA355)

2.8.3 PROTAMINE SULPHATE

Protamine sulphate 10 mg/ ml injection

2.9 ANTIPLATELET DRUGS

Aspirin 75 mg dispersible tablet

Notes: There is no evidence to support the use of enteric-coated aspirin preparations. These preparations are non-formulary.

Clopidogrel 75 mg tablet

Notes: **Clopidogrel** is restricted for intolerance or hypersensitivity to aspirin & for treatment of acute coronary syndrome (ACS)

Dipyridamole 200 mg m/r capsule, 25 mg & 100 mg tablets, 50 mg/ 5 ml suspension (*unlicensed*)

Notes: **Dipyridamole** tablets are licensed only for prophylaxis of thromboembolism associated with prosthetic heart valves.

Dipyridamole MR is also licensed for the secondary prevention of stroke or TIA (used alone or with aspirin)

Eptifibatide 2mg/ml injection
(Consultant Cardiologists only)

Prasugrel 5mg & 10mg f/c tablets

(1.For patients who have experienced a stent thrombosis during clopidogrel therapy.

2. On a consultant decision basis for selected high-risk patients with GRACE risk score ≥ 140 and low risk of bleeding meeting NICE criteria).

Ticagrelor 60mg & 90mg tablets

Notes: To be used according to NICE TA236 and NICE TA420

Abciximab

10 mg/ 5 ml injection

Refer to protocol

For administration of a bolus dose prior to transfer to the London Chest Hospital for acute MI patients for primary angioplasty.

(Consultant Neuro-Radiologist only, for thromboembolism involving cerebral arteries, unlicensed indication, needs patient consent)

2.10 MYOCARDIAL INFARCTION & FIBRINOLYSIS

2.10.2 FIBRINOLYTIC DRUGS

Streptokinase

250,000 units & 1.5 mega units injection

Notes: See B.N.F. for contra-indications to streptokinase. Refer to Trust ICP for CHD

Alteplase (Tissue Plasminogen Activator) (TPA)

nPbR = Indicates a drug excluded from HRG tariff price

50 mg injection
2mg (Actilyse Cathflo)

Alteplase (Actilyse Cathflo®) with Dornase Alpha (Pulmozyme) approved for Intrapleural administration for the treatment of Thoracic Empyema. (Respiratory consultants only)
See Protocol for administration of intrapleural alteplase and dnase for thoracic empyema at bhrut

Alteplase (Actilyse Cathflo®) approved for unblocking occluded small bore (Seldinger) chest drains. Protocol available on the Trust intranet.

Tenecteplase
50mg (10,000 units) injection

Urokinase injection
10,000 units & 50,000 units
(Unlicensed import, for unblocking TPN & Hickman lines only)

2.11 ANTIFIBRINOLYTIC DRUGS & HAEMOSTATICS

1st Choice: Tranexamic acid
500 mg tablet,
250 mg/ 2 ml injection

Etamsylate
500 mg tablet

Drotrecogin Alfa (activated)
Recombinant activated Protein C
(nPbR Drug)

NICE guidance: Drotrecogin alfa should be considered for adults with severe sepsis that has resulted in the failure of two or more major organs and who are receiving optimum intensive care support.

2.12 LIPID-REGULATING DRUGS

ANION-EXCHANGE RESINS

Colestyramine (Cholestyramine)

4 g sachet

Notes: other drugs should be taken at least 1 hour before or 4-6 hours after anion-exchange resins to reduce possible interference with absorption

EZETIMIBE

Ezetimibe 10 mg tablets

Notes: Ezetimibe is indicated for combination therapy with a statin and in patients intolerant to statins.

FIBRATES

Bezafibrate 200 mg & 400 mg tablets,
400 mg m/r tablet

STATINS

Atorvastatin

Pravastatin

Rosuvastatin

Simvastatin

Note: Statins, other than atorvastatin, should be taken at night for optimum effect

The following table recommends dosage advice for drugs which are known to interact with simvastatin, which may result in an increase in risk of myopathy or rhabdomyolosis

Interacting drug	Simvastatin Prescribing Recommendations
Erythromycin and Clarithromycin	Contraindicated. If unavoidable, suspend Simvastatin during course of treatment.
Ciclosporin	Maximum 10mg daily
Amiodarone	Maximum 20mg daily
Verapamil	Maximum 20mg daily
Diltiazem	Maximum 40mg daily
Warfarin	Caution: monitor INR

nPbR = Indicates a drug excluded from HRG tariff price

HIV protease inhibitors	Use Pravastatin
Grapefruit juice	AVOID

Note: The above list is not exhaustive. Please refer to the current edition of the BNF for further advice

Note: 600 mg Acetylcysteine injection can also be given orally (mixed with cola or orange juice) twice daily for 2 days, in those patients with renal dysfunction. First dose starting evening before angiogram. This is to protect the kidney from damage by the contrast dye. Please refer to ICP for Angiogram

LIPID-MODIFYING DRUG – OTHER

Alirocumab (Praluent®) 75mg/1ml & 150mg/1ml solution for injection pre-filled pen

Evolocumab (Repatha® and Repatha Sureclick) 140mg/1ml solution for injection pre-filled syringes/pre-filled disposable devices

Omega-3-Acid Ethyl Esters (Omacor ®) 1 g capsules)

Approved for anti-retroviral induced hyperlipidemia not responding to statins (GU and HIV initiation only)

2.13 LOCAL SCLEROSANTS

Absolute alcohol injection

Ethanolamine oleate injection

Sodium tetradecyl sulphate 0.5 %, 1 % & 3 % injection

2.14 PRE-ANGIOGRAM

Acetylcysteine (Parvolex ®) 2g/ 10 ml injection- *Unlicensed use*

N-Acetylcysteine 600mg tablets (*unlicensed*), to be used prophylactically before angiogram and in combination with prednisolone and azathioprine for the long-term management of patients with Idiopathic Pulmonary fibrosis.

nPbR = Indicates a drug excluded from HRG tariff price

3 RESPIRATORY SYSTEM

3.1 BRONCHODILATORS

3.1.1 ADRENOCEPTOR AGONISTS

3.1.1.1 SELECTIVE BETA₂ AGONISTS

1st Choice: Salbutamol

100 micrograms/ dose inhaler (CFC Free), 100 micrograms Easibreathe (mdi), Easyhaler, 2.5 mg/ 2.5 ml & 5 mg/ 2.5 ml nebuliser solution, 500 micrograms/ ml injection, 100 micrograms/ dose autohaler, 5 mg/ 5 ml injection for infusion, 2 mg & 4 mg tablets, 2 mg/ 5 ml syrup

Alternative: Terbutaline

250 micrograms/ dose inhaler, 500 micrograms/ dose turbobaler (dpi) (*Respiratory Physicians & Paediatricians only*)

LONG ACTING BETA₂ AGONISTS

1st Choice: Salmeterol

25 micrograms/ dose inhaler and 50 micrograms/ blister Accuhaler (in accordance with BTS guidelines)

Alternative: Formoterol (Eformoterol)

6 micrograms & 12 micrograms/ dose turbobaler

Indacaterol 150 & 300 microgram inhalation powder capsules (**Onbrez®**)

Indacaterol with Glycopyrronium 85/43 micrograms per dose (**Ultibro Breezhaler®**)

Olodaterol 2.5microgram per dose (**Striverdi Respimat®**)

Olodaterol with Tiotropium 2.5/2.5 micrograms/ per dose (**Spiolto Respimat®**)

3.1.2 ANTIMUSCARINIC BRONCHODILATORS and COMBINATIONS

Acridinium 400 micrograms/metered inhalation powder (**Eklira Genuair®**)

Acridinium with Formoterol 340micrograms/ 12 micrograms per dose (**Duaklir Genuair®**)

Glycopyrronium

50 micrograms/ hard capsule (inhalation powder) **Seebri Breezhaler®**

Ipratropium bromide

20 micrograms/ dose inhaler (CFC Free) 250 micrograms/ ml & 500 micrograms/ 2 ml nebuliser solution

Tiotropium

18 micrograms/ capsule (Dry powder for inhalation) “**Spiriva®**”

2.5 micrograms/metered inhalation (solution for inhalation) “**Respimat®**”

Umeclidinium bromide

55 micrograms/dose (dpi) (**Incruse®**)

Umeclidinium with Vilanterol 55/22 micrograms per dose (**Anoro Ellipta®**)

Notes: Spacers, autohalers & turbobalers are available for patients who are unable to use aerosol metered dose inhalers

3.1.3 THEOPHYLLINE

Aminophylline

250 mg/ 10 ml injection (**Phyllocontin Continus®**)

nPbR = Indicates a drug excluded from HRG tariff price

225 mg M/R tablet (being discontinued in the UK)

(Phyllocontin Forte Continus)

350mg M/R tablet (being discontinued in the UK)

Theophylline

(Uniphyllin Continus ®)

200 mg, 300 mg & 400 mg m/r tablets

(Slo-Phyllin ®)

60 mg, 125 mg & 250 mg m/r capsule

Notes: The brand name should be specified when prescribing m/r preparations of theophylline to distinguish one from another. The different formulations should not be regarded as interchangeable.

Caution when co-prescribing drugs which can affect metabolism of theophyllines, e.g. cimetidine, erythromycin, warfarin & ciprofloxacin

Caffeine citrate

10 mg/ ml solution & injection (as base)

(Unlicensed, neonates only)

3.1.5 PEAK FLOW METERS, INHALER DEVICES & NEBULISERS

Aerochamber

Volumatic

Nebuhaler

Haleraid

Peak flow meters

3.2 CORTICOSTEROIDS

1st Choice in adults: Beclometasone (CFC-free) (QVAR ®)

50 micrograms/ dose &

100 micrograms/ dose inhaler

(NOT recommended in children)

Beclomethasone & Formoterol

Fostair® and Fostair® NEXThaler

100 micrograms/ 6 micrograms/metered inhalation

200micrograms/6micrograms/metered inhalation

Beclometasone & Formoterol & Glycopyrronium Trimbrow®

87micrograms/5 micrograms/9 micrograms/metered inhalation

Budesonide 50 micrograms/ dose &

200 micrograms/ dose inhaler,

100 micrograms/ dose,

200 micrograms/ dose &

400 micrograms/ dose turbohaler

500 micrograms/ 2ml & 1 mg/ 2 ml respules

Budesonide & Formoterol

Symbicort ® 100/ 6 & 200/ 6 turbohaler

Duoresp Spiromax®160/4.5 & 320/9

micrograms

Fluticasone

50 micrograms/ dose,

125 micrograms/ dose &

250 micrograms/ dose inhaler

Fluticasone & formoterol

Flutiform® 50/5 micrograms,

125/5micrograms & 250/10

micrograms inhalers

Fluticasone & Salmeterol

Seretide® 50, 125, 250 Evohalers

100, 250micrograms & 500micrograms

Accuhalers

Fluticasone & Vilanterol

Relvar Ellipta®

92/22 micrograms per dose

Fluticasone & Umeclidinium &

Vilanterol

Trelegy Ellipta®

92 micrograms/55 micrograms/22

micrograms per dose

3.3 CROMOGLICATE, RELATED THERAPY & LEUKOTRIENE RECEPTOR ANTAGONISTS

nPbR = Indicates a drug excluded from HRG tariff price

3.3.1 CROMOGLICATE & RELATED THERAPY

Sodium cromoglicate

5 mg/ dose inhaler (*Paediatricians & Respiratory Physicians only*)

Nedocromil sodium 2 mg/ dose inhaler (*Respiratory Physicians only*)

Notes: Cromoglycate is more effective in children than adults. It may be useful in adults with 'exercise-induced' asthma

3.3.2 LEUKOTRIENE RECEPTOR ANTAGONISTS

Montelukast

10 mg tablet- Licensed for adults
5 mg chewable tablets- Licensed for 6-14 years of age.
4mg chewable tablets- Licensed for 2-5 years of age
Paediatric 4mg granules- Licensed for Paediatric patients aged 6 months- 5 years of age

Notes: Use in accordance with BTS guidelines

3.3 Phosphodiesterase type-4 inhibitor

Roflumilast 500micrograms fill-coated tablets

(*For the treatment of COPD- NICE TA 461*)

3.4 ANTIHISTAMINES, HYPOSENSITISATION & ALLERGIC EMERGENCIES

3.4.1 ANTIHISTAMINES

NON-SEDATING ANTIHISTAMINES

1st Choice: Cetirizine
(For adults and children 6 years and over)

10 mg tablet
5 mg/ 5 ml oral solution

(Not licensed for under 6 years)

Alternative: Desloratadine
(For children 1-5 years of age)

Syrup 2.5mg/5 mL
(Licensed for use in children 1-5 years of age)

Alternative: Fexofenadine

120 mg tablet- Licensed for Seasonal Allergic Rhinitis

180 mg tablet- Licensed for Chronic Idiopathic Urticaria

SEDATING ANTIHISTAMINES

Chlorphenamine (Chlorpheniramine)

4 mg tablet, 2 mg/ 5 ml syrup,
10 mg/ ml injection

Hydroxyzine

10 mg & 25 mg tablets,
10 mg/ 5 ml syrup

Promethazine hydrochloride

10 mg & 25 mg tablets, 5 mg/ 5ml elixir,
25 mg/ ml injection,

Alimemazine (Trimeprazine)

10 mg tablet, 7.5 mg/ 5 ml &
30 mg/ 5 ml syrup

3.4.3 ALLERGIC EMERGENCIES

Adrenaline (Epinephrine)

S/C or IM injection 1 in 1,000 (1 mg/ ml),
Min-I-Jet ® 1 in 1000 (1 mg/ ml),
EpiPen ® IM injection for self-administration,
IV injection 1 in 10,000 (1 mg/ 10 ml)
IV injection 5 mg/ 5 ml

Warning: Note strengths of adrenaline. See Anaphylaxis policy for more details

nPbR = Indicates a drug excluded from HRG tariff price

3.5 RESPIRATORY STIMULANTS & PULMONARY SURFACTANTS

3.5.1 RESPIRATORY STIMULANTS

Doxapram 1000 mg/ 500 ml infusion, 100 mg/ 5 ml injection

3.5.2 PULMONARY SURFACTANTS

Poractant alfa (Curosurf®)
120 mg/ 1.5 ml solution

3.7 MUCOLYTICS

Carbocisteine 375 mg capsules
250mg/5ml syrup
(Prescribe according to NICE guidelines)

Sodium Chloride 3% and 6% nebuliser solution (Mucoclear®)

Dornase Alfa 2.5mg/2.5mg nebuliser liquid (Pulmozyme)

Alteplase (Actilyse Cathflo®) with Dornase Alpha (Pulmozyme) approved for Intrapleural administration for the treatment of Thoracic Empyema. (Respiratory consultants only)

See Protocol for administration of intrapleural alteplase and dnase for thoracic empyema at bhrut

3.8 AROMATIC INHALATIONS

Benzoin Tincture Compound BP
Add one 5ml spoonful to a pint of hot, not boiling water and inhale the vapour

3.9 COUGH PREPARATIONS

COUGH SUPPRESSANTS

DEMULCENTS

Simple linctus BP (sugar free)

Pholcodine linctus (sugar free)

5 mg/ 5 ml

Codeine linctus BP

15 mg/ 5 ml

Menthol & Eucalyptus Inhalation BP

3.10 SYSTEMIC NASAL DECONGESTANTS

Pseudoephedrine
60 mg tablet, 30 mg/ 5 ml elixir

3.11 PRODUCTS FOR PLEURODESIS

Sterile Talc powder
(Unlicensed, Respiratory physicians only)

Notes: Sterile talc powder administered by doctor, in accordance with protocol. Usually 4g in 30 ml sodium chloride 0.9 % injection. Once procedure complete flush with 20 ml sodium chloride 0.9 % injection

Tetracycline
500 mg injection
(Unlicensed product for Pleurodesis. Respiratory physicians only)

nPbR = Indicates a drug excluded from HRG tariff price

4 CENTRAL NERVOUS SYSTEM

Notes: The NELMHT formulary is under revision. If there are any queries regarding psychiatric drugs, please contact the Principal Pharmacist for Mental Health

4.1 HYPNOTICS & ANXIOLYTICS

4.1.1 HYPNOTICS

Temazepam (CD)

10 mg tablet, 10 mg/ 5 ml syrup

Zopiclone 3.75 mg & 7.5 mg tablets

Zolpidem 5 mg & 10 mg tablets
(*Psychiatrists only*)

Notes: Hypnotics should be used only where insomnia is severe, disabling or where patient is extremely distressed, after due consideration to non-pharmacological measures. NICE recommends that they may be prescribed for one to two weeks. Tolerance/dependence develops rapidly

Chloral hydrate

500mg/ 5 ml mixture (*unlicensed*),
25 mg, 50 mg & 100 mg suppositories
(*unlicensed*)
143 mg/ 5 ml elixir
(*Paediatrics only*)

Cloral betaine (Welldorm ®)

707 mg tablet = 414 mg chloral hydrate

Clomethiazole 192 mg capsule,
250 mg/ 5 ml syrup (edisylate)

Note: Clomethiazole should not be used for alcohol withdrawal

Promethazine hydrochloride

10 mg & 25 mg tablets,
5 mg/ 5 ml elixir, 25 mg/ ml injection

Melatonin 2mg Capsule

Approved for insomnia and delirium in ICU patients)

Melatonin 2mg M/R tablet (Circadin®)

Approved for primary insomnia in patients over 55 years of age. For hospital use only up to a maximum of 13weeks. Initiation by Care of the Elderly consultants or Older Persons Psychiatrist only. On rare occasions, if required on discharge, review and clear documentation on discharge summary by initiating Care of the Elderly consultant or Older Persons Psychiatrist.

Approved for insomnia and delirium in ICU patients)

4.1.2 ANXIOLYTICS

Diazepam

2 mg & 5 mg tablets,
2 mg/ 5 ml oral solution,
10 mg/ 2 ml injection,
10 mg/ 2 ml (emulsion) injection,
2.5 mg, 5 mg & 10 mg per dose rectal tubes (solution)

Chlordiazepoxide

5 mg capsule, 10 mg tablet

Note: Chlordiazepoxide is the drug of choice for control of alcohol withdrawal

Lorazepam

1 mg tablet, 4 mg/ ml injection

4.2 DRUGS USED IN PSYCHOSES & RELATED DISORDERS

4.2.1 ANTIPSYCHOTIC DRUGS

Chlorpromazine

10 mg, 25 mg, 50 mg & 100 mg tablets,
25 mg/ 5 ml oral solution, 100 mg/ 5 ml syrup, 50 mg/ 2 ml injection

nPbR = Indicates a drug excluded from HRG tariff price

Note: Injection not to be used on psychiatric wards

Haloperidol

500 micrograms capsule,
1.5 mg, 5 mg & 10 mg tablets,
10 mg/ 5 ml liquid,
5 mg/ ml.

Haoperidol Decanoate

50 mg/ ml, 100mg/ml injection

Sulpiride

200 mg & 400 mg tablets,
200 mg/ 5 ml oral solution
(*Psychiatrists only*)

Trifluoperazine

1 mg & 5 mg tablets, 1 mg/ 5 ml
& 5 mg/ 5 ml oral solution

Zuclopenthixol dihydrochloride

2 mg, 10 mg & 25 mg tablets
(*Psychiatrists only*)

Zuclopenthixol acetate

(Clopixol Accuphase ®)
50 mg/ ml & 100mg/ 2 ml injection
(*Psychiatrists only*)

ATYPICAL ANTIPSYCHOTICS

Olanzapine

2.5 mg, 5 mg, 7.5 mg & 10 mg tablets,
5 mg, 10 mg, 15mg, 20mg oro-dispersible
tablets,
5 mg/ ml injection
(*see notes below on tablets & injection*)

tablets: *Neurologists for Parkinson's
psychosis, unlicensed use & Psychiatrists
only,*

injection: *Psychiatrists only*

Amisulpride

50 mg & 200 mg tablets,
100 mg/ ml oral solution
(*Psychiatrists only*)

Aripiprazole

7.5mg/ml vials (Abilify 9.75mg/1.3ml)
(*Restricted for Rapid Tranquilisation only*)

Clozapine 25 mg & 100 mg tablets
(*Psychiatrists only*)

Notes: For clozapine, the patient & Consultant must be registered with the clozapine monitoring system. Monitoring of white blood cell counts & neutrophils is mandatory. Consult pharmacy for further advice

Quetiapine

25 mg, 100 mg, 150 mg & 200 mg tablets
(*Neurologists for Parkinson's psychosis
(unlicensed use) & Psychiatrists only*)

Risperidone 1 mg/ ml liquid,
0.5 mg, 1 mg, 2 mg, 3 mg & 4 mg &
6 mg tablets, 1mg and 2mg

Orodispersible tablet, 25mg injection
(*Neurologists for Parkinson's psychosis,
unlicensed use & Psychiatrists only*)

Notes: The Committee on Safety of Medicines (CSM) has advised that risperidone or olanzapine should not be used for the treatment of behavioural symptoms of dementia because there is clear evidence of an increased risk of stroke in elderly patients with dementia. The mechanism by which these drugs are associated with stroke is unknown

4.2.2 ANTIPSYCHOTIC DEPOT INJECTIONS

4.2.3 ANTIMANIC DRUGS

Lithium carbonate

Camcolit ® 250 mg & 400 mg tablets
Priadel ® 200 mg & 400 mg m/r tablets
(*Psychiatrists only*)

Lithium citrate

Priadel ® 520 mg/ 5 ml liquid

Note: Lithium carbonate 204 mg is equivalent to 520 mg lithium citrate tetrahydrate

Valproic acid (Depakote ®)
250 mg & 500 mg e/c tablets
(*Psychiatrists only*)

nPbR = Indicates a drug excluded from HRG tariff price

Notes: Depakote ® is licensed for the treatment of manic episodes associated with bipolar disorder. This is not for maintenance therapy

4.3 ANTIDEPRESSANT DRUGS

4.3.1 TRICYCLIC & RELATED ANTIDEPRESSANTS

Amitriptyline

10 mg, 25 mg & 50 mg tablets,
25 mg/ 5 ml & 50 mg/ 5 ml oral solution

Dosulepin (Dothiepin)

25 mg capsule, 75 mg tablets,
25 mg/ 5 ml & 75 mg/ 5 ml liquid

Lofepamine

70 mg tablet, 70 mg/ 5 ml suspension

Imipramine

10 mg & 25 mg tablets,
25 mg/ 5 ml syrup

RELATED ANTIDEPRESSANTS

4.3.2 MONOAMINE-OXIDASE INHIBITORS (MAOI's)

4.3.3 SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRI's)

Fluoxetine

20 mg & 60 mg capsules,
20 mg/ 5 ml liquid

Sertraline 50 mg & 100 mg tablets

Citalopram

10mg & 20 mg tablet, 40 mg/ ml liquid

Notes: The dose used for citalopram liquid is lower than that given for the tablets. A 20 mg tablet is equivalent to 16 mg (8 drops) of the oral liquid

Paroxetine 20 mg & 30 mg tablets,
10 mg/ 5 ml liquid

Note: Recommended adult daily dose of paroxetine for depression is 20 mg

4.3.4 OTHER ANTIDEPRESSANTS

Duloxetine 30mg & 60mg capsules

(Treatment of diabetic neuropathic pain in adults, after tricyclic antidepressants and as an alternative to pregabalin)

Flupentixol (Flupenthixol)

500 micrograms & 1 mg tablets
(Consultant Psychiatrists only)

Mirtazapine 30mg and 45mg tablets, 15 mg, 30 mg & 45 mg oro-dispersible tablets

(Neurologists & Psychiatrists initiation only)

Venlafaxine

37.5 mg & 75 mg tablets,

75 mg & 150 mg m/r capsules

(Consultant Psychiatrists & Dr Quigley for menopausal symptoms in patients on tamoxifen, and/ or who are post chemotherapy, unlicensed use)

Notes: All antidepressants take up to 14 days or more for full therapeutic effect & adequate doses are needed.

Of the tricyclics, amitriptyline & dosulepin carry the greatest risk in overdose.

SSRI's have fewer antimuscarinic & cardiotoxic side effects than the tricyclics. However, they must still be used in caution in patients with poorly controlled epilepsy, cardiac disease & renal or hepatic impairment. Caution in pregnancy, consult Medicines Information. SSRI's are preferred in the elderly. Obtain advice when stopping or changing an antidepressant

4.4 CENTRAL NERVOUS SYSTEM STIMULANTS

Dexamfetamine (CD) 5 mg tablet

(Psychiatrists)

Methylphenidate 10 mg tablet,

18 mg & 36 mg m/r tablets (Concerta XL ®)

(Consultant Paediatricians, Psychiatrists only)

nPbR = Indicates a drug excluded from HRG tariff price

Solriamfetol 75mg & 150mg tablet.
NICE TA758

4.5 DRUGS USED IN THE TREATMENT OF OBESITY

Methylcellulose 500 mg tablet -
Discontinued

Orlistat 120 mg capsule
(*Dr Pearson only*)

4.6 DRUGS USED IN NAUSEA & VERTIGO

ANTIHISTAMINES

Cinnarizine
15 mg tablet

Cyclizine
50 mg tablet, 50 mg/ ml injection

Promethazine teoclate 25 mg tablet

Promethazine hydrochloride
(*See section 3.4.1 for formulations*)

PHENOTHIAZINES & RELATED DRUGS

Prochlorperazine
5 mg tablets, 5 mg/ 5 ml syrup,
5 mg & 25 mg suppositories,
12.5 mg/ ml injection (*IM only*)

Levomepromazine
(**Methotrimeprazine**)
25 mg tablet, 25 mg/ ml injection
(*Oncologists, Haematologists & Palliative care team only*)

DOMPERIDONE & METOCLOPRAMIDE

Metoclopramide
10 mg tablet, 5 mg/ 5 ml oral solution,
10 mg/ 2 ml injection

Notes: Metoclopramide may induce dystonic reactions, especially in young children, young adults and the elderly. Use of metoclopramide in patients under 20 years is not recommended. May cause confusion in the elderly. Avoid in Parkinson's disease

Domperidone
10 mg tablet, 5 mg/ 5 ml suspension,
30 mg suppositories

Note: Domperidone is less likely to cause central effects such as sedation & dystonic reactions

5-HT₃ ANTAGONISTS

1st Choice: Ondansetron
4mg & 8 mg tablets, 4 mg/ 5 ml syrup
4mg/ 2 ml & 8 mg/ 4 ml injection

2nd Choice: Granisetron
1 mg tablet, 1 mg/ 5 ml liquid,
1 mg/ ml injection

Aprepitant

Fosaprepitant (Ivemend)
150mg IV infusion

Palonosetron with netupitant
300mg/0.5mg capsules (**Akynzeo®**)

HYOSCINE

Hyoscine hydrobromide
300 micrograms tablet,
Scopoderm TTS ® 1.5 mg patch
(absorption of 1 mg/ 72 hour)
(*Unlicensed use to reduce secretions*)

OTHER DRUGS FOR MÉNIÈRE'S DISEASE

Betahistine 8 mg tablets

4.7 ANALGESICS

4.7.1 NON-OPIOID ANALGESICS

Aspirin
75mg dispersible tablets
300 mg dispersible tablets
300mg suppositories
500mg injection (unlicensed)

Paracetamol
500 mg tablet & dispersible tablets
120 mg/ 5 ml & 250 mg/ 5 ml suspension

nPbR = Indicates a drug excluded from HRG tariff price

15 mg, 30 mg &
60 mg suppositories (*Unlicensed*)
125 mg, 250 mg, 500 mg and 1g
suppositories
1g/100ml IV infusion
(IV infusion for intra- and post-operative
use for patients nil-by-mouth or unable to
take drugs by other routes)

**Co-dydramol (dihydrocodeine/
paracetamol) 10/ 500 tablet**

Co-codamol (codeine/ paracetamol)
8/ 500 tablet
8/ 500 effervescent tablet

Co-codamol (codeine/ paracetamol)
30/ 500 capsule or tablet
Note: Use separate tablets of 30mg
codeine and paracetamol where possible
as this is much cheaper

4.7.2 OPIOID ANALGESICS

**Refer to Management of acute and
chronic pain in adults policy**

Morphine sulphate injection (CD)
10mg, 15mg, 20mg and 30mg injection
100mg/ 50ml injection vials
50mg/ 50ml injection vials for PCA and
also pre-prepared as 50mg/50ml PCA
syringes

Morphine sulphate slow release (CD)
5 mg, 10 mg, 15 mg, 30 mg,
60 mg, 100 mg & 200 mg m/r tablets,
20 mg & 30 mg m/r granules

**Morphine sulphate oral solution
(Oramorph ®) (CD)**
10 mg/ 5 ml oral solution
100 mg/ 5 ml oral concentrated oral
solution,
10 mg/ 5 ml unit dose vials

**Morphine sulphate tablets- immediate
release
(Sevredol ®) (CD) 10 mg and 20mg**

Cyclimorph ® (CD)
Morphine sulphate (10 mg/ ml) &
cyclizine (50 mg/ ml) injection

Buprenorphine (CD) (Transtec ®)

300 micrograms injection
200 micrograms S/L tablet
35, 52.5 & 70 micrograms patches

*The Transtec patches should be changed
every 96 hours (4 days). For convenience
the patch can be changed twice a week
at regular intervals e.g. on Mondays and
Thursdays.*

(Patches: for chronic pain only)

Buprenorphine (CD) (BuTrans®)

Patches
Change Butrans patch every 7 days.
5 micrograms/hour
10 micrograms/hour
20 micrograms/hour
(Pain team only)

Codeine phosphate

15 mg & 30 mg tablets
25mg/ 5ml syrup
15mg/ 5ml linctus
30mg/ ml injection (CD) (*Unlicensed*)

Diamorphine hydrochloride (CD)

5 mg, 10 mg, 30 mg, 100 mg &
500 mg injections

Dihydrocodeine tartrate

30 mg tablet, 10 mg/ 5 ml elixir,
50 mg/ ml injection (CD)

Fentanyl (CD)

25 micrograms/ hour,
50 micrograms/ hour,
75 micrograms/ hour &
100 micrograms/ hour patches
200 micrograms, 400 micrograms, 600
micrograms & 800 micrograms
Sublingual tablet (“**Abstral ®**”)
100micrograms & 400micrograms/dose
nasal spray

*(Sublingual tablets are for Palliative care
team prescribing only as per Trust
guidelines)*

Notes: Fentanyl patches and sublingual
tablet are suitable for use only in those
patients with unacceptable opioid toxicity,

nPbR = Indicates a drug excluded from HRG tariff price

where oral route is unavailable, or when recommended by the Palliative care team. If patients are intolerant to morphine, oxycodone should be tried before fentanyl patches are prescribed. Each replacement patch should be applied to a non-hairy, different area of the body. The patches are not suitable for patients with chronic skin disorders

Meptazinol

200 mg tablet, 100 mg/ ml injection

Oxycodone hydrochloride oral-immediate release (CD) (OxyNorm ®)

5 mg, 10 mg & 20 mg capsules
5mg/ 5ml oral solution
50mg/5ml concentrated oral solution

Oxycodone hydrochloride- slow release (CD) (OxyContin ®)

5 mg, 10 mg, 20 mg,
40 mg & 80 mg m/r tablets

Oxycodone injection (CD) (OxyNorm)

10mg and 20mg injection
(For patients unable to tolerate morphine, in accordance with Trust guidelines)

Oxycodone injection (CD) (Oxynorm)

50mg in 1ml ampoule
[Approved for second line use for intravenous patient-controlled analgesia (PCA) and restricted to the Paim team]

Papaveretum (CD) 15.4 mg/ ml injection

Pethidine hydrochloride (CD)

50 mg tablet,
50 mg/ ml & 100 mg/ 2 ml injection
(Injection no longer used in A&E)

Notes: Pethidine is weaker than morphine or diamorphine & has a shorter duration of action. It is used mainly in obstetrics as it may cause less respiratory depression in the neonate.

It should not be used for continuous pain as toxic metabolites may accumulate on

extended use. Refer to acute, chronic pain & palliative care guidelines

Tramadol hydrochloride

50 mg capsules, 50 mg dispersible tablets, 100 mg & 200 mg m/r capsules & 100 mg/ 2 ml injection
(Refer to Management of acute and chronic pain policy)

Notes: NSAIDs are a useful addition in moderate to severe bony or musculo-skeletal pain, except where contraindicated. Enteric coated tablets should not be prescribed prn, as this has a delayed onset of action.

Laxatives: Narcotic analgesics will almost always require co-prescribing of laxatives

4.7.3 NEUROPATHIC PAIN

Carbamazepine, Amitriptyline or Sodium valproate *(Unlicensed indication)*
(see sections 4.3.1 & 4.8.1 for preparations)

Gabapentin

100 mg & 300 mg capsules
400mg tablets
(Not 1st line for trigeminal neuralgia)

4.7.4 ANTIMIGRAINE DRUGS

4.7.4.1 TREATMENT OF THE ACUTE MIGRAINE ATTACK

Notes: Simple analgesic such as paracetamol or a NSAID is often effective. Concomitant antiemetic may be required

1st Choice: Sumatriptan

50 mg & 100 mg tablets,
6 mg/ 0.5 ml injection

Note: Sumatriptan is to be used only when treatment with conventional analgesics & antiemetics have failed

2nd Choice: Zolmitriptan

2.5 mg tablet

4.7.4.2 PROPHYLAXIS OF MIGRAINE **Pizotifen**

nPbR = Indicates a drug excluded from HRG tariff price

500 micrograms & 1.5 mg tablets,
250 micrograms/ 5 ml elixir - **discontinued**

Clonidine 25 micrograms tablet

Methysergide 1 mg tablet - **discontinued**
(*Neurologists only*)

Propranolol
(*see section 2.4 for formulations*)

Flunarizine 5mg & 10mg tablets
(*Consultant Neurologists only*)

Stock will be ordered as needed

Erenumab (Aimovig) 70mg/ml &
140mg/ml solution of injection in pre-filled
pen (NICE TA682)

Fremanezumab (Ajovy) 225mg solution
of injection in pre-filled pen (Neurology
Only)

Galcanezumab (Emgality) 120mg/ml
solution of injection in pre-filled pen
(NICE TA659)

4.8 ANTIEPILEPTICS

4.8.1 CONTROL OF EPILEPSY

Brivaracetam (Briviact®) 10mg, 25mg,
50mg, 75mg and 100mg tablets,
10mg/ml oral solution and 50mg/5ml
solution for injection

(*Brivaracetam can only be initiated by an
epileptologist or neurologist with
special interest in epilepsy*)

Cannabidiol
100mg per ml oral solution

Carbamazepine
100 mg & 200 mg tablets,
200 mg & 400 mg m/r tablets,
100 mg/ 5 ml syrup,
125 mg & 250 mg suppositories

Eslicarbazepine 800 mg tablets

Oxcarbazepine 150mg, 300mg and
600mg tablets

Ethosuximide
250 mg capsules, 250 mg/ 5 ml syrup

Gabapentin
100 mg, 300 mg & 400mg capsules

Lacosamide 50mg, 150mg, 200mg f/c
tablets, 10mg/ml syrup and 10mg/ml
solution for infusion

Lamotrigine
25 mg 50 mg & 100 mg tablets
5 mg, 25 mg & 100 mg dispersible
tablets

Levetiracetam
250 mg, 500 mg & 1g tablets 100mg/ml
oral solution

Notes: Levetiracetam is for the
treatment of adults as per NICE
guidance. This includes patients who
have not benefited from treatment with
older antiepileptic drugs, or in whom
older drugs are unsuitable due to contra-
indications, interactions or poor
tolerability

(*Also for Consultant Paediatrician
initiation as add-on treatment for the
control of refractory partial seizures with
or without secondary generalisation in
children already on one or two
anticonvulsants*)

Perampanel (Fycompa®) 2mg, 4mg,
6mg, 8mg, 10mg, 12mg tablets

Phenobarbital (Phenobarbitone) (CD)
15 mg & 30 mg tablets,
15 mg/ 5 ml elixir (*contains alcohol*),
50 mg/ 5 ml suspension (*alcohol, sugar
& colour free, unlicensed preparation.*
Used in paediatrics & neonates)
15 mg/ ml, 30mg/ ml, 60 mg/ ml &
200 mg/ ml injection

Primidone 250 mg tablet

Phenytoin 25 mg 50 mg & 100 mg &
300 mg capsules, 30 mg/ 5 ml
suspension, 250 mg/ 5 ml injection

nPbR = Indicates a drug excluded from HRG tariff price

Note: 90 mg in 15 ml phenytoin (base) suspension is equivalent to 100 mg phenytoin sodium tablet or capsule. Patients admitted on tablets or Infatabs should remain on these preparations

Rufinamide 100mg, 200mg and 400mg tablets (*Specialist Paediatric Consultants Only*)

Note: For 2nd line treatment of Lennox-Gastaut syndrome in children who are refractory to other treatment and on multiple anti-epileptic agents.

GPs will only prescribe once patients have been stabilised in hospital.

Sodium valproate (Epilim)

100 mg crushable tablet, 200 mg & 500 mg e/c tablets, 200 mg/ 5 ml liquid, 400 mg injection, 200 mg, 300 mg & 500 mg m/r tablets

Topiramate 25 mg, 50 mg and 100mg tablets 15mg and 25mg sprinkle capsules

Vigabatrin 500 mg tablet & sachets

Zonisamide 25mg, 50mg and 100mg Capsules

(Also for Dr. Misbahuddin for treating tremor in Parkinson's disease)

Clobazam 10 mg tablet

Clonazepam 1 mg/ ml injection, 500 micrograms & 2 mg tablets

Cenobamate 12.5mg, 25mg, 50mg, 100mg, 150mg, 200mg
NICE TA753 - Cenobamate for treating focal onset seizures in epilepsy

4.8.2 DRUGS USED IN STATUS EPILEPTICUS

Diazepam
(see section 4.1.2 for preparations)

Clonazepam 1 mg/ ml injection

Phenytoin 250 mg/ 5 ml injection

Paraldehyde in olive oil 2 equal parts rectal solution 30ml
(Consultant Neurologists & Paediatricians only. Dose given diluted with olive oil & given rectally as enema)

4.9 DRUGS USED IN PARKINSONISM & RELATED DISORDERS

4.9.1 DOPAMINERGIC DRUGS USED IN PARKINSONISM

Co-beneldopa (benserazide hydrochloride & levodopa)

(Madopar ®)

62.5 mg, 125 mg & 250 mg capsules, 62.5 mg & 125 mg dispersible tablets
(Madopar CR ®) 125 mg m/r capsule
Co-careldopa (carbidopa & levodopa)

(Sinemet LS ®) 62.5 mg tablet

(Sinemet 110 ®) 110 mg tablet

(Sinemet Plus ®) 125 mg tablet

(Sinemet 275 ®) 275 mg tablet

(Half Sinemet CR ®) 125 mg m/r tablet

(Sinemet CR ®) 250 mg m/r tablet

Duodopa 5/20/ml Intestinal gel
(CCG's funding required)

Amantadine 100 mg capsule,
50 mg/ 5 ml syrup

Apomorphine

20 mg/ 2ml & 50 mg/ 5 ml injection
10 mg/ ml pre-loaded pen
(Consultant Neurologist only)

Cabergoline 1 mg tablet (Cabaser ®)

Entacapone 200 mg tablet

Opicapone 50mg capsule

Pramipexole 88mcg, 180mcg and 700mcg tablet *(for treatment of Parkinson's, Consultant Neurologists only)*

nPbR = Indicates a drug excluded from HRG tariff price

Ropinirole

“ReQuip” tablet (for treatment of idiopathic parkinsons disease)

“Requip XL” tablet

“Adartrel” 0.25mg, 0.5mg and 2mg tablets (for the treatment of restless legs syndrome) *Neurologists’ use only*

Rotigotine transdermal patches 2mg/24hr, 4mg/24hr and 8mg/24hr (for patients with swallowing difficulties)

Stalevo tablet (Levodopa/Carbidopa/Entacapone)

Rasagiline 1mg tablet (2nd line in patients who cannot tolerate Selegiline)

Selegiline 5 mg tablet, 10mg/5ml liquid

4.9.2 ANTIMUSCAROMOC DRUGS USED IN PARKINSONISM

Benzatropine (Benztropine) 2 mg/ 2 ml injection- **discontinued**

Orphenadrine 50 mg tablet, 25 mg/ 5 ml liquid

Procyclidine 5mg tablets

Trihexyphenidyll (Benzhexol) 2 mg & 5 mg tablets, 5 mg/ 5 ml syrup

4.9.3 DRUGS USED IN ESSENTIAL TREMOR, CHOREA, TICS & RELATED DISORDERS

Haloperidol 500 micrograms, 1.5 mg, 5 mg, 10 mg tablets, 10 mg/ 5 ml liquid, 5 mg/ ml injection

nPbR Riluzole 50 mg tablet (Consultant Neurologists only)

Tetrabenazine 25 mg tablet

TORSION DYSTONIAS & OTHER INVOLUNTARY MOVEMENTS

Botulinum A toxin-Haemagglutinin complex (Botox ® 100 unit injection Dysport ® 500 unit injection & Xeomin 100 unit injection)

Ophthalmologists & Neurologists use.

Consultant Gastroenterologists for achalasia when surgery is unsuitable (unlicensed use, needs patient consent)

Dr Gupta for relief of spasticity in stroke patients as second line therapy (unlicensed use, needs patient consent)

Consultant Surgeons & Dermatologists for Hyperhidrosis (N.B. Dysport is unlicensed for hyperhidrosis, needs patient consent)

nPbR Botulinum B toxin (NeuroBloc ®)

Dr. Gupta, Dr. McCauley & Prof. Findley for cervical dystonia resistant to Botox ® and Dysport ®

4.10 DRUGS USED IN SUBSTANCE DEPENDENCE

ALCOHOL DEPENDENCE

Chlordiazepoxide capsules (See section 4.1.2 for strengths)

Acamprosate 333 mg e/c tablet (Specialist Consultant use only)

CIGARETTE SMOKING

Nicotine

2mg and 4mg gum (Nicorette), 2mg lozenges, NiQuitin 1.5mg lozenges NiQuitin patches (‘7’, ‘14’, ‘21’), Nicorette10mg/16hr, 15mg/16hr and 25mg/16hr patches, Nicorette inhalator 15mg cartridge Nicorette nasal spray 500micrograms/metered spray Nicorette Quickmist mouthspray 1mg/metered dose

nPbR = Indicates a drug excluded from HRG tariff price

OPIOID DEPENDENCE

Methadone (CD) 1mg/ ml mixture
(Not to be confused with methadone
linctus 2 mg/ 5 ml for cough)
(*Specialist advice needed*)

4.11 DRUGS FOR DEMENTIA

Donepezil 5 mg & 10 mg tablets
(*Community dementia team, Memory
Clinic & Neurologists only*)

Galantamine 4 mg & 8 mg tablets,
4 mg/ ml oral solution
(*Community dementia team, Memory
Clinic & Neurologists only*)

Memantine

5mg, 10mg, 15mg & 20mg tablets
10mg/ml oral solution

Rivastigmine

1.5 mg, 3 mg, 4.5 mg & 6 mg capsules,
2 mg/ ml oral solution, 4.6mg/24 hours &
9.5mg/24 hours

(*Community dementia team, Memory
Clinic & Neurologists only*)

4.12 CALCITONIN GENE-RELATED PEPTIDE INHIBITORS

Fremanezumab

150mg/ml Pre-filled syringe (Neurology
only)

5 INFECTIONS

5.1 ANTIBACTERIAL DRUGS

Notes: Unless otherwise specified, refer
to the Trust Antibiotic Guidelines for
approved indications

5.1.1 PENICILLINS

5.1.1.1 Benzylpenicillin & Phenoxymethylpenicillin (Penicillin V)

Benzylpenicillin 600 mg injection

Penicillin V 250 mg tablet,
125 mg/ 5 ml & 250 mg/ 5 ml syrup

Benzylpenicillin & procaine penicillin
1485 mg & 300 mg injection
(*Unlicensed medicine*)

5.1.1.2 Penicillinase-resistant penicillins

Flucloxacillin 250 mg & 500 mg
capsules, 125 mg/ 5 ml & 250 mg/ 5 ml
syrup, 250 mg & 500 mg injection

5.1.1.3 Broad spectrum penicillins

Amoxicillin

nPbR = Indicates a drug excluded from HRG tariff price

250 mg & 500 mg capsules,
125 mg/ 5 ml & 250 mg/ 5 ml syrup,
250 mg & 500 mg injection,
3 g sachets

Co-amoxiclav (amoxicillin & clavulanic
acid) (*Often prescribed as Augmentin®*)
250/ 125 tablet, 500/ 125 tablet,
125/ 31 syrup & 250/ 62.5 syrup,
500 mg/ 100mg & 1000 mg/ 200 mg
Injection

Pivmecillinam hydrochloride 200mg
tablets

Notes: Prescribe in accordance with
microbiology guidelines.

5.1.1.4 Antipseudomonal penicillins

Piperacillin & tazobactam
2.25 g & 4.5 g injection

Temocillin (Negaban®) 1g injection

5.1.2 CEPHALOSPORINS

Cefadroxil 500 mg capsule,

Cefaclor 125mg/5ml & 250 mg/ 5 ml suspension

Cefiderocol 1g injection (*Consultant Microbiologist initiation only*)

Cefuroxime
250 mg, 750 mg & 1.5 g injection

Cefotaxime 500 mg & 1 g injection

Ceftazidime
250 mg, 500 mg, 1 g & 2 g injection

Ceftriaxone 250 mg, 1 g & 2 g injection

Ceftazidime 2g/ Avibactam 0.5g injection

3rd Line restricted –Microapproval only

Ceftolozane/Tazobactam (Zerbaxa®)
1g/0.5g powder for concentration for solution for infusion

OTHER BETA-LACTAM ANTIBIOTICS

Meropenem 500 mg & 1g injection

Ertapenem 1g injection

5.1.3 TETRACYCLINES

Doxycycline
50 mg & 100 mg capsules,
100 mg dispersible tablets
40mg m/r capsules (Efracea®) for the treatment of rosacea –
(*Dermatologist's use only*)

First choice: Limecycline 408mg capsule

Alternatives:

Minocycline
50 mg & 100 mg tablets,
100 mg m/r capsule
(*Dermatologists only for existing patients or those suffering treatment failure*)

Oxytetracycline 250 mg tablet

Notes: Tetracyclines must not be given to children under 12 years old or to pregnant or breast-feeding women

Tigecycline 50-mg vial (for multi-resistant organisms on a consultant microbiologist's recommendation)

5.1.4 AMINOGLYCOSIDES

Gentamicin
80 mg/ 2 ml injection

Amikacin
100 mg/ 2 ml & 500 mg/ 2 ml injection

5.1.5 MACROLIDES

Erythromycin
250 mg tablet, 1 g injection,
125 mg/ 5 ml & 250 mg/ 5 ml suspension

Azithromycin
250 mg capsule,
200 mg/ 5 ml suspension

Clarithromycin
250 mg tablets, 125 mg/ 5 ml syrup,
500 mg injection

Notes: Clarithromycin should be reserved for H.pylori eradication & HIV patients for MAI prophylaxis

5.1.6 CLINDAMYCIN

Clindamycin
150 mg capsule
300 mg/ 2 ml injection

5.1.7 SOME OTHER ANTIBACTERIALS

Chloramphenicol
250 mg capsule, 1 g injection

Sodium fusidate
250 mg e/c tablet,
500 mg injection

Fusidic acid 250 mg/ 5 ml suspension

nPbR = Indicates a drug excluded from HRG tariff price

Note: 750 mg fusidic acid suspension is equivalent to 500 mg sodium fusidate tablet. Monitor LFT's

Vancomycin

125 mg capsule (*as per C difficile treatment guidelines*)
500 mg injection

Teicoplanin

200 mg & 400 mg injection

Daptomycin 350mg & 500mg injection

Note: Daptomycin should be reserved for treatment of skin and soft tissue infection, allergy to Vancomycin and teicoplanin bacteraemia and endocarditis & for OPAT (Outpatient Parenteral Antibiotic Therapy) (Unlicensed).

Linezolid (Zyvox®)

600 mg tablet, 100 mg/ 5 ml suspension, 600 mg infusion

Colistin

1 & 2 million unit injection,
1.5 million unit tablet

Rifaximin (Targaxan®)

550mg tablets
(*For reduction in recurrence of hepatic encephalopathy*)

Fidaxomicin (Dificlir®)

200mg tablets
For recurrent cases of Clostridium difficile infection (CDI) and severe CDI under strict recommendation of a Consultant Microbiologist

Fosfomycin

3g granules sachets

5.1.8 SULPHONAMIDES & TRIMETHOPRIM

Trimethoprim

100 mg & 200 mg tablets,
50 mg/ 5 ml suspension,
100 mg/ 5 ml injection

Co-trimoxazole

480 mg & 960 mg tablets,
240 mg/ 5 ml suspension,
480 mg/ 5 ml injection
(*For PCP management & Microbiologist initiation only*)

5.1.9 ANTITUBERCULOUS DRUGS

Ethambutol 100 mg & 400 mg tablets

Isoniazid 100 mg tablet,
100 mg/ 5 ml elixir (*unlicensed*),
50 mg/ 2 ml injection

Pyrazinamide

500 mg tablet (*Unlicensed*)

Rifampicin 150 mg & 300 mg capsules,
100 mg/ 5 ml syrup,
300 mg/ 5 ml injection

Rifampicin & Isoniazid

150 mg & 100 mg (**Rifinah® 150**) tablet
300 mg & 150 mg (**Rifinah® 300**) tablet

Notes: Combination preparations should be prescribed whenever possible to aid compliance. They should preferably be given before breakfast

Streptomycin 1 g injection

5.1.10 ANTILEPTIC DRUGS

Dapsone 50 mg tablet

5.1.11 METRONIDAZOLE

Metronidazole

200 mg & 400 mg tablets,
200 mg/ 5 ml suspension,
500 mg & 1 g suppositories,
500 mg infusion,
0.75 % gel (Metrogel®) (*for malodorous fungating tumours*)
0.75% gel (Acea®) (*for acne rosacea, Dermatologists only*)

5.1.12 QUINOLONES

Ciprofloxacin

250 mg & 500 mg tablets,
250 mg/ 5 ml suspension,
200 mg/ 100 ml &

nPbR = Indicates a drug excluded from HRG tariff price

400 mg/ 200 ml infusion

Levofloxacin 250mg & 500mg tablets
500mg/ 100ml injection

Moxifloxacin 400mg tablet

Notes: Quinolones should be prescribed with caution in children. Convulsions may be induced in those with or without a history of this. **Quinolones have multiple drug interactions** (see BNF). **N.B. Their absorption is reduced** by concomitant administration of antacids, ferrous sulphate, calcium & zinc salts

5.1.13 URINARY TRACT INFECTIONS

Cefadroxil

(see section 5.1.2 for formulations)

Trimethoprim

(see section 5.1.8 for formulations)

Nitrofurantoin (Macrochantin®)
50 mg capsule, 100 mg tablet

Notes: Avoid Nitrofurantoin in mild renal impairment

5.2 ANTIFUNGAL DRUGS

Fluconazole

50 mg, 150 mg & 200 mg capsules,
50 mg/ 5 ml & 200 mg/ 5 ml suspension,
50 mg/ 25 ml & 200 mg/ 100 ml injection

Amphotericin 50 mg injection
(**Fungizone**®), (*1st line*)

(**Amphocil**®), (*2nd line to Fungizone*®,
where renal function has deteriorated)

nPbR Liposomal Amphotericin

50 mg injection (**Ambisome**®)
(*for premature neonates, Microbiologist &
Haematologist initiation only*)

nPbR Caspofungin intravenous infusion
50mg vial and 70mg vial

Flucytosine 2.5 g/ 250 ml injection

Griseofulvin

500 mg tablet, 125 mg/ 5 ml suspension

Itraconazole

100 mg capsules, 10 mg/ ml liquid
(*Haematologists only*)

nPbR Posaconazole

200mg/ml suspension

(*Haematologists only*)

Note: Posaconazole is for continuation of treatment after initiation at Bart's and the London Hospital

Terbinafine 250 mg tablet
(*Dermatologists only*)

nPbR Voriconazole 50mg 200mg tablets
200mg intravenous infusion

5.3 ANTIVIRAL DRUGS

Note: All HIV therapy is for specialist use only

5.3.1 HIV

NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS

nPbR Abacavir 300 mg tablet

nPbR Abacavir 600 mg tablet &
Lamivudine 300 mg (**Kivexa**®)

nPbR Abacavir 300 mg & **Lamivudine** 150 mg & **Zidovudine** 300 mg tablet (**Trizivir**®)

nPbR Cabotegravir 30mg tablet &
600mg/3ml pr suspension for injection
(NICE TA757)

nPbR Didanosine 100 mg, 125 mg & 200 mg tablets, 400 mg enteric coated capsules

nPbR Lamivudine 100 mg tablet

nPbR Entecavir 500micrograms and 1mg tablet

Oral Solution 50micrograms/ml

nPbR Abacavir 300 mg tablet

nPbR = Indicates a drug excluded from HRG tariff price

nPbR Rilpivirine 25mg tablet & 900mg/3ml
pr suspension for injection
(NICE TA757)

5.3.3.2 Chronic Hepatitis C

nPbR Simeprevir 150mg capsules

nPbR Ledipasvir 90mg/ Sofosbuvir 400mg
film-coated tablets (Harvoni®)
(In line with Interim NHSE Clinical
Commissioning Statement)

nPbR Sofosbuvir 400mg/velpatasvir
100mg film-coated tablets (Epclusa®)
(In line with Interim NHSE Clinical
Commissioning Statement)

nPbR Elbasvir 50mg/ Grazoprevir 100mg
film-coated tablets (Zepatier®)
(As per NICE recommendation)

nPbR Sofosbuvir 400mg / Velpatasvir
100mg / Voxilaprevir 100mg film
coated tablets (Vosevi®)
(Hepatology consultants only, in line with
NHSE commissioning position/ NICE
guidance)

5.3.4 INFLUENZA

Oseltamivir 30mg, 45mg, 75mg capsule
30mg/ 5ml suspension (For treatment
and prevention of influenza, see
pandemic contingency plan)

Zanamivir
5mg inhalation powder
10mg/ml Solution for infusion

5.3.5 RESPIRATORY SYNCYTIAL VIRUS

nPbR Palivizumab
50 mg & 100 mg IM injection
(Paediatrician initiation only)

nPbR Ribavirin (Tribavirin)
200 mg capsules (Consultant
Gastroenterologists only for
1st line treatment of Hepatitis C)

COVID TREATMENTS

Remdesivir 100 mg (5mg/ml)
concentrate for solution for infusion.

(See Remdesivir Prescribing,
Administration And Monitoring Guidelines
on intranet)

5.4 ANTIPROTOZOAL DRUGS

5.4.1 ANTIMALARIALS

Chloroquine sulphate
250 mg tablet = 155 mg base,
68 mg/ 5 ml syrup = 50 mg (base)/ 5 ml,
200 mg (base)/ 5 ml injection

Pyrimethamine 25 mg tablet

Quinine dihydrochloride
600 mg/ 2 ml injection
300mg/ ml injection
(Unlicensed)

Mefloquine 250 mg tablet (Restricted to
HIV)

Primaquine 7.5mg tablet (unlicensed-
named patient only)

Proguanil 100 mg & atovaquone
250 mg (**Malarone** ®) tablet

Atovaquone liquid 750mg/5ml
(**Wellvone**®)
3rd line secondary prophylaxis of PCP in
HIV patients.
(Consultant Microbiologist and GUM
Consultants initiation only)
(unlicensed)

Quinine sulphate
200 mg & 300 mg tablets

5.4.2 AMOEBICIDES

nPbR = Indicates a drug excluded from HRG tariff price

Diloxanide Furoate 500mg tablet

Metronidazole see section 5.1.11 for preparations

5.4.7 DRUGS FOR TOXOPLASMOSIS

Pyrimethamine 25 mg tablet

Sulfadiazine
500 mg tablet

5.4.8 DRUGS FOR PNEUMOCYSTIS PNEUMONIA

Co-trimoxazole
(See section 5.1.8 for formulations)

Pentamidine isethionate
300 mg/ 5 ml respiratory solution,
300 mg injection

Atovaquone suspension 750 mg/5ml

5.5 ANTHELMINTICS

Albendazole
400mg tablet

(unlicensed – named patient only)

See Antibiotic Guidelines for approved indications

Mebendazole
100 mg tablet,
100 mg/ 5 ml suspension

6 ENDOCRINE SYSTEM

6.1 DRUGS USED IN DIABETES

6.1.1.1 SHORT-ACTING INSULINS

SOLUBLE INSULIN

Actrapid® (Human)

100 units/ ml injection
10 ml vial, 3 ml cartridge
3 ml disposable pen

Insuman Rapid 100units/ml cartridge

Insulin Aspart

NovoRapid® 100 units/ ml injection
10 ml vial, 3 ml cartridge, 3 ml FlexPen

Insulin Glulisine

Apidra® 100 units/ml injection
10ml vial, 3ml cartridge, Solostar

Insulin Lispro

Humalog® 100 units/ ml injection
10 ml vial, 3 ml cartridge
3 ml disposable pen

6.1.1.2 INTERMEDIATE- & LONG-ACTING INSULINS

ISOPHANE INSULIN

Humulin I 100 units/ml, 10ml vials, 3ml cartridges, KwikPen

Insulatard® (Human)

100 units/ ml injection
10 ml vial, 3 ml cartridge
3 ml Novolet pen,
Innolet device: Initiation by *Diabetes team only*

Insuman Basal 100units/ml

3ml cartridges, pre-filled Solostar pen,
5ml vials

BIPHASIC INSULINS

Biphasic insulin Aspart

Novomix® 30, 100 units/ ml injection
3ml cartridge, 3 ml FlexPen

Biphasic Insulin Isophane

Humulin® M3, 100 units/ml injection 3ml cartridge, 3ml KwikPen

Insuman Comb 15, 100units/ml, 3ml cartridges, pre-filled Solostar pen, 5ml vials

Insuman Comb 25, 100 units/ml, 3ml cartridges

Insuman Comb 50, 100 units/ml, 3ml cartridges

Biphasic Insulin Lispro

Humalog® Mix 25
3 ml cartridge, 3 ml *Kwikpen* prefilled disposable injection devices

Humalog® Mix 50

3 ml disposable *Kwikpen* prefilled disposable injection devices

Insulin Degludec

Tresiba® Flextouch
100units/ml pre-filled pen, 100units/ml cartridges,
200units/ml pre-filled pen (**initiation by consultant endocrine only**)

Insulin Degludec with Liraglutide

Xultophy® 100units/ml insulin degludec + 3.6mg/ml Liraglutide, 3ml pre-filled pen (**consultant endocrine only**)

Insulin Detemir

Levemir® 100 units/ml injection
3ml cartridge, 3ml FlexpenFF

Insulin Glargine

Lantus® 100 units/ ml injection
10 ml vial, 3 ml cartridge & Solostar
(*Endocrinologists only in accordance*)

nPbR = Indicates a drug excluded from HRG tariff price

with protocol)

biosimilar

Abasaglar® 100 units/ml, 3ml cartridge & pre-filled pen

Semglee® 100units/ml, pre-filled pen

Toujeo® 300 units/ml, 1.5ml pre-filled Solostar pen pen (**consultant endocrine only**)

Notes: When **prescribing insulins**, specify the source (e.g. Human), the strength of the mixture (e.g. 30) & the device required (e.g. 10 ml vial). When specifying the dose, please **do not abbreviate the word 'units'**.

Flexpens have been approved for patients unable to use the cartridges on recommendation of the diabetes team

6.1.2 ORAL ANTIDIABETIC DRUGS

6.1.2.1 SULPHONYLUREAS

Gliclazide 80 mg tablet

Glimepiride 1 mg, 2 mg & 3 mg tablets

Tolbutamide 500 mg tablet

6.1.2.2 BIGUANIDES

Metformin 500 mg & 850 mg tablets

Glucophage 500mg & 1g sachets

Gucophage SR (Metformin) 500mg, 750mg & 1g tablets

6.1.2.3 OTHER ANTIDIABETICS

Acarbose 50 mg tablet

Canagliflozin (Invokana®) 100mg & 300mg f/c tablets

Dapagliflozin (Forxiga®) 5 mg & 10mg f/c tablets

Dapagliflozin is approved according to **NICE TA679** for treating chronic heart failure with reduced ejection fraction.

Dapagliflozin is approved according to **NICE TA775** for treating chronic kidney disease.

Dapagliflozin is no longer licensed for treating type 1 diabetes mellitus

Ertugliflozin (Steglatro®) 5mg & 15mg tablets

Empagliflozin (Jardiance®) 10mg & 25mgf/c tablets

Exenatide (Byetta®) 250micrograms/ml injection

Bydureon® 2 mg powder and solvent for prolonged-release suspension for injection

Liraglutide (Victoza®) 6mg/ml injection 2 x 3ml prefilled pens

Dulaglutide (Trulicity®) 0.75mg/0.5ml, 1.5mg/0.5ml pre-filled pen

Semaglutide (Rybelsus ®) 3mg, 7mg, 14mg tablet (*Endocrinologists initiation only in accordance with MOG approval*)

Semaglutide (Ozempic®) 0.25mg/0.19ml, 0.5mg/0.37ml, 1mg/0.74ml pre-filled pen

Repaglinide 500 micrograms, 1 mg & 2 mg tablets

Pioglitazone 15 mg tablet

Notes: **Acarbose, Repaglinide & Pioglitazone** are for initiation by Consultant Endocrinologists only

Alogliptin 6.25mg, 12.5mg, 25mg tablets

Linagliptin 5mg tablets (Can be used in severe renal impairment)

Sitagliptin 25mg, 50mg & 100mg tablets

6.1.4 TREATMENT OF HYPOGLYCAEMIA

Glucagon 1 mg injection

GlucoGel (23 g) glucose gel

6.1.5 TREATMENT OF DIABETIC NEPHROPATHY AND NEUROPATHY

Pregabalin 25mg, 50mg, 75mg, 100mg, 150mg, 200mg, and 300mg capsules. (to be used second line after

nPbR = Indicates a drug excluded from HRG tariff price

amitriptylline or duloxetine for painful diabetic neuropathy)

6.1.6 DIAGNOSTIC & MONITORING AGENTS FOR DIABETES MELLITUS

BLOOD GLUCOSE MONITORING

Advantage II ® Reagent strips

URINALYSIS

Diastix ®

Ketodiastix ®

Labstix ®

Multistix SG ®

Multistix 10 SG ®

Multistix GP ®

Multistix 8 SG ®

GLUCOSE TOLERANCE TEST

Anhydrous Glucose 75 g powder

6.2 THYROID & ANTITHYROID DRUGS

6.2.1 THYROID HORMONES

Levothyroxine (Thyroxine)

25 & 50 micrograms &
100 micrograms tablets

Liothyronine 20 micrograms tablet,
20 micrograms injection

Notes: 20 micrograms of Liothyronine is equivalent to 100 micrograms of Levothyroxine (Thyroxine)

6.2.2 ANTITHYROID DRUGS

Carbimazole 5 mg & 20 mg tablets

Propylthiouracil 50 mg tablet

Aqueous Iodine Oral Solution
(Lugol's Solution)

Notes: Carbimazole is the antithyroid drug of choice. Prescribers should be aware of the possibility of carbimazole-

induced bone marrow suppression. If neutropenia develops, stop the drug immediately

6.3 CORTICOSTEROIDS

6.3.1 REPLACEMENT THERAPY

Fludrocortisone 100 micrograms tablet

6.3.2 GLUCOCORTICOID THERAPY

Prednisolone

1 mg, 5 mg & 25 mg tablets,
2.5 mg & 5 mg e/c tablets,
5 mg soluble tablet
5mg/5ml oral solution

Prednisolone acetate

25 mg/ ml injection

Dexamethasone

500 micrograms & 2 mg tablets,
2 mg / 5 ml oral solution,
8 mg/ 2 ml injection

Hydrocortisone 10 mg & 20 mg tablets,
100 mg injection (sodium succinate &
phosphate salts),
25 mg/ ml injection (acetate)

Betamethasone 500 microgram tablet &
soluble tablet

Methylprednisolone sodium succinate

(Solu Medrone ®)
40 mg, 125mg, 500 mg & 1 g IM and IV
injection

Methylprednisolone (Depo-Medrone ®)

40 mg/ ml & 80 mg/ 2 ml
IM depot injection

Notes: Patients should be issued with and carry steroid treatment cards.

Withdrawal of systemic corticosteroids should be gradual in certain patient groups. Refer to B.N.F for further advice

6.4 SEX HORMONES

6.4.1 FEMALE SEX HORMONES

6.4.1.1 OESTROGENS & HORMONE REPLACEMENT THERAPY

nPbR = Indicates a drug excluded from HRG tariff price

**Oestrogen & progestogen
(Cyclical oral preparations)
Women with uterus**

Novofem® tablets
(Use when oestrogen of equine origin is not acceptable)

Premique Cycle® tablets
(Use when non-androgenic progesterone is needed)

Tridestra® tablets
*(Produces 3 monthly bleeds
For use in peri-menopausal women when monthly bleeds are unacceptable)*

Trisequens® tablets

**Oestrogen & progestogen
(Continuous oral preparations)
Women with uterus**

For use when cyclical bleeding is unacceptable. Only for truly menopausal women, i.e. >54 years of age or at least 12 months since last natural bleed

Climesse® tablets
(Use when oestrogen of equine origin is not acceptable)

Kliovance® tablets
(Lower strength HRT. For menopausal symptoms in patients unable to tolerate Climesse®)

**Oestrogen & progestogen (patches)
Women with uterus**

Evorel Conti®
Twice weekly patch
(For Consultant use in patients meeting criteria for continuous combined HRT in whom oral therapy undesirable)

**Oestrogen only (tablets)
Women without uterus**

1st Choice: Premarin® 0.625 mg & 1.25 mg tablets

Alternative: Climaval® 1 mg & 2 mg tablets
(Use when oestrogen of equine origin is not acceptable)

**Oestrogen only (patches)
Women without uterus**

Femseven®
Once weekly patch
(Transdermal preparation of choice)

Evorel®
Twice weekly patch
(Use when extended dosing range is required or once weekly patches have been unsuccessful)

IMPLANTS

Estradiol
25 mg, 50 mg & 100 mg implants

Raloxifene 60 mg tablet
(For prevention of vertebral fractures in post-menopausal women at increased risk of osteoporosis & intolerant of HRT)

Tibolone 2.5 mg tablet
(For use in women who exhibit idiosyncratic reactions to oestrogen or in whom oestrogen administration should be avoided. Consultant Gynaecologist only)

**6.4.1.2 PROGESTOGENS AND
PROGESTERONE RECEPTOR
MODULATORS**

Dydrogesterone 10 mg tablet

Medroxyprogesterone acetate
5 mg & 10 mg tablets
Norethisterone 5 mg tablet

Progesterone
200 mg & 400 mg pessaries,
4 % & 8 % gel,
100 mg/ 2 ml injection *(approved for post-natal depression, unlicensed use)*

Progesterone receptor modulators

Ulipristal acetate (Esmya®)* 5mg tablets *temporarily withdrawn from market due to safety concerns. See MHRA Alert.

6.4.2 MALE SEX HORMONES & ANTAGONISTS

TESTOSTERONE & ESTERS

Testosterone undecanoate

(Restandol® Testocaps) 40 mg capsule

1st Choice: Testosterone mucoadhesive buccal 30mg m/r tablets (Straint® SR)

2nd Choice: Testosterone 100 mg & 200 mg implant

3rd Choice: Testosterone 50 mg/5 g gel (Testim®)- to be applied topically for hypogonadism due to testosterone deficiency in men

Testosterone 20mg/1 g gel (Tostran®)

Testosterone enantate 250 mg/ ml injection

ANTIANDROGENS

Cyproterone acetate 50 mg & 100 mg tablets

Finasteride 5 mg tablet

6.5 HYPOTHALAMIC & PITUITARY HORMONES & ANTI-OESTROGENS

6.5.1 ANTI-OESTROGENS

Clomifene 50 mg tablet

CORTICOTROPHINS

Tetracosactide

Synacthen® 250 micrograms/ ml injection
Synacthen Depot® 1 mg/ ml IM injection

Notes: For short **Synacthen test** for the diagnosis of adrenocortical insufficiency. Give Synacthen® 250 micrograms by IV/ IM injection. Take blood for cortisol (serum SST tube) pre-injection, 30 minutes and 60 minutes. Send all three samples to biochemistry. Normal response is a rise of more than 200 nmol/ L to a level of greater than 550 nmol/ L

GONADOTROPHINS

For use at the Infertility Clinic only

Chorionic gonadotrophin 1500, 2000 & 5000 units injection

Follitropin alfa (Gonal-F®) 75 units & 450 units injection

Follitropin beta (Puregon®) 50 units injection

Human menopausal gonadotrophins
Gonadotrophins
Menogon® / Menopur® injection

GROWTH HORMONE

nPbR Somatropin 16 units, 18 units & 36 units injection (*as per shared care protocol*) (*Norditropin SimpleXx, NutropinAq, Saizen, Humatope, Genotropin, Omnitrope & Zomactan*)

HYPOTHALAMIC HORMONES

Gonadorelin (GnRH; LH-RH) 100 micrograms injection

Protirelin (TRH) 200 micrograms/ 2 ml injection

nPbR = Indicates a drug excluded from HRG tariff price

6.5.2 POSTERIOR PITUITARY HORMONES & ANTAGONISTS

POSTERIOR PITUITARY HORMONES

Vasopressin (Synthetic Argipressin)
20 units/ ml injection

Desmopressin 100 micrograms tablet,
100 micrograms/ ml intranasal solution,
10 micrograms/ metered dose spray,
4 micrograms/ ml injection

Terlipressin 1 mg injection

ANTIDIURETIC HORMONE ANTAGONISTS

Demeclocycline 150 mg capsule

Tolvaptan (Samsca®) 15mg & 30mg tablets

(Tolvaptan for the treatment of hyponatremia secondary to syndrome of inappropriate antidiuretic hormone secretion is to be prescribed and monitored by Endocrinologists and treatment course will not exceed 10 days. A tickbox form is required)

Tolvaptan has also been approved by NICE TA358 May 2016 for the treatment of autosomal dominant polycystic kidney disease. These patients are not being treated at BHRUT at this point, they are being referred to a dedicated clinic at Royal London Hospital

6.6 DRUGS AFFECTING BONE METABOLISM

6.6.1 CALCITONIN

Calcitonin (salmon) (Salcatonin)
50 units/ ml & 100 units/ ml injection
400 units/ 2 ml injection

nPbR Teriparatide

250 micrograms/ml injection

Reference medicine: Forsteo®

Biosimilar: Movymia®

nPbR = Indicates a drug excluded from HRG tariff price

(Consultant Rheumatologists only)

6.6.2 BISPHOSPHONATES

Alendronic acid (alendronate)
10 mg tablet (once daily)

70mg once weekly tablet

Notes: Daily alendronic acid is reserved for the treatment of osteoporosis in men only. **Once weekly preparations are unlicensed for this indication**

Risedronate sodium (Actonel®)

5 mg once daily tablet, 35 mg once weekly tablet

30mg tablet licensed for treatment of Paget's disease of bone 30mg daily for 2 months; maybe repeated if necessary after at least 2 months

Pamidronate disodium 15 mg injection

Ibandronic acid 50mg tablets and concentrate for IV infusion
(Bondronat®)

Sodium clodronate

400 mg capsule,
520 mg & 800 mg tablets
(Haematologists & Radiotherapists only)

nPbR Zoledronic acid (Aclasta®)

5mg in 100ml infusion
(Consultant Rheumatologists and Orthogeriatricians only)

Notes: Zoledronic acid is indicated in postmenopausal osteoporotic patients who are intolerant of oral bisphosphonates and have suffered two fractures despite oral treatment and have a secondary cause for osteoporosis.

Zoledronic acid (Zometa®)

4mg vial

(Consultant Oncologists only)

Notes: Zometa is indicated in oncology patients for hypercalcaemia of malignancy.

Denosumab Injection 60mg/ml 1ml pre-filled syringe (**Prolia®**) (Consultant Rheumatologists and Orthogeriatricians or as per NICE recommendations)

Notes: Prolia® is indicated in postmenopausal women at increased risk of fractures who are unable to comply with the special instructions for administering alendronate and either risedronate or ibandronic acid or have an intolerance of, or a contraindication to those treatments.

Denosumab 70mg/ml 120mg vial (**Xgeva®**). (Consultants oncologists only as per NICE recommendations)

Notes: Xgeva® is indicated for the prevention of skeletal-related events in adults with bone metastases from solid tumours.

6.7 OTHER ENDOCRINE DRUGS

6.7.1 BROMOCRIPTINE & OTHER DOPAMINERGIC DRUGS

Bromocriptine

1 mg, 2.5 mg & 5 mg tablets,
10 mg capsule

Cabergoline

500 micrograms tablet

6.7.2 DRUGS AFFECTING GONADOTROPHINS

Danazol 100 mg & 200 mg capsules

Goserelin (Zoladex ®) 3.6 mg Implant
(for prostate & breast cancer, please see section 8.3.4.2)

Leuprorelin (Prostap SR DCS®)

3.75 mg injection
(Gynaecologists only for Endometriosis unresponsive to other treatments)

nPbR = Indicates a drug excluded from HRG tariff price

7 OBSTETRICS, GYNAECOLOGY & URINARY-TRACT DISORDERS

7.1 DRUGS USED IN OBSTETRICS

7.1.1. PROSTAGLANDINS & OXYTOCICS

Carboprost 250 micrograms/ ml injection
(Available for patients unresponsive to ergometrine & oxytocin)

Dinoprostone (Prostin E2 ®)
3 mg vaginal tablet,
1 mg & 2 mg vaginal gel
10mg pessary within retrieval device
(Propess®)

Notes: Prostin E2 vaginal tablet & vaginal gel are not bioequivalent

Ergometrine maleate
500 micrograms/ ml injection

Ergometrine & oxytocin
(Syntometrine ®)
500 micrograms & 5 units/ ml injection

Gemeprost 1 mg pessaries

Oxytocin (Syntocinon ®)
5 units/ ml & 10 units/ ml injection

Misoprostol
25,100 & 200 micrograms tablets
(Induction of Labour,
Cervical priming prior to termination,
Medical termination in 2nd trimester,
Post-partum haemorrhage,
Unlicensed indications)

Methotrexate injection
(Ectopic pregnancy in line with protocol,
unlicensed indication)

7.1.1.1. DUCTUS ARTERIOSUS

MAINTENANCE OF PATENCY

Alprostadil (Prostin VR ®)
500 micrograms/ ml injection

CLOSURE

Ibuprofen (Orphan drug)
5 mg/ml injection- (*treatment of closing patent ductus arteriosus (PDA) in preterm newborn infants*) indomethacin is no longer used because of adverse effects such as necrotising enterocolitis (NEC).
Ibuprofen has a better side effect profile)

7.1.2 MIFEPRISTONE

Mifepristone 200 mg tablet

7.1.3 MYOMETRIAL RELAXANTS

Ritodrine hydrochloride
10 mg tablet, 50 mg/ 5 ml injection

Atosiban
37.5 mg/ 5 ml & 6.75 mg/ 0.9 ml injection-
(for use in patients with contraindications to ritodrine)

Salbutamol
(See section 3.1.1.1 for strengths of injection)

Terbutaline
0.5 mg/ ml & 2.5 mg/ 5 ml injection (for management of uterine hyperstimulation during induced labour-unlicensed use)

7.2 TREATMENT OF VAGINAL & VULVAL CONDITIONS

7.2.1 PREPARATIONS FOR VAGINAL ATROPHY

OESTROGENS, TOPICAL

Estriol (Ortho-Gynest ®)
0.01 % Intravaginal cream

Conjugated oestrogens (equine)

nPbR = Indicates a drug excluded from HRG tariff price

(Premarin ®) vaginal cream

Estradiol (Vagifem ®)
25 micrograms vaginal tablets

Estradiol (Estring ®)
7.5 micrograms/ 24 hours vaginal ring
(Use only when creams or vaginal tablets
& systemic administration are
inappropriate, Consultant Gynaecologists
only)

Estradiol (Lenzetto ®)
1.53mg/dose transdermal spray

7.2.2 ANTI-INFECTIVE DRUGS PREPARATIONS FOR VAGINAL & VULVAL CANDIDIASIS

Clotrimazole
100 mg, 200 mg & 500 mg pessaries,
1 %, 2% & 10 % vaginal cream

Econazole nitrate 150 mg pessary

PREPARATIONS FOR OTHER VAGINAL INFECTIONS

Clindamycin phosphate (Dalacin ®)
Cream

Metronidazole 0.75% gel (Zidoval®)
(*alternative to oral metronidazole for the
treatment of bacterial vaginosis*)

Povidone-iodine (Betadine ®)
200 mg pessary (*G.U. Medicine only*)

7.3 CONTRACEPTIVES

7.3.1 COMBINED HORMONAL CONTRACEPTIVES

LOW STRENGTH (ORAL)

Ethinylestradiol & Desogestrel
Mercilon ® tablet

LOW STRENGTH (VAGINAL)
Ethinylestradiol with Etonogestrel

NuvaRing® vaginal ring

STANDARD STRENGTH

Ethinylestradiol & Levonorgestrel
Levest 150/30 tablet
Logynon ®
Trinordiol ® tablet

Ethinylestradiol & Norethisterone
TriNovum ® tablet
Ovysmen ® tablet (*Havering Community
only*)

Ethinylestradiol & Norgestimate
Cilest ® tablet

Ethinylestradiol & Desogestrel
Gedarel ® tablet

Ethinylestradiol & Drospirenone
Yasmin ® tablet

Ethinylestradiol & Gestodene
Femodene ® tablet
Millinette ®

Note: Femodene, Gedarel, Mercilon & Millinette are associated with a higher incidence of thrombosis & are available only for women who have experienced problems with other oral contraceptives & who have given their full, informed consent

EMERGENCY CONTRACEPTION

Levonorgestrel (**Levonelle** ® 1500) tablet
(*Family planning & GUM clinic only*)

Ulipristal acetate 30mg (**ellaOne**®) tablet

nPbR = Indicates a drug excluded from HRG tariff price

7.3.2 PROGESTOGEN-ONLY CONTRACEPTIVES

7.3.2.1 ORAL PROGESTOGEN-ONLY CONTRACEPTIVES

Desogestrel (**Cerazette**®)
(*Dr Hollingworth only*)

Etinodiol (**Femulen**®) tablet

Norethisterone (**Micronor**®) tablet

Levonorgestrel (**Norgeston**®) tablet

7.3.2.2 PARENTERAL PROGESTOGEN-ONLY CONTRACEPTIVES

Medroxyprogesterone acetate
(Depo-Provera®)
150 mg pre-filled syringe

Subcutaneous Medroxyprogesterone acetate (Sayana Press®) 104mg

Etonogestrel (Nexplanon®) Implant
(*Family planning clinics only*)

7.3.2.3 INTRA-UTERINE PROGESTOGEN-ONLY CONTRACEPTIVES

Mirena® Intrauterine system

Jaydess® Intrauterine system

Levosert® Intrauterine system

Benilexa® Intrauterine system

Kyleena® Intrauterine system

7.3.3 SPERMICIDAL CONTRACEPTIVES

Nonoxinol '9' 2% Gel 30g
(Gygel®)

7.3.4 CONTRACEPTIVE DEVICES

GyneFix®

Nova-T® 380

7.4 DRUGS FOR GENITO-URINARY DISORDERS

7.4.1 DRUGS FOR URINARY RETENTION

ALPHA-BLOCKERS

Alfuzosin (Xatral XL®)
10 mg m/r tablet

Indoramin 20 mg tablet

Tamsulosin 400 micrograms m/r capsule

Notes: The use of alpha-blockers is associated with postural hypotension, particularly after the first dose. Elderly patients, those with a history of orthostatic hypotension or those who are receiving hypotensive therapy are particularly at risk

PARASYMPATHOMIMETICS

Bethanechol chloride 10 mg tablet

Distigmine bromide 5 mg tablet

7.4.2 DRUGS FOR URINARY FREQUENCY, ENURESIS & INCONTINENCE

1st Choice: Oxybutynin

2.5 mg & 5 mg tablet, 2.5 mg/ 5 ml elixir

2nd Choices

Solifenacin succinate (Vesicare®)
5mg and 10mg film-coated tablets

Tolterodine 1mg and 2mg immediate release tablets

Fesoterodine (Toviaz®)
4mg and 8mg m/r tablets

Propantheline 15 mg tablet

Duloxetine 20mg and 40mg capsules

nPbR = Indicates a drug excluded from HRG tariff price

(last line for stress urinary incontinence as per NICE)

Mirabegron (Betmiga®)
25mg and 50mg m/r tablets

7.4.3 DRUGS USED IN UROLOGICAL PAIN

Potassium citrate
3 g granules & mixture BP

Notes: These granules should be taken with plenty of water.

Caution: 3 g sachet or 10 ml of mixture contains 28 mmol of potassium

7.4.4 BLADDER INSTILLATIONS & UROLOGICAL SURGERY

Sodium Chloride 0.9 % (Uro-tainer ®)

Glycine 1.5 % Irrigation solution

7.4.5 DRUGS FOR ERECTILE DYSFUNCTION

Alprostadil
(Caverject ®) *(Urologists only)*
5 micrograms, 10 micrograms, 20 micrograms & 40 micrograms injection
(Viridal Duo®) starter pack
10 micrograms, 20 micrograms & 40 micrograms starter pack

(MUSE ®) *(Urologists only)*

250 micrograms, 500 micrograms & 1 mg urethral application

Papaverine
30 mg, 40 mg & 80 mg injection
(Unlicensed product, Urologists only)

1st Choice: Sildenafil 25 mg, 50mg & 100mg tablets

Alternatives treatments

Tadalafil 2.5mg, 5mg, 10mg & 20mg tablets *(1st or 2nd line in patients who require more spontaneity and post prostatectomy).*

Vardenafil 5mg, 10mg & 20mg tablets *(Urologists only). To be used 2nd line after Sildenafil in non-responders and older patients over 70 yrs old.*

Notes: Sildenafil is contraindicated in patients receiving nitrates. Prescriptions for erectile dysfunction need to be endorsed with SLS & signed by Consultant Urologists only. Supply is one tablet per week, with a maximum of one month supply only

PRIAPISM

Etilefrine 5mg tablets – unlicensed see Priapism guidelines on the intranet.

8 MALIGNANT DISEASE & IMMUNOSUPPRESSION

The drugs in this section are potentially highly toxic and should therefore, be used only by clinicians experienced in their use.

For advice on the use of the drugs the opinion of a Consultant in radiotherapy and oncology should be sought.

A central cytotoxic reconstitution service, based in the pharmacy, is in operation and should be always be used. The service presents the cytotoxic drug in its final form ready for use, i.e. the exact dose required drawn up in a syringe or in an infusion bag, labelled with the patient's name.

For advice on the handling of cytotoxic drugs please contact one of the numbers below.

For information about the reconstitution service, telephone Ext. 3029 (QH) or 8272 (KGH)

(Also, for Pterygium excision and trabeculectomy in Ophthalmology – Consultant Ophthalmologists only)

Mitoxantrone (Mitozantrone) infusion
Pixantrone injection (Pixuvri®)
(as per NICE 306)

Notes: Pixantrone monotherapy is recommended as an option for treating multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma in patients:

- Who have previously been treated with rituximab and
- Who are receiving third- or fourth-line treatment and
- If the manufacturer provides pixantrone with the discount agreed in the patient access scheme

8.1.1 ALKYLATING AGENTS

Busulfan	tablets
Bendamustine	injection
Carmustine	injection
Chlorambucil	tablets
Cyclophosphamide	tablets & injection
Ifosfamide	injection
Lomustine	capsules
Melphalan	tablets & injection

UROTHELIAL TOXICITY

Mesna	tablets & injection
--------------	---------------------

8.1.2 CYTOTOXIC ANTIBIOTICS

Bleomycin	injection
Daunorubicin	injection
Doxorubicin	injection
Epirubicin	injection
Idarubicin	capsules & injection
Mitomycin	injection

(Bladder instillation, Consultant Urologists only & Cytoreductive and HIPEC surgery)

8.1.3 ANTIMETABOLITES

Azacitidine	injection
Capecitabine	tablets
nPbR Cladribine	tablet & injection
Cytarabine	injection
Fludarabine	injection
Fluorouracil	injection & cream
	<i>(cream: Dermatologists only)</i>

Gemcitabine	injection
Mercaptopurine	tablets
Methotrexate	tablets, Injection

Pemtrexed	injection
Tegafur With	capsules

Uracil	
Tioguanine	tablets

Approved for use as second line maintenance therapy in IBD patients who have not tolerated azathioprine and mercaptopurine (or either in the case of pancreatitis) or (methotrexate in Crohn's only). Initiation by gastroenterologists only.

nPbR = Indicates a drug excluded from HRG tariff price

Liposomal cytarabine – daunorubicin
injection

FOLINIC ACID RESCUE

Calcium Folate tablets & injection

8.1.4 VINCA ALKALOIDS & ETOPOSIDE

Vinblastine injection
Vincristine injection
Vindesine injection
Vinorelbine injection & capsules

Notes: Vinca alkaloids should only be given IV. Inadvertent Intrathecal administration can be fatal

Etoposide capsules & injection

8.1.5 OTHER ANTINEOPLASTIC DRUGS

nPbR Abemaciclib tablets
nPbR Alectinib capsules
Amsacrine infusion
Altretamine capsules
(Radiotherapists only)
nPbR Anagrelide tablets
nPbR Bortezomib injection
nPbR Carfilzomib infusion
nPbR Cetuximab infusion
nPbR Crizotinib capsules
nPbR Dacarbazine injection
nPbR Eribulin capsules
Hydroxycarbamide (Hydroxyurea) capsules
nPbR Axitinib tablets
NICE TA645
nPbR Ceritinib capsules

nPbR Dasatinib tablets (for 2nd or 3rd line treatment of CML in line with Cancer network recommendations)

nPbR Everolimus tablets

nPbR Gilteritinib tablet

nPbR Ibrutinib capsules

nPbR Idelalisib 150mg tablets

nPbR Imatinib capsules

nPbR Ixazomib capsules

nPbR Lapatinib tablets

Notes: CCGs funding is required for Lapatinib

nPbR Lenvatinib (Kisplyx®) (Lenvima®) capsules

nPbR Nilotinib capsules

nPbR Niraparib capsules

nPbR Nintedanib capsules

nPbR Nivolumab injection

nPbR Osimertinib tablets

nPbR Pomalidomide capsules

nPbR Ponatinib tablets

nPbR Regorafenib tablets

nPbR Ribociclib tablets

nPbR Sorafenib tablets

nPbR Sunitinib capsules

Notes: CCGs funding is required for nilotinib, sorafenib and sunitinib

nPbR Venetoclax tablets

nPbR = Indicates a drug excluded from HRG tariff price

Pentostatin injection

(Haematologists only for multiple myeloma and myelofibrosis with cytopenias +/- splenomegaly)

PLATINUM COMPOUNDS

Carboplatin injection
Cisplatin injection
Oxaliplatin injection
Procarbazine capsules

ONCOLYTIC VIRAL THERAPY
nPbR Talimogene laherparepvec injection

TAXANES

Docetaxel infusion (Approved 3rd line therapy for metastatic prostate cancer)
Paclitaxel infusion
Paclitaxel (as albumin-bound nanoparticles) infusion
Cabazitaxel intravenous infusion 40mg/ml

TARGETED THERAPY
nPbR Radium 223 dichloride injection

ANTINEOPLASTIC DRUGS – Monoclonal Antibodies

nPbR Avelumab injection
 NICE TA645

nPbR Atezolizumab injection

nPbR Brentuximab vedotin injection

nPbR Daratumumab injection

nPbR Durvalumab injection

nPbR Nivolumab injection

nPbR Obinutuzumab injection

nPbR Ofatumumab injection

nPbR Pembrolizumab injection

nPbR Pertuzumab injection

nPbR Ramucirumab injection

nPbR Trastuzumab injection
 NICE TA704

TOPOISOMERASE I INHIBITORS

Irinotecan hydrochloride infusion
Topotecan infusion

nPbR Thalidomide tablets

8.2 DRUGS AFFECTING THE IMMUNE SYSTEM

8.2.1 ANTIPROLIFERATIVE IMMUNOSUPPRESSANTS

Azathioprine
 25 mg & 50 mg tablets, 50 mg injection

Mycophenolate mofetil
 250 mg capsule, 500 mg tablet
(Unlicensed use - Treatment of lupus nephritis in child-bearing age patients & other autoimmune diseases in similar age groups)
(Also for second-line treatment of severe psoriasis when other treatments have failed – Consultant Dermatologists only)

nPbR Cladribine
 10mg tablets
(For the treatment of relapsing-remitting multiple sclerosis – NICE TA493)

nPbR Ponesimod
 20mg tablets
(For the treatment of relapsing-remitting multiple sclerosis – NICE TA767)

8.2.2 CORTICOSTEROIDS & OTHER IMMUNOSUPPRESSANTS

Prednisolone
See section 6.3.2 for preparations)

Ciclosporin (Cyclosporin) Neoral®
 10 mg, 25 mg 50 mg & 100 mg capsules, 100-mg/ ml oral solution

nPbR = Indicates a drug excluded from HRG tariff price

(Specialist use only)

Ciclosporin 1mg per ml eye drops
0.3ml dose units (**Ikervis®**)
Ciclosporin 1mg/ml eye drops 0.3ml dose
units (**Verkazia®**)

8.2.3 RITUXIMAB

Rituximab

10mg/ml, 10ml and 50ml vial for infusion
(for Rheumatoid Arthritis)

8.2.4 OTHER IMMUNOMODULATING DRUGS

nPbR Glatiramer 20mg/L subcut. injection

Lenalidomide capsules

(3rd line treatment of multiple myeloma,
CCGs funding essential before
prescribing)

nPbR Interferon alfa (Roferon A ®) injection
3, 4.5 & 18 million-units vial,
3, 4.5 & 9 million-units pre-filled syringe,
18 million-units multidose cartridges

nPbR Interferon beta-1b (Betaferon ®)
9.6 million-unit injection
Consultant Neurologists only

nPbR Peginterferon alfa-2a
*(Check brands & strengths stocked with
Pharmacy)*
*(Consultant Gastroenterologist only, for
patients with chronic hepatitis B and C)*

*(Consultant Haematology for patients
with polycythaemia vera or essential
thrombocythaemia)*

nPbR Peginterferon beta-1a (Plegridy®)
(Consultant Neurologists Only)

BCG (Bacillus Calmette-Guerin)
Bladder installation
(Consultant Urologists only)

nPbR Dimethyl Fumarate
(Tecfidera®) 120mg & 240mg e/c
capsules

*(Consultant Neurologists only as per
NICE TA320)*
(Skilrance®) 30mg & 120mg GR tablets
for Plaque Psoriasis NICE TA 475

nPbR Glatiramer acetate
solution for injection

Fampridine 10mg MR tablets
(Consultant Neurologists only for
Episodic ataxia type 2)

**Siponimod (as Siponimod fumaric
acid)** (Mayzent®)
0.25mg & 1mg tablets

IMMUNOSUPPRESSANTS > MONOCLONAL ANTIBODIES > ANTI- LYMPHOCYTE

**Anti-lymphocyte monoclonal
antibodies**

nPbR Alemtuzumab 10mg/ml
concentrate for solution for infusion vials

nPbR Ocrelizumab 30mg/10ml
concentrate for solution for infusion vials

8.3 SEX HORMONES & HORMONE ANTAGONISTS IN MALIGNANT DISEASE

8.3.1 OESTROGENS

Diethylstilbestrol (Stilboestrol)
1 mg tablet

8.3.2 PROGESTOGENS

Medroxyprogesterone acetate
100 mg, 400 mg & 500 mg tablets
(See section 6.4.1.2 for other strengths)

Megestrol acetate
40 mg & 160 mg tablets

Norethisterone
5 mg tablet

nPbR = Indicates a drug excluded from HRG tariff price

8.3.3 ANDROGENS

(See section 6.4.2 for preparations)

8.3.4 HORMONE ANTAGONISTS

8.3.4.1 BREAST CANCER

Tamoxifen 10 mg & 20 mg tablets,
10 mg/ 5 ml oral solution

nPbR Fulvestrant 250mg/5ml solution
for injection

Anastrozole 1 mg tablet

Exemestane 25 mg tablet
(2nd line after 2 – 3yrs of tamoxifen
therapy)

Letrozole 2.5mg tablet

Patent Blue V (Sulphan Blue)
(Unlicensed product. Diagnostic dye used
to stain metastatic lymph nodes in axilla)

8.3.4.2 PROSTATE CANCER & GONADORELIN ANALOGUES

Notes: For patients receiving their first
course of treatment, anti-androgens
should be started three days before the
gonadorelin analogue & normally
continued for three weeks. This will help to
avoid the tumour 'flare' that may occur
after commencing gonadorelin therapy

Abiraterone (Zytiga®) 250mg tablets

(To be funded via Cancer Drugs Fund)

Bicalutamide
50 mg & 150 mg tablets
(Urologists only)

Cyproterone acetate
50 mg & 100 mg tablets

Flutamide 250 mg tablet

Degarelix injection 120mg vial (with
diluent)

Notes: Approved for first dose treatment
only with a switch to Triptorelin or
Goserelin 28 days later

Enzalutamide

40 mg tablets (NICE TA712)

Leuprorelin
(Prostap SR DCS)
3.75mg prefilled syringe

Triptorelin(Decapeptyl® SR)
(I/M injection)
3 mg prefilled syringe

Goserelin (Zoladex ®)
3.6 mg Implant

Notes: In-patients should be encouraged
to bring in their own supply. Patients on
10.8 mg (3 monthly injections) will receive
3.6 mg & their next injection scheduled to
be given in one month

8.3.4.3 SOMATOSTATIN ANALOGUES

nPbR Octreotide (Sandostatin ®) injection
50 mcg/ ml, 100 mcg/ ml & 500 mcg/ ml

nPbR Lanreotide
Somatuline ® LA
Somatuline ® Autogel
(For treatment of acromegaly,
neuroendocrine tumours and thyroid
tumours)
Refer prescriptions to Senior Principal
Pharmacist, Clinical Services)

nPbR = Indicates a drug excluded from HRG tariff price

9 NUTRITION & BLOOD

9.1 ANAEMIAS & SOME OTHER BLOOD DISORDERS

9.1.1 IRON DEFICIENCY ANAEMIAS

9.1.1.1 ORAL IRON

Table: Iron content of different salts

Iron salt	Amount	Content of ferrous iron
fumarate	200 mg 140 mg	65 mg 45 mg
sodium feredetate	190 mg	27.5 mg
glycine sulphate	141 mg	25 mg
gluconate	300 mg	35 mg
sulphate, dried	200 mg 325 mg	65 mg 105 mg

Ferrous sulphate

200 mg tablet,
325 mg m/r tablet (Ferrograd ®)

Ferrous fumarate (Fersamal ®)

140 mg/ 5 ml syrup

Ferrous gluconate

300 mg tablet

Sodium feredate (Sytron ®)

190 mg/ 5 ml elixir

FERROUS SULPHATE & FOLIC ACID

Pregaday ®

Ferrous fumarate (100 mg iron) &
350 micrograms folic acid tablet

Ferric Maltol (Ferracru®) 30mg Capsules

Notes: Ferric maltol is approved as a first line alternative to IV iron for the treatment of iron deficiency anaemia in adults with inflammatory bowel disease (IBD). A course of 12 weeks treatment is required

9.1.1.2 PARENTERAL IRON

Iron dextran (CosmoFer ®)

100 mg/ 2 ml IV/ IM injection

Notes: Parenteral Iron therapy is hazardous. Elevation of Hb is not significantly faster by this route. Parenteral iron should be reserved for patients in whom oral therapy or transfusion is inappropriate or where compliance is a problem. Oral iron therapy should be continued for at least three months to replenish iron stores

Iron Isomaltoside 1000 (Monofer®)

50mg/ml & 100mg/ml IV injection

Iron carboxymaltose (Ferinject®)

50mg/ml injection

9.1.2 DRUGS USED IN MEGALOBlastic ANAEMIAS

Folic acid

5 mg tablet
2.5 mg/ 5 ml syrup

Hydroxocobalamin (Vitamin B₁₂)

1000 micrograms/ ml injection

9.1.3 DRUGS USED IN HYPOPLASTIC, HAEMOLYTIC & RENAL ANAEMIAS

ERYTHROPOIETIN

Erythropoietin beta (NeoRecormon ®)

500, 1000, 2000, 4000, 5000 &
10,000 units pre-filled syringes

IRON OVERLOAD

nPbR 1st Choice: Desferrioxamine 500 mg & 2 g injection

nPbR 2nd Choice: Deferasirox 125mg, 250mg, 500mg Dispersible tablets
(Haematologists' use only- where

nPbR = Indicates a drug excluded from HRG tariff price

desferrioxamine is contraindicated or inadequate)

nPbR Alternative: Deferiprone 500 mg tablet (*Haematologists only- use where desferrioxamine therapy is contraindicated, has failed or has caused serious toxicity*)

9.1.4 DRUGS USED IN PLATELET DISORDERS

Romiplostim (Nplate®)

250 microgram s/c injection

nPbR Lusutrombopag (Mulpleo®) 3mg tablets

Consultant Hepatologists only, for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure (NICE TA 617).

9.1.6 DRUGS USED IN NEUTROPENIA

nPbR Filgrastim (G-CSF) (Zarzio®)
30 million- units (300 micrograms/0.5ml) pre-filled syringe for injection
48 million- units (480 micrograms/0.5ml) pre-filled syringe for injection

(Consultant Haematologist only, must be approved by Haematology Clinical Directorate Lead & Senior Principal Pharmacist, Technical Services)

9.2 FLUIDS & ELECTROLYTES

9.2.1.1 ORAL POTASSIUM

Potassium chloride

(Sando K®)

12 mmol K⁺ per effervescent tablet

(Kay-Cee-L®) 1 mmol/ ml syrup

(Slow-K®)

600 mg or 8 mmol K⁺ per m/r tablet

(For those intolerant to Sando-K®)

Notes: Slow-K is generally no longer used because it has association with oesophageal or small bowel ulceration

POTASSIUM REMOVAL

Calcium polystyrene sulphonate powder (Calcium Resonium®)

30g kit (for rectal administration)

Notes: U&E's *must* be monitored daily.
300g pot

Resonium A may be used in patients who have a high calcium. However it is not recommended for use in patients with congestive heart failure as it contains sodium. These resins can be given rectally (see BNF for further advice)

Patiromer calcium (Veltassa®)

8.4g oral powder sachets

16.8g oral powder sachets

Patiromer is to be used only by consultant nephrologists

Sodium Zirconium Cyclosilicate

5g and 10g sachet (Lokelma®) (NICE TA 599)

9.2.1.2 ORAL SODIUM AND WATER

Sodium chloride (Slow Sodium®)

10 mmol or 600 mg m/r tablet

nPbR = Indicates a drug excluded from HRG tariff price

ORAL REHYDRATION SALTS

Sodium chloride & glucose oral powder (Dioralyte ® sachet)

9.2.1.3 ORAL BICARBONATE

Sodium bicarbonate

Provides 6 mmol each of Na⁺ & HCO₃⁻ per 600 mg tablet & 500mg capsules

9.2.2 PARENTERAL PREPARATIONS FOR FLUID & ELECTROLYTE IMBALANCE

9.2.2.1 ELECTROLYTES & WATER

SODIUM CHLORIDE

0.9 %

2 ml, 5 ml & 10 ml amp,
50 ml vial,
100 ml, 250 ml, 500 ml & 1000 ml bags,
500 ml polyfusor

0.45 %: 500 ml bag

0.18 %, 0.9 %, 1.8 %, 5 %:
500 ml polyfusors

SODIUM CHLORIDE & GLUCOSE

0.18 % & 4 %: 500 ml & 1000 ml bags
0.45 % & 5 %: 500 ml bags

SODIUM LACTATE INTRAVENOUS INFUSION, COMPOUND (HARTMANN'S; RINGER-LACTATE)

500 ml & 1000 ml bags

Plasma-Lyte 1000ml bags

(In critical care areas i.e. ITU, HDU and Theatres only)

GLUCOSE

5 %: 100 ml, 250 ml, 500 ml &
1000 ml bags

10 %: 500 ml & 1000 ml bags

50 %: 50 ml vial & minijet

POTASSIUM CHLORIDE & GLUCOSE 5 % INTRAVENOUS INFUSION

10 mmol K⁺: 500 ml bag

20 mmol K⁺: 500 ml & 1000 ml bags

40 mmol K⁺: 1000 ml bag

Unlicensed preparation:

40 mmol K⁺: 500 ml bag

POTASSIUM CHLORIDE & SODIUM CHLORIDE 0.9 % INTRAVENOUS INFUSION

10 mmol K⁺: 500 ml bag

20 mmol K⁺: 500 ml & 1000 ml bags

40 mmol K⁺: 1000 ml bag

Unlicensed preparations:

40 mmol K⁺: 100 ml (used in KGH ITU)
& 500 ml bags

50 mmol K⁺: 50ml

60 mmol K⁺: 1000 ml bag

80 mmol K⁺: 1000 ml bag

Notes: The above unlicensed preparations, 40 mmol K⁺ in 500 ml bag, 60 mmol & 80 mmol K⁺ in 1000 ml bags are available on consultation with a Pharmacist. Refer to Trust Potassium Policy for further information. The Policy is also available on the Trust Intranet

POTASSIUM CHLORIDE, SODIUM CHLORIDE 0.18 % & GLUCOSE 4 % INTRAVENOUS INFUSION

10 mmol K⁺: 500 ml bag

20 mmol K⁺: 500 ml & 1000 ml bags

40 mmol K⁺: 1000 ml bag

POTASSIUM CHLORIDE, SODIUM CHLORIDE 0.45 % & GLUCOSE 5 % INTRAVENOUS INFUSION

Unlicensed preparation:

20 mmol K⁺: 500 ml bag

(For paediatric DKA patients only)

POTASSIUM CHLORIDE CONCENTRATE 15 %, STERILE

20 mmol K⁺: 10 ml amp.

Notes: This is available in designated areas, but ready mixed bags should be used in the first instance. This is treated as a Controlled Drug. See Trust Potassium Policy

nPbR = Indicates a drug excluded from HRG tariff price

Notes: Potassium Chloride Concentrate 15% has been approved for specific indication in Obstetrics. See Fetal Medicine Guidelines

SODIUM BICARBONATE

1.4 %: 500 ml polyfusor

4.2 %: 10 ml amp.
500ml polyfusor & 4.2 % minijet

8.4 %: 10 ml amp, 50 ml minijet &
100 ml infusion bottle

WATER FOR INJECTION

2 ml, 5 ml, 10 ml & 20 ml amps.

9.2.2.2 PLASMA & PLASMA SUBSTITUTES

Albumin solution (Human)

Isotonic solutions: 4.5 %

Concentrated solutions: 20 %

Notes: Supply obtained from:

- Pathology (KGH)
- Pharmacy (Queens)

PLASMA SUBSTITUTES

Dextran 70

In 500 ml glucose 5 % or sodium chloride 0.9 % infusion

Gelatin 4 % (Gelofusine ®)

500 ml & 1000 ml infusion bags

Succinylated gelatine (Gelaspan®)

500ml & 1L infusion bags

Etherified starch

HAEMOFILTRATION FLUIDS

Table: Fluids stocked on ITU

	HCO ₃ ⁻ free, Contains 40 mmol/ L Lactate	HCO ₃ ⁻ buffered, Contains 3 mmol/ L Lactate
20 mmol K ⁺ per 5L bag	Hemolactol	Prismasol 4

K ⁺ free	Lactasol	Hemosol B0
---------------------	----------	------------

Buffered Dialysis Solution

Prismocal

Phosphate Solution for haemodialysis/ haemofiltration

PHOXILIUM 1.2 mmol/l

Ready-to-use sterile solution for regional citrate anticoagulation

Prismocitrate 10/2 solution

Note: Liaise with the ITU pharmacist if there are any queries on the above haemofiltration fluids

9.3 INTRAVENOUS NUTRITION

There is a multi-disciplinary nutrition team available to advise on any aspect of nutritional care. For information or help bleep the Nutrition Sister/Team or a Dietitian.

A Total Parenteral Nutrition compounding service is available from the Pharmacy Manufacturing unit. TPN solution formulae are based on Kabiven ® range of products.

Each TPN solution must be prescribed on a TPN prescription sheet.

For advice telephone the Pharmacy Production unit on Ext. 3029 (QH) or 8272 (KGH). Adult TPN is **never an emergency & need not be initiated outside normal hours**

9.4 ORAL NUTRITION

Notes: For advice & information on the products available, please consult a dietitian

9.5 MINERALS

Notes: When using the following supplements, it is essential to monitor

nPbR = Indicates a drug excluded from HRG tariff price

plasma concentrations of calcium, phosphate, potassium & other electrolytes

9.5.1.1 CALCIUM (Ca²⁺) SUPPLEMENTS

Calcium gluconate

10 % (2.2 mmol Ca²⁺/ 10ml) injection

Calcium chloride

5 mmol/ 10 ml injection,
10 % minijet for Resus.

Calcium carbonate (Adcal ®)

1.5 g chewable tablets,
600 mg or 15 mmol Ca²⁺/ tablet

Notes: Adult Patients admitted with other brands of calcium (including those with 12.6 mmol Ca²⁺/ tablet), should be converted to Adcal. The DTC has approved for pharmacists to change the prescription

Calcium carbonate (Cacit ®)

1.25 g effervescent tablets,
500 mg or 12.6 mmol Ca²⁺/ tablet
(*Paediatric patients*)

Notes: If patients are on **Cacit ® tubes**, as part of **Didronel PMO ®**, they should use their own supply. If this is impossible, then a Cacit tube may be supplied. Ensure the in-patient chart states '**as part of Didronel PMO ®**', but on discharge **ensure the TTA states** patient has OWN supply. If they are on last Cacit tube & do not have another box for discharge, a supply of Didronel PMO may be made

Calcium-Sandoz ®

2.7 mmol (108.3 mg) Ca²⁺/ 5 ml syrup
(*Paediatrics only*)

Cinacalcet 30 mg & 60 mg tablets
(*Approved for Renal physicians only in dialysis patients for the treatment of secondary hyperparathyroidism associated with chronic renal failure*)

9.5.2.2 HYPERCALCAEMIA

(*See section 6.6.2 for preparations*)

9.5.1.3 MAGNESIUM (Mg²⁺)

Magnesium aspartate anhydrate 6.5g sachet containing 10mmol of Mg²⁺ (**Magnaspartate®**)

Magnesium sulphate

50 % (2 mmol Mg²⁺/ ml) injection

2 ml & 10 ml amps.

Pre-filled syringes for Resus.

20% (0.8mmol Mg²⁺/ ml) injection

Unlicensed. Obstetric and gynaecology consultant only

Magnesium glycerophosphate

4mmol tablet

(*Unlicensed, named patient only*)

Magnesium oxide

4 mmol (160 mg) capsule

(*Unlicensed, named patient only*)

Note: Absorption of magnesium is poor when given orally

9.5.2.1 PHOSPHATE (PO₄³⁻) SUPPLEMENTS

Phosphate-Sandoz ®

16.1 mmol (500 mg) PO₄³⁻ effervescent tablet

Phosphates polyfusor

50 mmol PO₄³⁻ / 500 ml infusion

Addiphos ®

40 mmol PO₄³⁻ / 20ml solution

Refer to Guidelines for correcting Hypophosphataemia prior to the introduction of large volumes of feed (IV)

Notes: 20 ml solution of addiphos contains 30 mmol potassium. This is treated as a Controlled Drug & kept in designated areas.

See Trust Potassium policy

9.5.2.2 PHOSPHATE (PO₄³⁻) BINDING AGENTS

Calcium carbonate (Adcal ®)

1.5 g chewable tablets,
600 mg or 15 mmol Ca²⁺/ tablet

Calcium carbonate (Cacit ®)

1.25 g effervescent tablets,
500 mg or 12.6 mmol Ca²⁺/ tablet

nPbR = Indicates a drug excluded from HRG tariff price

9.5.4 ZINC (Zn²⁺) SUPPLEMENTS

Zinc sulphate (Zincomed ®)
220 mg (50 mg Zn²⁺/capsule)

9.6 VITAMINS

9.6.2 VITAMIN B GROUP

Thiamine (Vitamin B1)
50 mg & 100 mg tablets

Vitamins B & C (Pabrinex ®)
High potency IV and IM injections

Notes: The CSM warns of potentially serious allergic adverse reactions, which may occur during, or shortly after, administration of Intravenous injection of Vitamins B & C (Pabrinex ®), See B.N.F

Pyridoxine (Vitamin B6)
10mg, 20 mg & 50 mg tablets,
50 mg/ ml injection

VITAMIN B COMPLEX PREPARATIONS

Vitamin B compound strong tablet

Notes: The term Vitamin B complex is a generic one, which embraces various brand & generic compound formulations of Vitamin B

9.6.3 VITAMIN C

Ascorbic acid
100 mg, 200 mg & 500 mg tablets
1g soluble tablets

9.6.4 VITAMIN D

Calcium (2.4 mmol) & **ergocalciferol**
(Vitamin D₂, Calciferol) (400 units)
tablets

Ergocalciferol 3000 units/ ml solution
(Unlicensed product)

Alfacalcidol (1 α -Hydroxycholecalciferol)
(One-Alpha ®)
0.25 & 1 micrograms capsules

Calcitriol (1,25-Dihydroxycholecalciferol)
0.25 micrograms capsule

Calcium 600 mg or 15.1 mmol & Colecalciferol (Vitamin D₃)
10 micrograms (400 units) tablet

Colecalciferol Capsule 20
micrograms/800 units

Colecalciferol tablet 20 micrograms/800
units

High dose oral vitamin D 50,000 units
tablets (Unlicensed)

Adcal-D₃® and Adcal-D3 Dissolve®
(Adcal-D3 soluble for those with
swallowing difficulties)

9.6.5 VITAMIN E

Alpha tocopheryl acetate (Vitamin E)
500 mg/ 5 ml suspension

9.6.6 VITAMIN K

Menadiol sodium phosphate
10 mg tablet (*Water-soluble*)

Phytomenadione (Vitamin K₁)
(See under Konakion brands below)

Phytomenadione

Konakion ® 10 mg tablet (unlicensed)

Konakion MM ® 10 mg/ ml injection
(*Slow IV or IV infusion in
glucose 5 % only*) NOT FOR IM injection

Konakion MM Paediatric ®

2 mg/ 0.2 ml injection

(*May be administered by mouth, IM or
IV injection*)

Notes: When Vitamin K is required, prescribe by brand name to avoid confusion.

For prevention of Vitamin K deficiency in malabsorption states, such as biliary obstruction or hepatic disease, the water-soluble Vitamin K preparation, menadiol, must be used.

IM injections are generally inappropriate in patients with bleeding disorders

nPbR = Indicates a drug excluded from HRG tariff price

9.6.7 Multivitamin preparations

Multivitamin tablet & capsule

Abidec ® drops

Forceval ® capsule

(Dietitian recommendation only)

Ketovite tablet & liquid

9.8 METABOLIC DISORDERS

9.8.1 WILSON'S DISEASE

Penicillamine 125 mg & 250 mg tablets

Notes: Patients who are penicillin-allergic, may react rarely to penicillamine

Other metabolic disorders.

Biotin 5mg tablet and 5mg/ml injection

10 MUSCULOSKELETAL & JOINT DISEASE

10.1 DRUGS USED IN RHEUMATIC DISEASES & GOUT

10.1.1 NON-STEROIDAL ANTI-INFLAMMATORY DRUGS

Ibuprofen

200 mg & 400 mg tablets,
100 mg/ 5 ml suspension,
800 mg Retard tablets
(Rheumatologists only)
5 mg/ml injection
(Paediatricians only, for closure of PDA)

Diclofenac

25mg & 50 mg e/c tablets,
50 mg dispersible tablets,
12.5 mg, 25 mg, 50 mg &
100 mg suppositories,
100mg SR tablets (Rheumatologists only)

Note: E/c tablets should not be used PRN, as this has a delayed onset of action

Arthrotec ® 50 (Diclofenac 50 mg & Misoprostol 200 micrograms) tablet
(Rheumatologists, Gastroenterologists & Geriatricians only)

Arthrotec ® 75 (Diclofenac 75 mg & Misoprostol 200 micrograms) tablet
(Rheumatologists, Gastroenterologists & Geriatricians only)

Celecoxib

100 mg & 200 mg capsules
(Consultant Rheumatologist, 2nd line within set criteria)

Flurbiprofen

50 mg & 100 mg tablets
(Ophthalmologists only)

Indometacin (Indomethacin)

25 mg & 50 mg capsules,
75 mg m/r capsule,
100 mg suppositories

Ketoprofen

50 mg & 100 mg capsules,
100 mg m/r capsule

Mefenamic acid

250 mg capsule, 500 mg tablet,
(Menorrhagia & Dysmenorrhoea only)

Meloxicam

7.5 mg & 15 mg tablets
(Rheumatologists only)

Nabumetone

500 mg tablet
(Rheumatologists.
Off label use for pain control by Palliative Care)

Naproxen

250 mg tablet & e/c tablet,
25 mg/ ml suspension

Diclofenac solution for injection
75mg/ml
(Theatres only)

Piroxicam

10 mg & 20 mg capsules
20mg (Feldene Melt) tablet

ASPIRIN & THE SALICYLATES

Aspirin

300 mg tablet & suppository

10.1.2 CORTICOSTEROIDS

10.1.2.1 SYSTEMIC CORTICOSTEROIDS

(See section 6.3 for preparations)

10.1.2.2 LOCAL CORTICOSTEROID INJECTIONS (Specialist use only)

Hydrocortisone acetate

(Hydrocortistab ®) 25 mg/ ml injection

Methylprednisolone acetate

(Depo-Medrone ®)
40 mg/ ml and 80 mg/ 2 ml injection

nPbR = Indicates a drug excluded from HRG tariff price

Methylprednisolone acetate (Depo-Medrone ®) with Lidocaine

40 mg (Methylprednisolone) & 10 mg (Lidocaine)/ ml
1ml and 2ml vials

Prednisolone acetate (Deltastab ®)
25 mg/ ml injection

Triamcinolone acetonide (Adcortyl ®) 10mg/ ml injection
1ml and 5ml vials
(*Intra-articular or Intradermal administration only*)

(Kenalog ®) 40mg/ ml injection
1ml vial and 1ml prefilled syringe
(*Intra-articular or Intramuscular administration only*)

10.1.3 DRUGS WHICH SUPPRESS THE RHEUMATIC DISEASE PROCESS

Sodium Aurothiomalate (Gold)
10 mg, 20 mg & 50 mg in 0.5 ml injection
(*Consultant Rheumatologists only*)

Auranofin 3 mg tablet

Penicillamine 125 mg & 250 mg tablets

Notes: Patients who are hypersensitive to penicillin may react rarely to penicillamine

ANTI-MALARIALS

Chloroquine (*see section 5.4.1 for preparations*)

Hydroxychloroquine sulphate
200 mg tablet

DRUGS AFFECTING THE IMMUNE RESPONSE

Azathioprine
25 mg & 50 mg tablets

Ciclosporin (Cyclosporin) (Neoral ®)
25 mg, 50 mg & 100 mg tablets
(*Specialist use only*)

Cyclophosphamide

50 mg tablet
(*Specialist use only*)

Leflunomide

10 mg, 20 mg & 100 mg tablets
(*RA in patients unresponsive to other DMARDs, Consultant Rheumatologists only*)

Methotrexate

2.5 mg tablets (*Specialist use only*)
injection (*Contact the Production unit for advice*)

Notes: Methotrexate for Rheumatoid Arthritis is a **ONCE WEEKLY DOSE** only. Refer to Methotrexate policy

SULFASALAZINE (SULPHASALAZINE)

Sulfasalazine (Sulphasalazine)

500 mg e/c tablet,
250 mg/ 5 ml suspension

CYTOKINE INHIBITORS

nPbR Adalimumab

(Consultant Rheumatologists only) See below.

Biosimilars:

1st line choice Hyrimoz®
2nd line choice Amgevita®
3rd line choice Humira®
4th line choice Idacio®

nPbR Certolizumab Pegol 200mg/ml
solution for injection pre-filled syringes

nPbR Etanercept 25 mg injection **Enbrel®**

nPbR Etanercept Biosimilars 25 mg
injection **Benepali®**

Notes: Adalimumab is an alternative for etanercept failures or if patient cannot self-inject. Usual starting dose frequency is every two weeks

nPbR = Indicates a drug excluded from HRG tariff price

nPbR Golimumab 50mg & 100mg solution for injection pre-filled syringes

nPbR Infliximab 100 mg IV infusion
(Refer to a Senior Principal Pharmacist)

nPbR Sarilumab 131.6 mg and 175mg solution for injection pre-filled pens
(Refer to a Senior Principal Pharmacist)

nPbR Secukinumab 150mg/ml solution for injection pre-filled pens/syringes (NICE TA 719)

(Refer to a Senior Principal Pharmacist)

nPbR Tocilizumab 80, 200 and 400mg IV infusion
(Refer to a Senior Principal Pharmacist)

nPbR Ustekinumab (Stelara)

90mg/ml sol
(Refer to a Senior Principal Pharmacist)

PHOSPHODIESTERASE TYPE-4 INHIBITORS

nPbR Apremilast 10mg, 20mg and 30mg tablets

PROTEIN KINASE INHIBITORS

nPbR Baricitinib (Olumiant®) 2mg and 4mg tablets. NICE TA681

nPbR Entrectinib (Rozlytrek) capsule. NICE TA644

nPbR Larotrectinib (Vitrakvi) capsule & oral solution. NICE TA630

nPbR Pemigatinib (Pemazyre) tablet. NICE TA722

JANUS KINASE (JAK) INHIBITORS

nPbR Filgotinib (Jyseleca®) 100mg, 200mg tablets (NICE TA676)

nPbR Tofacitinib (Xeljanz®) 5mg, 10mg tablets

nPbR Upadacitinib (Rinvoq®) 15mg tablets. NICE TA665, NICE TA744

10.1.4 GOUT & CYTOTOXIC-INDUCED HYPERURICAEMIA

ACUTE ATTACKS OF GOUT

High dose NSAIDs:

Aspirin is *not* indicated in gout

Colchicine 500 micrograms tablet

Notes: Maximum total dose of colchicine for treatment of gout is 6 mg

Etoricoxib

60 mg, 90mg & 120 mg tablets
(Consultant Rheumatologists only for acute gouty arthritis and pseudo gout)

LONG-TERM CONTROL OF GOUT

1st Choice : Allopurinol

100 mg & 300 mg tablets

2nd Choice: Febuxostat 80mg and 120mg tablets

Benzbromarone 100mg e.c tablets

(Consultant Rheumatologists use only)
Unlicensed

HYPERURICAEMIA ASSOCIATED WITH CYTOTOXIC DRUGS

nPbR Rasburicase

(Fasturtec®)

1.5mg and 7.5mg vial for intravenous infusion. Store in the refrigerator.

nPbR = Indicates a drug excluded from HRG tariff price

10.2 DRUGS USED IN NEUROMUSCULAR DISORDERS

10.2.1 DRUGS WHICH ENHANCE NEUROMUSCULAR TRANSMISSION ANTICHOLINESTERASES

Neostigmine 2.5 mg/ ml injection

Edrophonium 10 mg/ ml injection

Pyridostigmine 60 mg tablet

10.2.2 SKELETAL MUSCLE RELAXANTS

Baclofen

10 mg tablet, 5 mg/ 5 ml liquid,
50 micrograms/ ml intrathecal injection
(*Injection: Dr. Ather only.*)

Tablets are also for pain management in severe chronic fatigue syndrome grade 4, unlicensed use (Prof. Findley only)

Dantrolene 25 mg & 100 mg capsules

Diazepam

(See section 4.1.2 for formulations)

Tizanidine

2 mg & 4 mg tablets
(*Consultant Neurologists & Rehabilitation Medicine Consultant only.*
Last line after baclofen and diazepam)

NOCTURNAL LEG CRAMPS

Quinine sulphate

200 mg & 300 mg tablet

10.3 DRUGS FOR THE RELIEF OF SOFT-TISSUE INFLAMMATION

10.3.1 ENZYMES

Hyaluronidase 1500 units injection

10.3.2 RUBEFACIENTS & OTHER TOPICAL ANTIRHEUMATICS

Movelat® cream & gel

Balmosa® cream

PR Freeze Spray®

Kaolin Poulitice 100g, 200g

TOPICAL NSAIDS

Notes: In line with local policy. Restricted to patients with local soft tissue injury or single arthritic joints, in whom oral NSAIDs are not appropriate & paracetamol-based drugs are ineffective

Ibuprofen 5% gel

Ketoprofen 2.5 % gel

nPbR = Indicates a drug excluded from HRG tariff price

11 EYE

11.3 ANTI-INFECTIVE EYE PREPARATIONS

11.3.1 ANTIBACTERIALS

Azithromycin (Azyter®)
15mg/g eye drops

Cefuroxime sodium (Aprokam)
50mg powder for solution for injection
vials

Chloramphenicol
0.5% eye drops and TTA pack
1% eye ointment and TTA pack
0.5% Minims®

Ciprofloxacin 0.3% eye drops
(*Ophthalmologists*)

Notes: Ciprofloxacin licensed for corneal ulcers & superficial bacterial infections.

Ciprofloxacin 3mg/ml & Dexametasone
1mg/ml ear drops

Levofloxacin 5mg/ml Preservative free
eye drops

Notes:
Licensed for aotitis media in patients with tympanostomy tubes & acute otitis externa

Fusidic acid 1% m/r eye drops and TTA
pack (Fucithalamic®)
(*Ophthalmologists only*)

Gentamicin 0.3% ear/eye drops &
Minims®

Neomycin sulphate 0.5 % eye drops,
eye ointment

Ofloxacin 0.3% eye drops and TTA pack
(*Ophthalmologists only*)

Notes: Ofloxacin is licensed for external Ocular infections, e.g. Conjunctivitis & keratoconjunctivitis, **not corneal ulcers**

Polymyxin B sulphate (Polyfax®)
Polymyxin B sulphate 10,000units,
bacitracin zinc 500 units/ gram
eye ointment

11.3.3 ANTIVIRALS

Aciclovir 3% eye ointment and TTA pack

Notes: Apply five times daily & continue for at least three days after complete healing

Ganciclovir 0.15% eye gel

PREPARATIONS FOR THE TREATMENT OF KERATITIS

Polyhexamethylene biguanide (PHMB)
0.02% eye drops
Natamycin 5% Eye drops

11.4 CORTICOSTEROIDS & OTHER ANTI INFLAMMATORY PREPARATIONS

11.4.1 CORTICOSTEROIDS

Betamethasone (Betnesol®)
0.1% ear/ eye/ nose drops
0.1% eye ointment

Betamethasone 0.1% with neomycin 0.5% (Vista-Methasone N®) ear/ eye/nose drop

(Maxidex®) Dexamethasone 0.1% & Hypromellose 0.5% eye drops and TTA pack & Minims

nPbR = Indicates a drug excluded from HRG tariff price

(Maxitrol ®) Dexamethasone 0.1%, neomycin 0.35% & polymyxin B sulphate 6000 units/ml eye drops & eye ointment

(Sofradex ®) Dexamethasone 0.05%, framycetin 0.5% & gramicidin 0.005% ear/ eye drops and TTA pack

Fluorometholone (FML ®)
Fluorometholone 0.1%, polyvinyl alcohol (Liquifilm®) 1.4% eye drops)

Prednisolone sodium phosphate (Predsol ®)
0.5% ear/eye drops & Minims®

Prednisolone acetate (Pred Forte ®)
1% eye drops

(Predsol N ®) Prednisolone 0.5% & neomycin 0.5% ear/eye drops

Rimexolone 1% eye drops
(*Ophthalmologists only*)

Hydrocortisone 3.35mg/ml eye drops, solution in single-dose container (Softacort®)

INTRAVITREAL CORTICOSTEROIDS

Ozurdex® Dexamethasone intravitreal implant 700micrograms
(*Ophthalmologists only*)

11.4.2 OTHER ANTI-INFLAMMATORY PREPARATIONS

(Otrivine-Antistin ®)
Antazoline sulphate 0.5% & Xylometazoline 0.05% eye drops and TTA pack

Lodoxamide 0.1% eye drops
(*Ophthalmologists only*)

Sodium cromoglicate 2% eye drops

Nedocromil 2% eye drops

Ketotifen 0.25mg/ml preservative free eye drops

11.5 MYDRIATICS & CYCLOPLEGICS

Atropine sulphate 0.5% eye drops

nPbR = Indicates a drug excluded from HRG tariff price

1% eye drops, ointment & Minims®

Cyclopentolate
0.5% and 1% eye drops
0.5% and 1% Minims®

Homatropine 1% & 2% eye drops

Tropicamide 0.5% & 1% eye drops & Minims®

SYMPATHOMIMETICS

Phenylephrine
2.5% and 10% Minims®

Phenylephrine hydrochloride 5.4mg & Tropicamide 280 micrograms
(**Mydrisert®** ophthalmic insert)

11.6 DRUGS FOR THE TREATMENT OF GLAUCOMA

1st LINE EYE DROPS

- a. * **Lumigan ®** (Bimatoprost 100 & 300 micrograms/ml)
- b. * **Ganfort®** (Bimatoprost 300 micrograms/ml & Timolol 5mg/ml)
- c. * **Timolol LA ®** (Timolol) 0.25%, 0.5%

2nd LINE EYE DROPS

- a. * **Xalatan ®** (Latanoprost) 0.005%
* **Monopost ®** (Latanoprost) 0.005% unit dose
- b. * **Xalacom ®** (Latanoprost 0.005% & Timolol 0.5%)
* **Fixapost ®** (Latanoprost 0.005% & Timolol 0.5%) unit dose
- c. * **Cosopt ®**
(Dorzolamide 2 % & Timolol 0.5%)
- d. * **Trusopt ®** (Dorzolamide) 2%
- e. * **Alphagan ®** (Brimonidine) 0.2%
- f. * **Combigan ®** (Brimonidine 0.2% & timolol 0.5%)
- f. * **Pilocarpine ®** 1%, 2%, 4%

ORAL TREATMENTS

* **Diamox ®** & * **Diamox SR ®**

(Acetazolamide) 250 mg tablet & SR capsule

*(*Ophthalmologists only*)

3rd LINE EYE DROPS

Travatan® (Travaprost 40micrograms/ml) 2.5ml eye drops

Azopt® (Brinzolamide) 10mg/ml eye drops

Azarga® (Brinzolamide 10mg, timolol 5mg/ml)

BETA-BLOCKERS

Betaxolol (Betoptic ®) 0.25% m/r & 0.5% eye drops

Levobunolol (Betagan ®) and 0.5% polyvinyl alcohol (Liquifilm®) eye drops and Minims

Note: Use dorzolamide drops (Trusopt ®) where beta blockers are contra-indicated or not effective alone

11.7 LOCAL ANAESTHETICS

Oxybuprocaine 0.4 % Minims ®

Proxymetacaine 0.5 % Minims ®

Proxymetacaine 0.5 % & **Fluorescein** 0.25 % Minims ®

Tetracaine hydrochloride (Amethocaine hydrochloride) 0.5 % & 1 % Minims ®

11.8 MISCELLANEOUS OPHTHALMIC PREPARATIONS

11.8.1 TEAR DEFICIENCY, OCULAR LUBRICANTS & ASTRINGENTS

Hypromellose 0.3%, 0.5% eye drops, 0.3% preservative free eye drops (*Unlicensed*)
2% eye drops (*Unlicensed*)

Carbomers (Viscotears ®) 0.2 % liquid gel & Preservative-free dose units (*Ophthalmologists only*)

Carmellose Sodium

1% eye drops in dose units (**Celluvisc®**)

0.5% eye drops + glycerol (**Optive®**)

Hydroxypropyl guar, Polyethylene glycol 400 propylene glycol 0.3% (Systane®)

10ml bottle and 0.8ml minims

Liquid paraffin (Lacri-Lube ®) eye ointment

Polyvinyl alcohol

(Liquifilm®) eye drops

Potassium ascorbate

10% eye drops (unlicensed)
RUM drug

Sodium chloride

0.9 % eye drops (Minims ®)

Sodium Hyaluronate 0.15% with Trehalose 3% pf eye drops (Thealoz Duo®)

Balanced salt solution

11.8.2 OCULAR DIAGNOSTIC & PERI-OPERATIVE PREPARATIONS & PHOTODYNAMIC TREATMENT

OCULAR DIAGNOSTIC PREPARATIONS

Fluorescein sodium

1 % & 2 % Minims ® & 1 mg strips

OCULAR PERI-OPERATIVE DRUGS

Acetylcholine chloride (Miochol-E ®)

1% Intra-ocular irrigation (*Ophthalmologists only*)

Apraclonidine (Iopidine ®)

0.5 % & 1 % ophthalmic solution (*Ophthalmologists only*)

Diclofenac sodium 0.1 % unit dose eye drops (single use) (*Ophthalmologists only*)

Ketorolac 0.5 % eye drops (*Ophthalmologists only*)

nPbR = Indicates a drug excluded from HRG tariff price

Nepafenac 1mg/ml eye drops
(for reducing the risk of postoperative macular oedema in diabetic patients undergoing cataract surgery)

OPHTHALMIC VISCOELASTIC DEVICE
Healon® Sodium Hyaluronate 1%
Healon 5® Sodium Hyaluronate 2.3%
Healon GV® Sodium Hyaluronate 1.4%
(Ophthalmologists only)

SUBFOVEAL CHOROIDAL NEOVASCULARISATION

Aflibercept (Eylea®)

Brolucizumab (Beovu®)
Ranibizumab (Lucentis®)

Bevacizumab (Avastin®) *(unlicensed)*
(Cons. Ophthalmologist only for treatment of age-related macular degeneration in patients that meet NICE criteria)

Indocyanine Green (ICG) injection
(Approved for Consultant Ophthalmologist's use for choroid related diagnosis and Vascular Neurosurgeons for Intracranial Aneurysms)

12 EAR, NOSE & OROPHARYNX

12.1 DRUGS ACTING ON THE EAR

12.1.1 OTITIS EXTERNA

ANTI-INFLAMMATORY PREPARATION

Betamethasone (Betnesol ®)

0.1% ear/ eye/ nose drops

Prednisolone (Predsol ®)

0.5% ear/ eye drops

ANTI-INFLAMMATORY PREPARATION WITH ANTIBACTERIAL

Betamethasone 0.1% & neomycin

0.5% ear/ eye/ nose drops

(Vista-Methasone N ®)

Dexamethasone 0.05%, framycetin

0.5% & gramicidin 0.005% ear/ eye drops

(Sofradex ®)

Dexamethasone 0.1% & neomycin 3250 units/ml ear spray **(Otomize ®)**

Flumetasone 0.02% & clioquinol 1% ear drops **(Locorten-Vioform ®)**

Hydrocortisone 1% & gentamicin 0.3% ear drops **(Gentisone HC ®)**

Hydrocortisone 1%, neomycin 3400 units & polymyxin B 10000 units/ ml **(Otosporin ®)**

Prednisolone 0.5 % & neomycin 0.5 % **(Predsol-N ®)**

ANTI-INFECTIVE PREPARATIONS

Chloramphenicol 5%

Ear drops

Clioquinol (Locorten-Vioform ®)

Ear drops

Clotrimazole (Canesten)

1% solution

(Sofradex ®)

Dexamethasone 0.05%, framycetin 0.5% & gramicidin 0.005% ear/ eye drops

Gentamicin (Genticin) 0.3% eye/ ear drops

(Gentisone HC ®) Gentamicin 0.3 % & Hydrocortisone 1 % ear drops

Neomycin

(Predsol-N ®) ear/ eye drops,
(Otosporin ®) ear drops,

nPbR = Indicates a drug excluded from HRG tariff price

(Vista-Methasone N ®) ear/ eye/ nose drops,
(Otomize ®) ear spray

12.1.2 OTITIS MEDIA

Boric acid powder – not from pharmacy
(for chronic discharge from ear secondary to chronic otitis media, ENT Surgeons only, unlicensed)

12.1.3 REMOVAL OF EAR WAX

Sodium bicarbonate BPC ear drops
Cerumol ® ear drops- unsuitable for patients with nut allergy
(2nd line after sodium bicarbonate ear drops have failed. Contains arachis (peanut) oil)

12.2 DRUGS ACTING ON THE NOSE

12.2.1 DRUGS USED IN NASAL ALLERGY

Beclometasone dipropionate
50 mcg/ dose nasal spray
(First line)

Betamethasone (Betnesol ®)
0.1 % ear/ eye/ nose drops

Fluticasone furoate (Avamys®)
27.5mcg/dose/dose nasal spray

Mometasone (Nasonex ®)
50 mcg/ dose nasal spray

Triamcinolone acetonide
(Nasacort ®) 55 mcg/ dose nasal spray

Dexamethasone isonicotinate
(Dexa-Rhin spray Duo ®)
20mcg/ dose nasal spray

Sodium cromoglicate
(Rynacrom ®) 4 % nasal spray

Second Line

Once existing formulary treatments and self-care options have been exhausted.

Fluticasone with azelastine
50microgram/137microgram per actuation

Dymista®

DRUGS USED FOR NASAL CRUSTING

Glucose in Glycerol 25% nasal drops
(unlicensed) *(ENT consultants use only)*

Note: 2nd line treatment of nasal crusting in patients with vasculitis after saline douche in combination with steroid inhalers

12.2.2 TOPICAL NASAL DECONGESTANTS

Ephedrine hydrochloride
0.5% & 1% drops

Sodium chloride 0.9 % drops

Xylometazoline
0.05% paediatric drops,
0.1% drops & spray (adult)

Ipratropium bromide
(Rinatec ®) 0.03% nasal spray

NASAL STAPHYLOCOCCI

Mupirocin 2% (Bactroban Nasal ®) ointment
As per MRSA Policy (May 2007)
If MRSA positive:

1st Choice: Apply to both nostrils three times daily for one week and re-swab 48 hours post-treatment.
Negative screen result- stop treatment
Positive screen result- continues treatment until 7th day then rescreen 48 hours post-treatment.

Alternative: Polyfax (Polymixin Sulphate and Bacitracin) if Mupirocin (Bactroban) resistant.

EPISTAXIS

Chlorhexidine 0.1% & Neomycin 0.5%

nPbR = Indicates a drug excluded from HRG tariff price

cream (Naseptin ®)- Contains Arachis (Peanut Oil.) Unsuitable for nut allergy sufferers

Bismuth Subnitrate & Iodoform Paste

12.3 DRUGS ACTING ON THE OROPHARYNX

12.3.1 DRUGS FOR ORAL ULCERATION & INFLAMMATION

Benzydamine hydrochloride 0.15%
Difflam ® oral rinse
Difflam ® spray (*Paediatrics only*)

Carmellose (Orabase ®) paste

CORTICOSTEROIDS

Hydrocortisone
2.5 mg pellets

SALICYLATES

Choline Salicylate Dental Gel, BP
(Bonjela ®) Not for children <16 years

12.3.2 OROPHARYNGEAL ANTI-INFECTIVE DRUGS

Amphotericin (Fungilin ®)
10 mg lozenges

Miconazole (Daktarin ®)
20mg/g oral gel

Nystatin
100,000 units/ml oral suspension

12.3.4 MOUTHWASHES, GARGLES & DENTIFRICES

Chlorhexidine gluconate
0.2% mouthwash (From general stores, not pharmacy)
1% dental gel

Hydrogen Peroxide Solution 3% (10 vol)

Mouthwash effervescent tablets

12.3.5 TREATMENT OF DRY MOUTH

Artificial saliva oral spray

Treatment of bony cavities post removal of odontogenic keratocyst.

Carnoy's solution (unlicensed product)
(*For use by Oral and Maxillofacial Consultants only*)

13 SKIN

13.2 EMOLLIENT & BARRIER PREPARATIONS

Note: please check availability of pack sizes with the pharmacy

Aquamax™ cream

Cetraben ® cream

Hydromol ® ointment

Emulsifying ointment, BP

Liquid & white soft paraffin 50%

Unguentum M ® cream

White soft paraffin

Yellow soft paraffin

Note: Aqueous cream and emulsifying ointment are useful as soap substitutes

13.2.1.1 EMOLLIENT BATH ADDITIVES

Balneum Plus ® bath treatment

Emulsiderm ®

nPbR = Indicates a drug excluded from HRG tariff price

Dermol 200® shower emollient
(*Dermatologists only*)

Dermol 600® bath emollient
(*Dermatologists only*)

Dermol 500® Lotion (Occupational
Health use only)

Oilatum® emollient

Baby bath

13.2.2 BARRIER PREPARATIONS

Zinc & castor oil ointment, BP

Metanium® ointment

Sudocrem® cream

Conotrane® cream

Drapolene® cream

Sprilon® spray

13.3 TOPICAL LOCAL ANAESTHETICS & ANTIPRURITICS

Calamine lotion (from general stores)

Crotamiton 10% cream (Eurax®)

Doxepin 5% cream (*Dermatologists only*)

13.4 TOPICAL CORTICOSTEROIDS

Note: Relative potencies of topical corticosteroids:

Mild: hydrocortisone 0.1-2.5%

Moderate: clobetasone butyrate 0.05%

Potent: betamethasone valerate 0.1%
& hydrocortisone butyrate

Very potent: clobetasol propionate 0.05%

Hydrocortisone 0.5%, 1% & 2.5% cream
& ointment

HYDROCORTISONE COMPOUND PREPARATIONS

Alphaderm® (hydrocortisone 1% & urea
10%) cream

Canesten HC® (hydrocortisone 1% &
clotrimazole 1%) cream

Daktacort® (hydrocortisone 1% &
miconazole 2%) cream-store in fridge
ointment-store at room temperature

Eurax-Hydrocortisone®
(hydrocortisone 0.25% & crotamiton
10%) cream

Fucidin H® (hydrocortisone 1% & fusidic
acid 2%) cream & ointment

Nystaform-HC® (hydrocortisone 0.5%,
nystatin 100,000 units/g & chlorhexidine
hydrochloride 1%) cream & ointment

Timodine® (hydrocortisone 0.5%,
nystatin 100,000 units/g, benzalkonium
chloride 0.2% & dimethicone '350' 10%)
cream

Vioform-Hydrocortisone®
(hydrocortisone 1% & clioquinol 3%)
cream & ointment

Notes: Corticosteroids should be applied
once or twice daily & should be used for
not more than 5-7 days, unless advised.
The more potent the preparation the more
sparingly it should be applied

HYDROCORTISONE BUTYRATE 0.1 %

Locoid® lipocream, ointment & scalp
application (*Dermatologists only*)

Locoid C® (with chlorquinaldol 3 %)
cream & ointment (*Dermatologists only*)

ALCLOMETASONE DIPROPIONATE

Modrasone® (alclometasone
dipropionate 0.05 %) cream & ointment

nPbR = Indicates a drug excluded from HRG tariff price

(Dermatologists only)

BETAMETHASONE ESTERS

Betnovate® (betamethasone valerate 0.1%) cream, ointment & scalp application

Betnovate-RD® (betamethasone valerate 0.025%) cream & ointment

Betnovate-C® (betamethasone valerate 0.1% & clioquinol 3%) cream & ointment

Diprosalic® (betamethasone dipropionate 0.05 %)

with salicylic acid 3 % ointment,
with salicylic acid 2 % scalp application

Lotriderm® (betamethasone dipropionate 0.05% & clotrimazole 1%) cream *(Dermatologists only)*

FuciBET® (betamethasone valerate 0.1% & fusidic acid 2%) cream *(Dermatologists only)*

CLOBETASONE PROPIONATE 0.05%

Dermovate® cream, ointment & scalp application

Etrivex® shampoo (for psoriasis)

CLOBETASONE BUTYRATE 0.05%

Eumovate® cream & ointment

Trimovate® (with oxytetracycline 3% & nystatin 100,000 units/g) cream *(Dermatologists only)*

Note: Trimovate® *stains clothing*

FLUDROXYCORTIDE (FLURANDRENOLONE)

Haelan® tape *(Dermatologists only)*

FLUOCINOLONE ACETONIDE

Synalar® 0.025% cream & gel

FLUOCINONIDE 0.05%

Metosyn® cream & ointment

MOMETASONE FUROATE

Elocon® 0.1% cream & ointment *(Dermatologists only)*

TRIAMCINOLONE ACETONIDE 0.1%

Aureocort® (with chlortetracycline 3%) Ointment *(Dermatologists only)*

Tri-Adcortyl® (with gramicidin 0.025%, neomycin 0.25% & nystatin 100,000 units/g) ointment & cream

Notes: The use of topical antimicrobial agents is to be discouraged as this can cause sensitisation & contribute towards bacterial resistance

13.5 PREPARATIONS FOR ECZEMA AND PSORIASIS

13.5.1 PREPARATIONS FOR ECZEMA

Glycerin of Ichthammol liquid
(Unlicensed)

Oral retinoid for eczema

Alitretinoin (Toctino®) 10mg & 30mg capsules
(Dermatologists only as per NICE, it is recommended for the treatment of severe chronic hand eczema that has not responded to potent topical corticosteroids TA 177)

13.5.2 PREPARATIONS FOR PSORIASIS

5-Methoxypsoralen
20 mg tablet- not in the BNF
(Dermatologists only)

8-Methoxypsoralen
10 mg tablet, 0.15 % emulsion (paint) & 1.2 % bath lotion- not in the BNF

Notes: Methoxypsoralen preparations are unlicensed preparations, which are in the exempt list of the Trust Unlicensed Medicines Policy. They are treated as named patient items. *(For use with PUVA by Dermatologists only)*

nPbR = Indicates a drug excluded from HRG tariff price

Calcitriol 3micrograms/g ointment
Silkis® (*Dermatologists only*)

Dovobet® ointment and gel
(betamethasone as dipropionate 0.05%
and Calcipotriol 50micrograms/g)

Enstilar® cutaneous foam
(betamethasone dipropionate
500micrograms/g and Calcipotriol
50micrograms/g)

TAZAROTENE

Tazarotene 0.05% gel
(*Dermatologists only, 2nd line*)

COAL TAR

Sebco® scalp ointment (Compound
Coconut ointment)

Polytar Emollient® bath additive

Notes: Polytar Emollient® contains
arachis (peanut) oil

Alphosyl HC®
(with hydrocortisone 0.5%) cream

DITHRANOL

Dithranol (Dithrocream®)
0.1%, 0.25% & 2% cream
(*Dermatologists only*)

ACITRETIN

Acitretin (Neotigason®)
10 mg & 25 mg capsules
(*Hospital only medicine, Dermatologists
only*)

13.5.3 DRUGS AFFECTING THE IMMUNE RESPONSE

Ciclosporin (Cyclosporin) (Neoral®)
25 mg, 50 mg & 100 mg capsules
(*Dermatologists only*)

Methotrexate 2.5 mg tablets
(*Dermatologists only*)

Warning: Methotrexate is given once
weekly for this indication. Follow Trust
Methotrexate policy

Tacrolimus (Protopic)
0.03% & 0.1% ointment
(*Dermatologists only*)

nPbR Adalimumab (NICE TA 715)

nPbR Anakinra (NICE TA685)

nPbR Bimekizumab (NICE TA723)

nPbR Brodalumab

nPbR Dupilumab

nPbR Etanercept

nPbR Guselkumab

nPbR Infliximab

**nPbR Ixekizumab (Rheumatology &
Dermatology use)(NICE TA 718)**

nPbR Risankizumab 2 x 75mg solution for
injection in pre-filled syringe to be
replaced by single pack of 150mg pf pen

nPbR Tildrakizumab

nPbR Ustekinumab 90mg/ml injection
0.5ml (45mg) vial

13.6 ACNE & ROSACEA

Azelaic acid 25% cream
(*Consultant Dermatologist only for
melasma. Unlicensed indication*)

Benzoyl peroxide
2.5% & 5% gel

Clindamycin phosphate (Dalacin T®)
1% lotion

Clindamycin 1% & benzoyl peroxide
5% (Duac®) topical Gel

Zineryt® (erythromycin 40 mg/ml & zinc
acetate 12 mg/ml) topical lotion

Adapalene 0.1% gel (Differin®)

Adapalene 0.1% & benzyl peroxide
2.5% gel (Epiduo®)
(*Dermatologists only*)

nPbR = Indicates a drug excluded from HRG tariff price

Tretinoin (Retin-A ®)
0.025% cream & 0.01% gel
(*Dermatologists only*)

13.6.2 ORAL PREPARATIONS FOR ACNE

Cyproterone 2 mg & ethinyloestradiol 35 micrograms tablets (**Dianette ®**)
(*Dermatologists only*)

Isotretinoin 5 mg & 20 mg capsules (**Roaccutane ®**) (*Hospital only medicine*)
(*Dermatologists only*)

13.7 PREPARATIONS FOR WARTS & CALLUSES

SALICYLIC ACID

Cuplex ® 11% gel

Occlusal ® 26% application

Duofilm ® 16.7% paint

Verrugon ® 50% ointment
(*GUM clinic only*)

FORMALDEHYDE

Notes: Formaldehyde foot wash is extemporaneously prepared in pharmacy

SILVER NITRATE 75% sticks

ANOGENITAL WARTS

Imiquimod (Aldara ®) 5% cream
(*GUM clinic for genital & perianal warts when all other drug treatments have failed. Dermatologists for last line treatment for anogenital warts only*)

PODOPHYLLUM

Condyline ® 0.5% solution
TTA pack available
(*GUM only*)

Warticon ® 0.15% cream
TTA pack available
(*GUM only*)

Warticon ® 0.5% solution for men (with mirror for women- **Warticon Fem®**)
(*GUM only*)

13.8 SUNSCREENS & CAMOUFLAGERS

13.8.1 SUNSCREEN PREPARATIONS

RoC Total Sunblock ®

Ingenol mebutate (Picato®)150 micrograms/g & 500 micrograms/g gel

CAMOUFLAGERS

Hydroquinone 2 % and 5% cream
Unlicensed product and short expiry date
(*Dermatologists only*)

13.9 SHAMPOOS & OTHER PREPARATIONS FOR SCALP

Selsun ® shampoo

Capasal ® shampoo

Polytar ® liquid

Notes: Polytar ® contains arachis (peanut) oil

Nizoral ® (Ketoconazole) shampoo
(*Dermatologists only*)

13.10 ANTI-INFECTIVE SKIN PREPARATIONS

13.10.1 ANTIBACTERIAL PREPARATIONS

Fusidic acid (Fucidin ®)
2% cream & ointment
(*Dermatologists or Microbiologists only*)

Metronidazole (Metrogel ®) 0.75% gel
(*For acne rosacea, Dermatologists only*)

(Metrotop ®) 0.8% gel
(*Malodorous tumours & skin ulcers*)

Mupirocin (Bactroban ®) 2% ointment

Notes: Bactroban ointment contains macrogol. Manufacturers advise caution in renal impairment, may sting

Polymyxin B sulphate (Polyfax ®) ointment
(*Microbiologists only*)

nPbR = Indicates a drug excluded from HRG tariff price

Silver sulfadiazine (Flamazine ®)
1 % cream

13.10.2 ANTIFUNGAL PREPARATIONS

Clotrimazole 1 %
cream, dusting powder & solution

Ketoconazole 2 % cream
(*Dermatologists only*)

Miconazole (Daktarin ®) 2 % cream

Terbinafine 1% cream
(*Dermatologists only*)

13.10.3 ANTIVIRAL PREPARATIONS

Aciclovir 5 % cream

Notes: Aciclovir cream should be used five times a day at the first sign of any symptoms for 5 to 10 days. It is not very effective once vesicles have appeared. Confirm whether systemic treatment is more appropriate

13.10.4 PARASITICIDAL PREPARATIONS

For treatment of scabies- refer to infection control policy

1st Choice: Malathion (Derbac-M ®)
0.5 % liquid (in aqueous base)
(*First line*)

Alternative: Permethrin (Lyclear ®)
1 % cream rinse & 5 % dermal cream
(*Dermatologists & Microbiologists only*)

Alternative: Ivermectin 3 mg tablet
(*Unlicensed medicine, named patient. Dermatologists & Microbiologists for resistant scabies only*)

Notes: There is a Regional policy for the treatment and prevention of head lice. Compliance with manufacturers' instructions for these preparations is especially important

13.10.5 PREPARATIONS FOR MINOR CUTS & ABRASIONS

Proflavine cream, BPC

Magnesium sulphate paste, BP

Flexible Collodion, BP-

Contraindications: allergy to colophony in elastic adhesive plaster and tape

13.11 SKIN CLEANSERS & ANTISEPTICS

13.11.1 ALCOHOLS & SALINE
Sodium Chloride 0.9 %
25 ml sterile sachets

13.11.2 CHLORHEXIDINE SALTS
Hydrex ®

13.11.4 IODINE COMPOUNDS
Videne ®

13.11.5 PHENOLICS (TRICLOSAN)
Aquasept ® 2 % skin cleanser
Octenisan ®

13.11.6 ASTRINGENTS, OXIDISERS & DYES

Hydrogen peroxide
3 % w/ v (10 vols) solution

Hydrogen peroxide 1% cream

Potassium permanganate
400 mg solution tablets

(*Dermatology Use Only*)

13.11.7 DESLOUGHING AGENTS
Sterile Larvae (maggots) therapy

13.12 ANTIPERSPIRANTS

Aluminium chloride hexahydrate
(Driclor ®) 20 % application

13.12 WOUND MANAGEMENT PRODUCTS

Notes: In line with local policy. Products are sourced differently across the sites. Other dressings may be

nPbR = Indicates a drug excluded from HRG tariff price

available from clinical supplies (Havering)
or central stores (KGH)

13.13.1 ALGINATE DRESSINGS

Kaltostat ® dressing
Kaltostat ® wound packing

Sorbsan ®
Sorbsan ® ribbon
Sorbsan ® packing

13.13.2 FOAM DRESSINGS

Allewyn ®

adhesive, cavity, sacral, thin & heel

Lyof foam ® dressing

Tielle ® dressing

Cavi-Care ®

13.13.3 HYDROGEL DRESSINGS

Granugel ®

Intrasite ® gel

13.13.4 HYDROCOLLOID DRESSING

Granuflex ® bordered dressing & paste

13.13.6 LOW ADHERENCE DRESSING & WOUND CONTACT MATERIALS

Povidone-iodine fabric dressing

13.13.7 ODOUR ADSORBENT DRESSING

Denidor ® (Charcoal) dressing

13.13.9 MEDICATED BANDAGES

Zipzoc ® tubular bandage
(*Dermatologists only*)

13.13.10 OTHER WOUND MANAGEMENT PRODUCTS

Opsite ® plastic spray

Bactigras ® (chlorhexidine acetate tulle)

13.13.11 THEATRE PRODUCTS

Palacos LV with gentamicin ®

Palacos R with gentamicin ®

Collatamp G ®

Geliperm ® wet dressing

Haemostatic Adsorbant Gauze

Horsley's Bone wax
(*Unlicensed*)

13.14 TOPICAL CIRCULATORY PREPARATIONS

Hirudoid ® 0.3 % cream

14 IMMUNOLOGICAL PRODUCTS & VACCINES

14.4 VACCINES & ANTISERA

Notes: For up to date vaccine
information, please refer to
www.dh.gov.uk/ "Green Book" (search for
immunisation)

BCG (Bacillus Calmette-Guerin)
vaccine (for chest clinic and occ. Health
use only)

Notes: It is essential to use the supplied
diluent to reconstitute

**Diphtheria, tetanus, pertussis
(acellular) and inactivated polio**
(DtaP/IPV) vaccine (Infanrix IPV ®)

**Diphtheria, tetanus, pertussis
(acellular) and inactivated polio**
(dtaP/IPV) vaccine (Repevax ®)

nPbR = Indicates a drug excluded from HRG tariff price

Notes: These are interchangeable in the childhood immunisation scheme. Use for children aged 3 to 10.

Diphtheria, tetanus and inactivated polio

Haemophilus influenzae type B (Hib) vaccine

Haemophilus influenzae type b conjugate vaccine and Meningococcal Group C Conjugate vaccine (Menitorix®)

Hepatitis A vaccine (Havrix Monodose® for Occ. Health use only)

Hepatitis A and B vaccine

Hepatitis B vaccine (Engerix B®)

Hepatitis B paediatric vaccine

Influenza vaccine

Measles, Mumps & Rubella (MMR) Vaccine (LIVE) MMRvaxPro® Priorix®

Meningitis C conjugate vaccine Meningitec®, Menjugate Kit®, NeisVac C®

Meningococcal groups A CWY vaccine

Pneumococcal polysaccharide vaccine (Pneumovax II® vaccine)

Notes: Pneumovax II® is for children over 2 years of age

Pneumococcal polysaccharide conjugated vaccine (Prevenar®)

Notes: Prevenar® is for children under 2 years of age

Typhoid vaccine

Varicella-zoster vaccine (Varilix®▼ , Varivax®▼

Anti-tetanus Immunoglobulin

(available from Public Health Laboratory)

Anti-hepatitis Immunoglobulin

(Available from Public Health Laboratory)

Anti-D Immunoglobulin 500 & 1500 units injection

DIAGNOSTIC TESTS

Tuberculin PPD 2TU injection

There is no licensed preparation currently available. Contact Chest Clinic for advice. For chest clinic and occ. Health use only

Notes: * used for Mantoux test

14.5 IMMUNOGLOBULINS

nPbR Normal Immunoglobulin

For intravenous use

(Please refer to pharmacy for brands & strengths stocked)

Notes: Please refer to BHRUT Demand management Plan for Immunoglobulin Use ([link](#))

Immunoglobulin request form and Immunoglobulin Follow Up form available on the intranet ([link](#))

Use must be approved by Panel before supply from Pharmacy.

Specific Immunoglobulins

Consult Microbiologist to arrange if indicated.

Tetanus Immunoglobulin (Antitetanus Immunoglobulin Injection)

Hepatitis B immunoglobulin

nPbR = Indicates a drug excluded from HRG tariff price

15 ANAESTHESIA

15.1 GENERAL ANAESTHESIA

15.1.1 INTRAVENOUS ANAESTHETICS

Thiopental sodium 500 mg injection

Etomidate 20 mg/10 ml injection

Ketamine injection

10 mg/ml, 100 mg/ml, 50 mg/ml

Propofol injection

10mg/ml, 500 mg/50ml, 200mg/20ml

Propofol 1% injection (Diprifusor® TCI System)

(for endarterectomies anaesthetised by Dr. Igielman & Dr. Khalil only)

15.1.2 INHALATIONAL ANAESTHETICS

Isoflurane

Sevoflurane

Enflurane

Halothane

15.1.3 ANTIMUSCARINIC DRUGS

Atropine sulphate

600 micrograms/ml injection

Glycopyrronium bromide

200 micrograms/ml &
600 micrograms/3ml injection

Hyoscine hydrobromide

400 micrograms/ ml injection

15.1.4 SEDATIVE & ANALGESIC PERI-OPERATIVE DRUGS

15.1.4.1 ANXIOLYTICS & NEUROLEPTICS

Diazepam

(See section 4.1.2 for preparations)

Lorazepam 4 mg/ml injection

Midazolam

10 mg/2ml & 10 mg/5ml injection

Clonidine

150 micrograms/ml injection

(Anaesthetists for inadequate sedation in ITU, with high dose midazolam and opioids, unlicensed use)

15.1.4.2 NON-OPIOID ANALGESIC

Diclofenac

12.5 mg, 25 mg, 50 mg & 100 mg suppositories,

75 mg/ 2ml injection *(Maximum treatment for 2 days)*

Methoxyflurane (Penthrox® Inhaler)

999mg per 1g

For use in ED only.

15.1.4.3 OPIOID ANALGESICS

Alfentanil (CD)

1 mg/ 2 ml, 5 mg/ ml &

500 micrograms/ ml injection

Fentanyl (CD)

100 micrograms/ 2 ml &

500 micrograms/ 10 ml injection

Remifentanil (CD)

1 mg & 2 mg injection

(For Neurosurgery in accordance with protocol)

Morphine sulphate (CD)

2 mg/ ml injection (50 ml vials for PCA)

15.1.5 MUSCLE RELAXANTS

NON-DEPOLARISING MUSCLE RELAXANTS

Atracurium

25mg/ 2.5 ml & 50mg/ 5 ml injection

Pancuronium 4mg/ 2 ml injection

Rocuronium 50mg/ 5 ml injection

(Theatres only, Critical areas and A&E)

Vecuronium 10 mg injection

nPbR = Indicates a drug excluded from HRG tariff price

DEPOLARISING MUSCLE RELAXANTS

Suxamethonium 50 mg/ml injection

15.1.6 DRUGS FOR REVERSAL OF NEUROMUSCULAR BLOCKADE

Neostigmine 2.5 mg/ml injection

Robinul-Neostigmine ® 1 ml injection
(Neostigmine 2.5 mg & glycopyrronium 500 micrograms)

Other drugs for reversal of neuromuscular blockade

Sugammadex 100mg/ml injection

15.1.7 ANTAGONISTS FOR CENTRAL & RESPIRATORY DEPRESSION

Doxapram

2mg/ ml infusion, 100 mg/5ml injection,

Notes: Only the injection is licensed for post-operative respiratory depression

Flumazenil

500 micrograms/5ml injection

Naloxone

400 micrograms/ml injection,
40 micrograms/ 2ml injection
(Check availability of neonatal,
40 micrograms/ 2ml injection with the
Pharmacy)

15.1.8 DRUGS FOR MALIGNANT HYPERTHERMIA

Dantrolene 20 mg injection

15.2 LOCAL ANAESTHESIA

Cocaine hydrochloride 10 % solution
(Unlicensed)

Lidocaine (Lignocaine)

0.5 % injection (20 ml)
1 % injection (2 ml, 5 ml, 10 ml & 20 ml)
2 % injection (2 ml, 5 ml & 20 ml)
4% topical solution,
4% jet spray (for anaesthesia of vocal
cords for patients undergoing ENT/
Maxillo-facial surgery),

10% spray,

2% gel

700mg (5%) medicated plaster (Palliative care use only)

(Please check sizes stocked on hospital site)

Lidocaine 4%, Adrenaline 0.1%, Tetracaine 0.5% (LAT) gel (unlicensed)

Lidocaine 1 % (10 mg/ ml) with adrenaline 1 in 200,000
(5 micrograms/ ml) (**Xylocaine** ®)
20 ml injection

Lidocaine 2 % (20 mg/ ml) with adrenaline 1 in 200,000
(5 micrograms/ ml) (**Xylocaine** ®)
20 ml injection

Lidocaine 5 % with phenylephrine 0.5 % solution
(ENT only)

Lidocaine with prilocaine
(Emla ®) cream

Lidocaine with chlorhexidine gluconate
(**Instillagel** ®) in sterile lubricant

Bupivacaine

0.1 % infusion (100 ml)
0.25 % & 0.5 % injection (10 ml)

(**Marcain** ®) 0.25 % & 0.5 % injection
(**Marcain Heavy** ®) 0.5 % injection

Bupivacaine with adrenaline

Bupivacaine 0.125 % with fentanyl 2 micrograms/ ml
(Unlicensed)

Levobupivacaine

Injections:
2.5mg/ml, 5mg/ml &
7.5mg/ml (10ml amp)

Epidural infusion:
1.25mg/ml (100ml and 200ml)

Unlicensed formulations:

nPbR = Indicates a drug excluded from HRG tariff price

Levobupivacaine 0.1% with Fentanyl
2mcg in 1 ml (500ml infusion)

Levobupivacaine 0.1% with Fentanyl
4mcg in 1 ml (500ml infusion)

Levobupivacaine 0.1% with Fentanyl
5mcg in 1 ml (200ml infusion)

Prilocaine 1% Injection

Prilocaine 2% Injection

For Spinal anaesthesia in short term surgical
procedures

Prilocaine 30mg/ ml **with octapressin**
(felypressin) 0.03 units/ ml injection

Mepivacaine 3 % injection

(Chiropody, Colposcopy unit, and Dr
Jenine Bignall use ONLY)

Tetracaine (Amethocaine) 4 %

Ametop ® gel

Ethyl chloride BP spray

ABLATIVE NERVE BLOCK

(Unlicensed products)

6 % phenol in water

5 % phenol in glycerin

6 % phenol, Niopam 300 40 %, in sodium
chloride 0.9 %

BARKING, HAVERING & REDBRIDGE HOSPITALS NHS TRUST

POLICY AND GUIDELINES FOR PRESCRIBING FOR SELF, FAMILY, COLLEAGUES AND FRIENDS

Under normal circumstances, prescribers should not prescribe for themselves or family, but it is recognised that there are occasions when it may be necessary to prescribe for yourself or immediate family in order to remain at work. In which case the following guidance should be followed:

1. EMERGENCY PRESCRIBING FOR SELF AND FAMILY

1.1 GMC Standard (April 1998)

Doctors should not treat themselves or their families

It is good practice for doctors and their families to be registered with a general practitioner outside the family, who takes responsibility for their health care.

This gives the doctor and family members ready access to objective advice and avoid the conflicts of interest that can arise when doctors treat themselves or those close to them.

From time to time, sad cases occur where a doctor's loss of objectivity in treating a family member results in misconduct; or where self-medication – for example, with Controlled Drugs – leads to drug misuse.

It is hard to lay down an absolute rule: it makes sense for a doctor to treat minor ailments, or take emergency action where necessary.

But doctors should avoid treating themselves or close family members wherever possible. This is a matter of common sense as well as good medical practice.

- 1.2 Prescribing should only be for immediate family, i.e. self, spouse, children, directly from the hospital pharmacy and not on FP10 (HP) forms.
- 1.3 Prescribing should normally be for acute illness only, not regular medication e.g. infections, acute pain, headache, hayfever etc. In emergency other medication e.g. insulin, inhalers may be prescribed, but this should not be a regular occurrence.
- 1.4 Prescribing should be short-term i.e. a maximum of 7 days treatment.
- 1.5 Prescribing should follow Barking, Havering & Redbridge Trust Formulary guidelines i.e. non-Formulary medicines will not be ordered for personal use by medical staff.
- 1.6 Controlled drugs may not be prescribed.
- 1.7 Drugs with potential for misuse may not be prescribed e.g. hypnotics, sedatives.

nPbR = Indicates a drug excluded from HRG tariff price

1.8 In an emergency, prescribers ideally should be seen in A/E and obtain a prescription with an A/E record number.

1.9 **Charges:** Normal prescription charges per item with no exemption.

2. PRESCRIBING FOR COLLEAGUES AND STAFF

2.1 Prescribing for colleagues and staff without a consultation and examination is not deemed good practice and is not in accordance with GMC advice on Good Clinical Practice. Such prescribing should not take place except as part of a regular consultation and follow-up.

3. PRESCRIBING FOR FRIENDS

3.1 Such prescribing is not allowed unless that person is a bona-fida patient seen at a normal consultation.

4. FP10(HP) FORMS

4.1 The costs of all items dispensed are charged to the Trust.

4.2 FP10(HP) forms are returned to the Trust and audited.

4.3 If doctors are found to have prescribed for themselves for an un-registered person outside these guidelines, they may be charged the cost of the prescription.

4.4 Consistent abuse of these guidelines will be a disciplinary matter.

5. NON-EMERGENCY PRESCRIBING

Non-emergency prescribing for regular medication for self and family is not permitted within the Trust.

Approved by MOG: Via Monthly Medicines Optimisation Group Meetings

Review Date: Ongoing review

nPbR = Indicates a drug excluded from HRG tariff price

16 Unlicensed & Specialists Use Drugs Approved by MOG

Ruxolitinib (INC424)

“Incyte®” 5mg tablets

(Approved for 2nd line compassionate treatment in patients with high risk myelofibrosis)

Requested by Dr. K Saja (Cons. Haematologist)

Intrathecal Fluorescein Sodium

(For diagnosis of CSF leak by Dr. P Chatrath Consultant ENT surgeon)

Sativex “Cannabis Extract” Oromucosal Spray

(For muscle spasticity, to be funded by Neurosciences directorate)

(For Dr. A Chaudhuri’s use only)

Thalidomide tablets

(Haematologists only for multiple myeloma and myelofibrosis with cytopenias +/- splenomegaly)

Peginterferon alfa-2a (Pegasys®)

(Consultant Haematology for patients with polycythaemia vera or essential thrombocythaemia)

nPbR Bevacizumab (Avastin®)

(For the treatment of neovascular glaucoma and non-NICE indicated choroidal neovascular membranes in non-wet age related macular oedema or non-myopia for patients under the age of 50 years)

Ophthalmologists Only

Diphenylcyclopropenone/diphencypropane (DPCP/DCP)

(For alopecia areata after topical and lesional steroids) Dr. Wade’s use only

Andexanet alfa 200mg powder for solution for infusion (**Ondexxya®**) (**NICE TA697**)

Idarucizumab 2.5g/50ml solution for injection/infusion (**Praxbind®**)

5-aminolevulinic acid 30mg/ml powder for oral solution (5-ALA) (**Gliolan®**)

nPbR = Indicates a drug excluded from HRG tariff price